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Abstract 
 
South Africa, with an estimated 5.7 million people living with HIV, continues to have one 
of the largest epidemics in the world. The introduction of HAART resulted in prolonged 
and improved quality of life of many infected patients. However, adverse effects caused 
by these drugs have become a major concern as they affect the adherence of patients 
and in some cases even result in the death of patients. Although much research has 
been and is still being conducted in the area of understanding, preventing and 
management of ARV adverse effects, there is still a need for patients to be actively 
involved in self-monitoring for adverse effects. This will assist health care professionals 
in early identification of serious or potentially serious ARV effects. This study aimed at 
evaluating the usefulness of strategies developed and employed in the identification, 
recording and monitoring of adverse effects.  
The study was conducted with patients receiving HAART from a private HIV and AIDS 
clinic in Uitenhage, Eastern Cape, South Africa. The research project was approved by 
the Nelson Mandela Metropolitan University Research and Ethics Committee and the 
research site. This was an experimental, randomized controlled study carried out over a 
period of three months (August to October 2009), with a sample size of 160 patients 
divided into four study groups of 40 patients each. Two monitoring strategies, namely an 
ARV adverse effect monitoring tool and a patient self-monitoring diary were developed 
and used for the identification and recording of adverse effects. The four study groups 
included a Control group, a Tool group, a Diary group and a Tool-Diary group. Willing 
patients, after signing an informed consent form, were randomly assigned to one of the 
four groups by participating health care workers at the study site.  Data was retrieved 
from the patient files by the researcher. Descriptive statistical analysis of the findings of 
the study was conducted using SPSS®. 
One hundred and forty nine patients were included in the final data analysis. Of the 80 
diaries handed out to patients, only 33 were returned and due to errors only 31 were 
suitable for analysis. Monitoring tools were completed and analysed for 36 patients. The 
tool was found to be more effective in identifying adverse effects of a physical nature 
(such as peripheral neuropathy and lipodystrophy) than the usual methods of monitoring 
 xiii 
 
employed by the clinic, whilst the diary, used alone, was found to be less effective.  Use 
of the tool and diary combined resulted in the most significant identification and 
recording of central nervous system related adverse effects and physical adverse 
effects. However due to the low return rate of the diaries and the majority of the 
monitoring tool not being completed in many instances the results of this study may not 
be generalisable.   
The study results did however suggest that combining the tool and the diary methods of 
adverse effect identification, yielded the most favourable results when compared to 
each method alone. This may be attributed to the fact that the tool is useful in identifying 
objective symptoms and the diaries subjective symptoms, particularly in instances 
where the patients forget to report their symptoms to healthcare professional whilst at 
the clinic. The diaries were also reported to improve adherence for more than 90% 
(n=31) of the patients. More research would be needed in order to verify the exact 
significance of the tool and the diary in identifying and recording adverse effects and 
symptoms of adverse effects.  
1 
CHAPTER 1 
 
INTRODUCTION 
 
 
More than twenty years have gone by since the initial reports of the Human 
Immunodeficiency Virus (HIV) and its resultant Acquired Immune Deficiency Syndrome 
(AIDS) (Chao, 2006). HIV infection is characterized by slow progressive immune 
deficiency with a prolonged period of clinical latency, which varies between different 
individuals, but on average lasts approximately eight years (Regensberg and Whitelaw, 
2007). If left untreated, patients eventually develop one or more serious events, known 
as AIDS-defining illnesses. AIDS is a collection of opportunistic infections commonly 
experienced by HIV immuno-compromised patients.  
According to the Joint United Nations programme on HIV/AIDS (UNAIDS) global report 
(2008), significant positive changes are being seen in several countries most affected 
by the AIDS epidemic. These positive changes include increasing condom use among 
people especially the youth with multiple partners, and young people waiting longer to 
have sexual intercourse (UNAIDS Global Report, 2008). Despite tremendous advances 
in the understanding and management of HIV/AIDS, it remains a worldwide epidemic 
(Chao, 2006).  
UNAIDS estimates that an average of 33.4 million adults and children are infected with 
HIV. Sub-Saharan Africa remains the global epicenter of the epidemic, accounting for 
two thirds (67%) of all people living with HIV and for three quarters (75%) of AIDS 
deaths in 2007. An estimated 22.4 million people in sub-Saharan Africa are living with 
HIV. South Africa, with an estimated 5.7 million people living with HIV, continues to be 
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the largest epidemic in the world.  (UNAIDS Global Report, 2009) It is also estimated by 
the UNAIDS (2008) that for every two people who start HIV treatment, five more are 
infected. Therefore, despite the positive changes, much still has to be done to curb this 
epidemic. 
Long-term reduction of HIV infection is readily achieved by combinations of 
antiretrovirals (ARVs) (Montessori et al., 2004). These combinations are referred to as 
Highly Active Antiretroviral Therapy (HAART). The overall effectiveness of HAART is 
established by measuring the number of life-years added due to ARV therapy. Between 
1996 and 2008, an estimated 11.7 million life-years were added globally and this 
number is expected to rise rapidly should ARV programmes continue (UNAIDS Global 
Report, 2009).  
The range of ARV agents available for the treatment of HIV/AIDS patients has 
expanded to more than 20 medications since the first agent, zidovudine (AZT), was 
approved in 1987 (Cohen, 2006). AZT appeared to be effective, in that many patients 
responded to monotherapy, with a transient decrease in viral load and an increase in 
CD4 cell count. Eventually, in 1991 didanosine (ddI) was approved and combination 
therapy became the standard of care for HIV/AIDS patients since it yielded favourable 
results when compared to monotherapy. It was however noted that the effectiveness of 
nucleoside reverse transcriptase inhibitor (NRTI) therapy was often not sustained due to 
resistance with mono or dual NRTI therapy (Cohen, 2006).  
The current standard of care for initial HAART has been defined based on the results 
from numerous randomized studies and consists of two NRTIs and either a non-
nucleoside reverse transcriptase (NNRTI) or a ritonavir-boosted protease inhibitor (PI). 
The rationale for prescribing a minimum of three drugs is to reduce viral resistance, 
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allow for a reduction in individual ARV doses (and thus decrease risk of toxicity) and to 
provide for a maximal and durable suppression of viral load, to a point where viral load 
is undetectable (Regensberg and Whitelaw, 2007). By suppressing the viral load and 
thus gradually increasing CD4 cell count, ARVs allow for the restoration and 
preservation of the immune system. Figure 1.1 below shows the average progression of 
HIV disease characterized by CD4 cell drop and increase in viral load without treatment.  
 
Figure 1.1 The average progression of HIV disease without treatment 
(Source: Bennett and Gilroy, 2010) 
 
Although HAART is not a cure for AIDS, it may significantly prolong the lives of patients 
by improving the quality of their lives. The rates of transmission of HIV as shown by a 
recent study are at 0.5 per 100 person-years for those receiving ARV treatment and 5.6 
per person-years for those not receiving treatment (UNAIDS Global Report, 2009). 
Therefore the use of ARVs is not only useful to the infected patient, but also useful in 
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preventing infection of others. With the use of ARVs, the viral load may be reduced to 
undetectable concentrations. This however does not mean that the patient is cured as 
the virus is still found to be latent in memory T cells. It forms part of the host’s genome, 
serving as a potential source for reactivation if treatment is stopped or fails (Fletcher 
and Kakuda, 2003). 
The effective management of HIV infection requires complete patient adherence to 
HAART regimens. Adherence is defined as the engaged and accurate participation of 
an informed patient in a care plan. It is a broader term than compliance (the extent to 
which patients follow the instructions of their healthcare professionals (HCPs)), and 
implies understanding, consent and partnership. Adherence includes entering into and 
continuing in a program or care plan, attending appointments and tests as scheduled, 
taking medications as prescribed, modifying lifestyle as required, and avoiding risk 
behaviours. It includes both adherence to care and medication (Rabkin, El-Sadr and 
Abrams, 2004). Ideally, adherence to HAART means a patient must take more than 
95% of their doses, that is, missing less than 3 doses in a month (Department of Health, 
2004). 
Adherence to HAART is complicated by several factors including the therapeutic 
complexity of the drug regimens, special food requirements, the associated drug 
interactions and severe side effects (Schiller, 2005). It is further complicated by the fact 
that HAART is a lifelong treatment, and patients are required to take at least three 
different ARVs twice a day, at the same time each day, for the rest of their lives 
(Regensberg and Whitelaw, 2007).  
With the continuing development of new ARVs, efforts to maximize the effectiveness of 
the currently available ARV drugs include attempts to better understand and manage 
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adverse effects. All ARVs can have both short and long-term adverse effects 
(Montessori et al., 2004). Adverse effects of ARVs are common and often difficult to 
avoid, and can range from mild to life threatening. Determining the exact causative ARV 
of a specific adverse effect is often difficult (Shibuyama et al., 2006), even though each 
ARV is associated with its own specific adverse effects class adverse effects also often 
occur. 
Approximately 50% of patients on HAART experience adverse effects. Up to 25% of 
patients who experience adverse effects, stop their treatment within the first year of 
treatment, leaving them defenseless against the virus and possibly resulting in drug 
resistance, a loss of drug efficacy and the loss of future treatment options (Schiller, 
2005). Approximately a further 25% of patients do not take the recommended dose of 
their medication as a consequence of concerns regarding the side effects. Patients, who 
report significant side effects, are frequently non-adherent (Schieferstein and Buhk, 
2006).  
Common but relatively mild adverse effects that occur early in most ARV regimens 
include gastrointestinal effects such as bloating, nausea and diarrhea, which may be 
transient or persistent throughout therapy. Fatigue and headache caused by AZT and 
nightmares associated with efavirenz (EFV) are also common trouble-some adverse 
effects. Rare but severe adverse effects such as AZT-associated anaemia, stavudine 
(d4T) associated peripheral neuropathy, PI-associated retinoid toxicity and NNRTI-
associated hypersensitivity reactions are managed according to standard treatment 
protocols, in the same way that these  conditions would be managed in patients not 
receiving HAART (Montessori et al., 2004). Other serious adverse effects include lactic 
acidosis, hepatic steatosis, hyperlactataemia, hepatotoxicity, hyperglycaemia, fat 
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maldistribution, hyperlipidemia, bleeding disorders, osteoporosis and skin rash. These 
are discussed in more detail in Chapter 2.  
Much research has been and is still being conducted in the area of understanding, 
preventing and managing ARV adverse effects, particularly those that threaten either 
the life of the patient or their adherence to treatment. However, there is still a need for 
patients to be actively involved in self-monitoring for adverse effects, in order to assist 
the HCPs in early identification of serious or potentially serious ARV effects and hence 
manage them appropriately.  
The aim of this research was to try and develop a practical way of involving patients in 
their care plan, particularly with regards to reporting adverse effects or symptoms of 
adverse effects they may have experienced while receiving HAART. Thus two different 
monitoring methods including a patient journaling or diary system, which would not only 
monitor adverse effects but also adherence, and an adverse effect monitoring tool were 
developed and tested. The primary aim of the study was thus to evaluate the extent to 
which these monitoring strategies may contribute to the early identification and 
management of adverse effects associated with ARVs. This was to be achieved by 
modifying the adverse effect monitoring tool previously developed and piloted by 
Diergaardt (2005) and modified by Mulinge (2008) and developing and implementing 
the patient self-monitoring diary for the patients to monitor their own adverse effects. 
The extent to which the above strategies facilitate the identification of adverse events 
associated with ARV treatment as well as the perceived ease of use of the monitoring 
tool by HCPs and the diaries by the patients would then be determined. 
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CHAPTER 2 
ANTIRETROVIRAL TREATMENT 
2.1 Introduction to Antiretroviral Treatment 
Many years of research have yielded treatment advancements able to slow the impact 
of HIV infection (Shibuyama et al., 2006). These treatments have essentially 
transformed HIV and AIDS from a terminal disease to a chronic disease. As a result of 
the emphasis, HIV and AIDS management has moved from palliative care to “promoting 
adherence, minimizing treatment- and disease-related morbidities, optimizing outcome 
and controlling the costs of ongoing treatment” (Chao, 2006).  
The range of antiretroviral (ARV) drugs approved by the United States Food and Drug 
Administration (FDA) for the treatment of HIV and AIDS has increased to about 27 
medications since zidovudine (AZT) was first approved in 1987.  Until 1991, AZT was 
the only approved drug for the treatment of HIV infection with many patients responding 
favourably to monotherapy, with a decrease in viral load and an increase in CD4+ cell 
count (Cohen, 2006).  
Didanosine (ddI) was the second antiretroviral drug to be approved in 1991, and in 
combination with AZT produced favorable and superior results compared to those 
experienced with AZT monotherapy. However, the effectiveness of these NRTIs was 
often not sustained and patients eventually became viremic. This necessitated the 
development of other ARVs to overcome the problem of resistance to mono or dual 
NRTI therapy (Cohen, 2006). Eventually research resulted in the development of 
protease inhibitors (PIs) and combination of a PI with NRTIs in a three-drug regimen 
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was shown to be more potent and to achieve more durable suppression than dual NRTI 
therapy. Table 2.1 below shows the approval of the available ARVs. 
 
Table 2.1 Antiretroviral drug FDA approval  
Adapted from: Corbett, 2007 
ARV Drug Year approved Available in South 
Africa 
Zidovudine (AZT) 1987 Yes 
Didanosine (ddI) 1991 Yes 
Zalcitabine (ddC) 1992 No 
Stavudine (d4T) 1994 Yes 
Saquinavir (SQV) 
Lamivudine (3TC) 
1995 Yes 
Yes 
Ritonavir (RTV) 
Indinavir (IDV) 
Nevirapine (NVP) 
1996 Yes 
Yes 
Yes 
Nelfinavir (NFV) 
Delavirdine (DLV) 
1997 Yes 
No 
Efavirenz (EFV) 
Abacavir (ABC) 
1998 Yes 
Yes 
Amprenavir (APV) 1999 Yes 
Lopinavir-ritonavir (LPV/r) 2000 Yes 
Tenofovir (TDF) 2001 Yes 
Fosamprenavir (FPV) 
Emtricitabine (FTC) 
Atazanavir (ATV) 
Enfuvirtide (T-20) 
2003 Yes 
Yes 
Yes 
No 
Tipranavir (TPV) 2004 No 
Darunavir (DRV) 2006 No 
Maraviroc (MVC) 
Raltegravir (RAL) 
2007 No 
No 
Etravirine (ETV) 2008 No 
 
Most patients initially started treatment with AZT and other drugs were added to their 
regimen as they became available. This type of sequential combination therapy was 
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observed to have a considerably lower response when compared with simultaneously 
initiated combination therapy (Cohen, 2006). The current standard of care for initial 
HAART has been defined, based on the results from numerous randomized studies and 
consists of a dual NRTI backbone and either a NNRTI or a ritonavir-boosted PI. The 
rationale for prescribing a minimum of three drugs is to reduce viral resistance, allow for 
a reduction in individual ARV doses (and thus decrease risk of toxicity) and to provide 
for a maximal suppression of viral load, to a point where viral load is undetectable 
(Regensberg and Whitelaw, 2007).  
Although HAART is not a cure for AIDS, it may significantly prolong the lives of patients, 
by decreasing the morbidity and mortality associated with HIV infection (Stanic and 
Grana, 2009). According to Jevtović and colleagues (2009), HIV infected patients 
receiving ARV therapy have their life expectancy increased by more than 10 years. 
Increasing numbers of patients enrolled on HAART has resulted in decreased mortality 
(Pitt, Myer and Wood, 2009). With the use of ARVs, the viral load may be reduced to 
undetectable concentrations (< 40 copies/ml) and the CD4+ cell count increased 
sometimes to normal levels (400-1600 cells/ml) which is a desired outcome of HAART. 
This however does not mean that the patient is cured as the virus is still found to be 
latent in memory T cells. The virus forms part of the host’s genome, serving as a 
potential source for reactivation if treatment is stopped or fails (Fletcher and Kakuda, 
2003).  
2.1.1 Goals of HIV treatment 
The primary goal of antiretroviral therapy (ART) is to suppress viral replication (Cohen, 
2006). Suppressing or preventing HIV replication results in: 
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 Maximal and durable suppression of viral load 
 Reducing damage to the immune system of the host 
 Restoration and preservation of immunologic function. (Cohen, 2006) 
Other goals of HIV treatment include: 
 Prolonging life expectancy 
 Improving quality of life 
 Reducing HIV-related morbidity and mortality 
 Preventing transmission of the virus (e.g. mother to child). (Regensberg and 
Whitelaw, 2007) 
ART is considered effective when it consistently results in sustained suppression of HIV 
RNA replication and steady increases in CD4 cell count, sometimes to normal levels, 
even in persons with advanced HIV infection (Kojic and Carpenter, 2006). 
2.1.2 Initiation of ARV treatment 
The timing of when to commence ART is not a simple decision as it involves 
consideration of a number of factors. The benefits of initiation of ART must be carefully 
weighed against risks. The trend is increasingly moving toward early ART initiation, 
since research has shown that the risks associated with ARV therapy are less than 
those resulting from delayed treatment. (Thompson, Aberg and Cahn, 2010)  
The patient’s commitment to ARV treatment is a crucial part of the decision to initiate 
therapy. The patient must be willing to accept and adhere to a complex regimen of 
drugs before embarking on therapy (Regensberg and Whitelaw, 2007). In South Africa, 
the final decision to initiate treatment lies with a multi-disciplinary team consisting of 
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community adherence supporters, counsellors, nurses, pharmacists, doctors, 
nutritionists and social workers (Department of Health, 2008).  
Patients on the ARV rollout program are prescribed a 28-day course of co-trimoxazole, 
a broad spectrum antibiotic used for prophylaxis and treatment of opportunistic bacterial 
infections, to assess for adherence. The patients are given a return date on which a co-
trimoxazole pill count is conducted and the patients’ adherence determined, based on 
the number of tablets remaining. Once the patient has been assessed for readiness and 
accepts the proposed treatment option, the clinician initiates treatment (Department of 
Health, 2008).  
Ideally, the initial regimen should be individualized taking the following into 
consideration; 
 Resistance patterns of the HIV strain 
 Predicted virologic efficacy 
 Drug toxicity profiles 
 Tolerability, pill burden, dosing frequency, 
 Possible drug interactions 
 Other comorbidities 
 Patient and provider preferences. (Thompson, Aberg and Cahn, 2010)  
The criteria for ART initiation in adults and adolescents in South Africa, including 
pregnant women, are summarized in table 2.2 below. 
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Table 2.2: The South African criteria for ART initiation in adults 
(Source: Department of Health, 2010, p.8) 
Eligible to start ART 
CD4 count <200cells/ml irrespective of clinical stage 
OR 
CD4 count <350cells/ml 
o In patients with TB/HIV 
o Pregnant women 
OR 
WHO stage IV irrespective of CD4 count 
OR 
MDR/XDR irrespective of CD4 
 
Require fast track (i.e. ART initiation within 2 weeks of being eligible 
Pregnant women eligible for lifelong ART 
OR 
 Patients with very low CD4 (<100cells/ml) 
OR 
Stage 4, CD4 count not yet available 
OR 
MDR/XDR TB 
 
Not yet eligible for ART 
 Transfer to a wellness programme for regular follow up and repeat CD4 
testing 6-monthly 
 Advice on how to avoid HIV transmission to sexual partners and children 
 Initiate INH prophylaxis if asymptomatic for TB 
 Contraceptives and annual Pap smear 
 
ARV therapy needs to be individualized and each patient assessed for adverse effects 
and effectiveness. Effective ART should reduce the plasma HIV RNA by >90% (1 log10) 
within 2 weeks of treatment. Poor adherence, viral resistance, or inadequate exposure 
to the drug may result in suboptimal results. An increase in the CD4 count usually 
follows the decrease in viral load (Kojic and Carpenter, 2006). 
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2.1.2.1 Initiation of ARV treatment in patients with TB 
In patients with TB who are not already on ART, the commencement of ART is guided 
by the CD4 count. This is because, although TB is considered an AIDS-defining illness, 
it can occur at any stage of HIV infection in countries where TB is endemic. The 
following recommendations are therefore followed in such instances; 
 CD4 > 350 cells/ mm3: ART is commenced after TB treatment is completed provided 
the above criteria is met (Department of Health, 2010). 
 CD4 50-350 cells/ml: ART is delayed until the intensive phase of TB treatment (2 
months). If however the patient has other serious HIV-related illnesses, ART should 
be introduced once the patient is stable on TB therapy (approximately 2 weeks) 
(Department of Health, 2010). 
 CD4 < 50 cells/ mm3: ART is introduced once the patient is stabilized on TB therapy 
(Regensberg and Makiwane, 2009). 
According to the South African Department of Health (2010), the following is 
recommended for patients who develop TB while on ART; 
 ART should be continued throughout TB treatment 
 Patients on Lopinavir/Ritonavir should have their dose doubled slowly over two 
weeks (to 800/200 mg twice a day); all other regimens can be continued unmodified. 
These changes to Lopinavir/Ritonavir should be continued until 2 weeks after 
completion of TB medication 
 Patients should be monitored and investigated appropriately for hepatotoxicity 
symptoms 
Immune reconstitution inflammatory syndrome (IRIS) which may be a major concern 
while commencing HAART is also of importance.  IRIS occurs when commencement of 
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ART causes a paradoxical flare up of opportunistic infections such as TB, 
cytomegalovirus infections, and pneumonia due to the restoration of the immune system 
(Garciarena, Juarbe and El-Abassi, 2009). This is common when ART is commenced 
within the intensive phase of TB treatment and in patients with advanced disease 
(indicated by low CD4 cell counts). In the case of TB, IRIS would manifest as a return of 
the symptoms of TB and a paradoxical enlargement of TB lesions. 
2.2 ARV Classes 
2.2.1 Currently approved ARVs 
Several classes of ARVs have been developed but not all are currently available in 
South Africa. The older agents include: 
 Reverse Transcriptase Inhibitors (RTIs), which are divided into three subgroups 
o Nucleoside Reverse Transcriptase Inhibitors (NRTIs) 
o Nucleotide Reverse Transcriptase Inhibitors (NtRTIs) 
o Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) 
 Protease Inhibitors (PIs) 
 Ribonucleotide Reductase Inhibitors (RnRIs). (Regensberg and Whitelaw, 2007) 
Newer ARV agents include:  
 Entry inhibitors  
 Fusion inhibitors 
 Integrase inhibitors  
 Chemokine coreceptor antagonists (Chen, Hoy and Lewin, 2007) 
 The table below shows the antiretrovirals currently approved by the FDA.  
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Table 2.3 ARVS currently approved by the FDA 
(Shibuyama et al., 2006, p. 1077) 
Class Drug Examples of Trade 
names 
 
 
 
 
 
NNRTIs/ NtRTIs 
AZT Retrovir® 
ddI Videx®/Videx EC® 
ddC** Hivid® 
d4T Zerit® 
3TC Epivir® 
ABC Ziagen® 
TDF Viread® 
FTC Emtriva® 
 
 
NNRTIs 
NVP Viramune® 
DLV Rescriptor® 
EFV Sustiva, Stocrin® 
ETV Intelence® 
 
 
 
 
 
 
PIs 
SQV 
Hard Gelatin Capsule 
Soft Gelatin Capsule 
 
Invirase® 
Fortovase® 
RTV Norvir® 
IDV Crixivan® 
NFV Viracept® 
APV** Agenerase® 
LPV/r Kaletra® 
FPV Lexiva® 
DRV Prezista® 
ATV Reyataz® 
TPV Aptivus® 
RnRIs Hydroxyurea (HU) Hydrea® 
Fusion Inhibitors  T-20 Fuzeon® 
CCR5 
Antagonists 
MVC Selzentry®/ Celsentri® 
Integrase 
Inhibitors 
RAL Isentress® 
**Discontinued in the US 
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2.2.2 ARV targets in the HIV lifecycle 
The figure below shows the different steps in HIV replication and the potential targets 
for the different classes of ARVs. The mechanism of action of the different available 
ARVs is discussed below.  
 
 
Figure 2.1 ARV targets in the HIV lifecycle  
(Source: Ananworanich, 2007) 
2.3 Specific ARV Classes 
2.3.1 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) 
“The HIV genome is a diploid consisting of two RNA copies with identical polarity inside 
the HIV-1 virion” (Agrawal et al., 2006). The virion contains an enzyme, reverse 
transcriptase that catalyzes the conversion of RNA to DNA. Reverse transcriptase uses 
the viral genomic RNA as a template for the replication of RNA to DNA by binding to 
one RNA strand and copying the RNA nucleotides using corresponding DNA 
nucleotides.  The infected host cell provides the nucleosides which are activated by the 
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addition of three phosphate radicals. The nucleosides are important for the formation of 
proviral DNA by viral reverse transcriptase. 
NRTIs are prodrugs that require activation in the cell, through phosphorylation, before 
they are able to inhibit their target. The host cell enzymes phosphorylate the NRTIs to 
5’-triphosphates, which then act as false substrates mimicking naturally occurring 
nucleosides (Safrin, 2004). The pseudo-analogues compete with the naturally occurring 
nucleosides to bind to viral reverse transcriptase, thus blocking the active site and 
getting incorporated into the growing viral DNA chain. The incorporation of the 5’-
triphosphate into the chain results in chain termination and inhibition of viral cell 
production (Agrawal et al., 2006).  
The NRTIs are subdivided into Thymidine analogues and Non-Thymidine analogues as 
listed in Table 2.4 below.  
 
Table 2.4 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) 
(Adapted from: Gibbon, 2005) 
Thymidine Analogues Non-Thymidine Analogues 
Stavudine (d4T) Didanosine (ddI) 
Zidovudine (AZT) Zalcitabine (ddC) 
 Lamivudine (3TC) 
 
2.3.2 Nucleotide Reverse Transcriptase Inhibitors (NtRTIs) 
The difference between the NtRTIs and the NRTIs is that the NtRTIs contain a 
phosphate group and therefore only require two phosphorylation steps to be converted 
to the active metabolite that serves as a false substrate in the reverse transcriptase 
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reaction (Fletcher and Kakuda, 2003). Reverse transcriptase fails to distinguish the 
phosphorylated NRTIs from the naturally occurring nucleotides, and incorporates the 
pseudo-analogues in the synthesis of viral DNA, which leads to inhibition of the 
addition of further nucleotides and hence a full-length copy of the viral DNA is not 
produced (Coffey and Peiperl, 2008). Tenofovir is an example of an NtRTI. 
2.3.3 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) 
The NNRTIs specifically interact with a non-substrate binding site, closely associated, 
but distinct from the substrate binding site of reverse transcriptase enzyme, denaturing 
it in a way that inhibits the enzyme's activity and therefore preventing the conversion of 
viral RNA to viral DNA and inhibiting replication. The use of NNRTIs is limited by 
emergence of resistant strains hence NNRTIs are normally used in combination with 
NRTIs. Examples of NNRTIs include nevirapine (NVP), efavirenz (EFV) and delavirdine 
(DLV). Newer NNRTIs which have been recently approved include etravirine and 
rilpivirine. Further NNRTIs in the developmental process include capravirine which has 
shown promise in early clinical trials. Capravirine and etravirine have been shown to be 
effective in viral strains resistant to the currently available NNRTIs. Thiocarboxanilide 
UC-781 is yet another NNRTI in the developmental stages for use as a topical 
microbicide for the prevention of sexual transmission of HIV. (Agrawal et al., 2006)  
2.3.4 Protease Inhibitors (PIs) 
Viral protease is the enzyme that catalyses the packaging, maturation and budding of 
new viruses, during viral cell production (Fletcher and Kakuda, 2003). This leads to the 
production of the mature infectious virions. PIs bind to the active site of the viral 
protease enzyme, preventing the processing of viral proteins into functional particles. 
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Viral particles are still produced when the protease is inhibited, but these particles are 
immature and non infectious (Coffey and Peiperl, 2008). 
Since protease is not found naturally within the host, it serves as a good target 
associated with resistance and must therefore be used in combination treatment. High 
intracellular concentrations increase efficacy of PIs, hence in most cases (except for 
nelfinavir) a PI is boosted with a low dose of ritonavir (100-400mg/d) in order to 
enhance the plasma concentration of the PI through the inhibition of the PI’s metabolism 
via the CYP3A4 system (Stanic and Grana, 2009).  This mechanism is referred to as PI 
boosting, and in some cases it has led to the reduction of dosage frequency, pill burden 
and reducing food restrictions hence improving adherence (Weston, Portsmouth and 
Benzie, 2006). PIs are typically reserved for second line therapy (Fletcher and Kakuda, 
2003).  
2.3.5 Ribonucleotide Reductase Inhibitors (RnRIs) 
RnRIs inhibit the enzyme ribonucleotide reductase thereby blocking the transformation 
of ribonucleotides into deoxynucleotides, depleting the intracellular deoxynucleotide 
triphosphate pool and imparing viral replication. This results in decreased production of 
nucleotides essential in DNA synthesis. Used in combination with NRTIs, RnRIs forces 
viral reverse transcriptase to use the pseudonucleotides formed by the NRTIs, thus 
giving rise to a synergistic effect of these agents inhibiting viral replication (Kelly, 
Lisziewicz and Lori, 2004). Hydroxyurea is an RnRI available for the treatment of HIV 
infection. 
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Hydroxyurea has been used for many years in hematology, particularly in the treatment 
of myeloproliferative disorders and recently for the treatment of sickle-cell anaemia 
(Kelly, Lisziewicz and Lori, 2004). Hydroxyurea provides two anti-HIV mechanisms 
described below:  
Antiviral Mechanism 
 A direct antiviral effect by blocking viral replication in macrophages which mediate 
neuronal damage in HIV infection  
 An indirect effect by potentiating the activity of NRTIs by;  
o decreasing the relative concentration of the intracellular deoxynucleotide 
triphosphates, particularly the deoxyadenosine triphosphate pool hence 
acting synergistically with nucleotide analogues such as ddI (an adenosine 
analog) which mimic naturally occurring nucleotides 
o enhancing the activity of deoxycytidine and thymidine kinases which are 
involved in the conversion of NRTI pro-drugs to active metabolites (the 
triphosphorylated form) (Kelly, Lisziewicz and Lori, 2004). 
Immunomodulating/Cytostatic Mechanism 
 HU prevents T-cell proliferation, reducing HIV cellular targets, and therefore 
exhibiting an immunomodulating, cytostatic effect on HIV replication by (Kelly, 
Lisziewicz and Lori, 2004). 
HU when prescribed alone has the following adverse effects; 
 Mild toxicity- GI complaints such as nausea, vomiting, diarrhoea and anorexia 
 Prolonged use- Infrequently causes alopecia, hyperpigmentation, erythema and leg 
ulcers 
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 Severe toxicity- Includes neutropenia, anaemia and thrombocytopenia which are 
dose related and potentiated when used in combination with other myelosuppressive 
drugs such as AZT (Kelly, Lisziewicz and Lori, 2004). 
HU is teratogenic and is therefore not to be used in pregnancy or for lactating mothers. 
The HU-ddI combination is a synergistic cytostatic and virostatic one with an excellent 
resistance profile and potent antiviral activity that is valuable for long term treatment of 
HIV infection. (Kelly, Lisziewicz and Lori, 2004) 
2.3.6 Entry Inhibitors 
At the initial stage of its replication cycle, HIV gp120 attaches to the host CD4 receptors, 
which allows binding to chemokine coreceptors on CD4 cells, specifically chemokine 
coreceptor 5 (CCR5) expressed on dendritic cells, macrophages and T-lymphocyte cells 
or CXC chemokine coreceptor 4 (CXCR4) expressed only on T-lymphocytes (Stanic 
and Grana, 2009). This binding results in conformational changes that allow viral gp41 
to form a pore in the membrane through which the virus can enter the host cell (Boyd 
and Pett, 2008). Entry inhibitors target this initial step in the HIV life cycle.  
Entry inhibitors are mainly used in the treatment of HAART-experienced adults whose 
HIV infection is resistant to multiple classes of antiretrovirals or who are intolerant of 
other antiretrovirals (Weston, Portsmouth and Benzie, 2006).  
Entry inhibitors are divided into two subclasses namely fusion inhibitors and CCR5 
inhibitors (Stanic and Grana, 2009). The two classes are further discussed below. 
2.3.6.1 Fusion Inhibitors (FIs) 
HIV fusion inhibitors represent a novel class of antiretroviral drugs with enfuvirtide (T-
20) as the first drug within this class to be approved by the FDA. T-20 acts by binding to 
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the first heptad repeat region of gp41, preventing conformational changes that result in 
interactions with the second heptad repeat region. This results in interruption of the 
fusion reaction and prevents the virus from penetrating and infecting the host cell. (Boyd 
and Pett, 2008) 
Enfuvirtide is a large peptide which is broken down in the digestive tract before 
absorption takes place and hence cannot be orally administered (Boyd and Pett, 2008). 
It is administered as a subcutaneous injection twice daily. Although this route of 
administration is favorable due to insignificant potential for drug-drug interactions, it also 
presents a disadvantage as the patients require training on administration and may 
experience injection site reactions (Weston, Portsmouth and Benzie, 2006).  
T-20 does not appear to have toxicity profiles similar to the other antiretrovirals, with its 
adverse effects including hypersensitivity reactions manifesting as rash, fever, chills, 
nausea and vomiting. The most common adverse effect is injection site reaction, 
characterized by local pain, erythema, pruritus, induration, ecchymosis, nodules and 
cysts, which occurs in about 90% of enfuvirtide users. (Boyd and Pett, 2008)  
2.3.6.2 Chemokine Co-receptor (CCR5) Inhibitors 
Maraviroc was the first CCR5 inhibitor to be approved by the FDA for use in 
combination with other antiretrovirals in patients experiencing resistance to other ARVs. 
Maraviroc is specifically indicated for patients infected with CCR5-tropic HIV-1 (Yost, 
Pasquale and Sahloff, 2009). 
The HIV cell entry step involves the binding of the HIV glycoprotein complex consisting 
of gp41 and gp120 with the CD4 receptor on the membrane of the host cell. 
Subsequent conformational changes on gp120 lead to the exposure of coreceptor 
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binding sites as shown in the left section of Figure 2.2 below. The two major chemokine 
coreceptors involved in viral entry are CCR5 and CXCR4. “CCR5-tropic strains are 
predominant during the early stages of HIV infection while the CXCR4-tropic viruses are 
associated with faster disease progression and are more likely to be encountered in 
later stages of HIV infection” (Yost, Pasquale and Sahloff, 2009). The exposed 
coreceptor sites bind to CCR5 or CXCR4 on the host cell membrane as shown on the 
centre panel of Figure 2.2,  initiating the fusion of the HIV envelope with the host cell 
and entry of viral contents into the host cell (see centre panel inset). Maraviroc 
competitively and selectively binds to CCR5 and undergoes conformational changes 
such that it is not recognized by gp120 coreceptor binding sites as shown on the right 
section of Figure 2.2. Infection of the host cell is therefore prevented (Yost, Pasquale 
and Sahloff, 2009).  
 
Figure 2.2 Mechanism of action of maraviroc  
(Source: Yost, Pasquale and Sahloff, 2009, p. 716) 
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Studies have shown that maraviroc is only active against CCR5-tropic virus and it has 
no activity against CXCR4-tropic or dual- or mixed- tropic HIV (Yost, Pasquale and 
Sahloff, 2009). Tropism assays must therefore be performed to determine the 
coreceptor specificity of a patient’s HIV strain before initiation of therapy with maraviroc. 
Recent studies have evaluated the use of maraviroc as a first line therapy and it has 
been proposed that maraviroc may be more useful in acute and early infection as CCR5 
coreceptors are predominantly encountered in early HIV disease (Stanic and Grana, 
2009). CXCR4 tropic viral strains are predominantly encountered in advanced HIV 
disease.  The change in tropism from CCR5- to CXCR4-tropic viruses is often seen with 
disease progression and is under investigation as a cause for treatment failure with 
maraviroc (Yost, Pasquale and Sahloff, 2009). 
Following oral administration, maximal absorption of maraviroc occurs in about 0.5 to 4 
hours. Studies have shown that maraviroc may be administered without regard for food. 
Maraviroc is metabolized by the CYP3A system to inactive metabolites. The use of 
maraviroc in patients with hepatic or renal dysfunction has not been adequately studied. 
Therefore, maraviroc should be used with caution in patients co-infected with hepatitis B 
or C and in patients with hepatic dysfunction due to potential for increased maraviroc 
concentrations as it is mainly metabolized by the liver. (Yost, Pasquale and Sahloff, 
2009) 
Maraviroc has generally been well tolerated. The adverse effects of maraviroc include 
abdominal pains, sleep disturbances, upper respiratory tract infections, cough, pyrexia, 
rash, bronchitis, herpes infection, sinusitis, constipation, appetite disorders, dizziness or 
postural dizziness, joint signs and symptoms and musculoskeletal or connective tissue 
signs and symptoms (Yost, Pasquale and Sahloff, 2009). The most commonly observed 
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of these include upper respiratory tract infections, cough, pyrexia, rash and dizziness 
(Stanic and Grana, 2009). At the recommended dosage, postural hypotension is 
unlikely. However, if appropriate dosage adjustments are not made for concomitant 
interacting drugs, increased exposure to maraviroc may occur leading to an increase in 
the potential risk of postural hypotension (Yost, Pasquale and Sahloff, 2009).  
Concern regarding the potential for CCR5 antagonists to increase the risk of infection 
and malignancies has been expressed. The CCR5 coreceptor has a role in human 
infections that is still not fully understood. So far, no definitive association between the 
use of CCR5 inhibitors and the onset of malignancies has been determined. In reported 
studies, it was found that some of the patients who developed malignancies were 
already predisposed to malignancies. (Yost, Pasquale and Sahloff, 2009) 
In the USA, maraviroc contains a black-box warning regarding hepatotoxicity. 
Symptoms such as an itchy rash, increased eosinophils or liver inflammation warrant 
immediate medical attention. Maraviroc should be used with caution in patients with risk 
factors for cardiovascular disease as some patients with cardiac risk factors developed 
myocardial ischaemia or infarction in clinical trials. (Yost, Pasquale and Sahloff, 2009) 
Maraviroc is metabolized by CYP3A4 and subsequently drug-drug interactions with 
inducers and inhibitors of the same system may lead to decreased or increased 
maraviroc plasma levels respectively.  Maraviroc is formulated in 150- and 300mg 
tablets, and its standard dosing is 300mg orally twice daily. Studies have been 
conducted with regards to maraviroc interactions with other agents and a summary is 
provided below: 
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 Maraviroc dose is to be reduced to 150mg twice daily if concomitantly administered 
with CYP3A inhibitors, for example ketoconazole, itraconazole, clarithromycin, 
telithromycin and protease inhibitors- except tipranavir. 
 Maraviroc dose should be increased to 600mg twice daily in the presence of CYP3A 
inducers for example efavirenz, rifampicin, carbamazepine, Phenobarbital and 
phenytoin.  
Since approximately 25% of total maraviroc is cleared via the kidneys, it should be used 
in caution in patients with creatinine clearance of <50ml/min, particularly when co-
administered with a CYP3A inhibitor as maraviroc may accumulate to toxic levels. 
Maraviroc should also be used with caution in patients with hepatic insufficiency as its 
metabolism may be impaired, leading to accumulation and potential adverse effects. 
(Yost, Pasquale and Sahloff, 2009) 
Vicriviroc is another CCR5 inhibitor under development that is currently in phase III 
clinical trials. 
2.3.7 Integrase Inhibitors 
Integrase inhibitors are a new class of ARVs with raltegravir as the first in this class to 
be approved by the FDA. Raltegravir was approved in October 2007 for use in the 
treatment of HIV in treatment-experienced patients and patients who have ongoing viral 
replication while receiving ART. Studies have been conducted in treatment-naïve 
patients, and raltegravir was approved as initial treatment in July 2009. (Coffey, 2010) 
Raltegravir inhibits the catalytic activity of HIV-1 integrase, an enzyme required for viral 
replication. Inhibition of integrase prevents incorporation of viral DNA into the host cell 
genome thus preventing the formation of the HIV-1 provirus. The provirus directs the 
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production of progeny virus, therefore inhibiting integration prevents propagation of the 
viral infection. (Stanic and Grana, 2009)  
Raltegravir is formulated in 400mg tablets and administered orally (400mg) twice daily 
without regard for food. Raltegravir is not a substrate of the cytochrome P450 enzymes, 
and has no significant drug interactions via this route. However, raltegravir is 
metabolized by a uridine diphosphate glucoronosyltransferase (UGT) 1A1-mediated 
glucoronidation pathway.  Thus drug-drug interactions with inducers and inhibitors of 
this system may occur with co-administration with raltegravir. For instance, rifampicin 
which induces UGT1A1 significantly reduces plasma concentrations of ralgetravir; 
therefore the dose of raltegravir should be increased to 800mg twice daily when co-
administered with rifampicin. The impact of other inducers of drug metabolizing 
enzymes such as phenytoin and phenobarbital on UGT1A1 is unknown. Co-
administration with inhibitors of UGT1A1 may increase plasma levels of raltegravir. 
(Merck & Co., 2007) 
While mild to moderate hepatic impairment does not require dosage adjustment, the 
effect of severe hepatic impairment on the pharmacokinetics of raltegravir has not been 
studied. However, since raltegravir is primarily eliminated by glucoronidation in the liver, 
caution should be used in these patients. Renal clearance of raltegravir is a minor 
pathway and studies have shown that no dosage adjustments are needed in renal 
impairment. (Merck & Co., 2007) 
The long term effects of raltegravir are unknown although it currently appears to be well 
tolerated (Graziano and Djuricich, 2009). The most common adverse effects of 
raltegravir include diarrhea, nausea, headache and fever. Less common adverse effects 
include abdominal pain, vomiting, fatigue, weakness, dizziness, genital herpes, herpes 
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zoster, renal failure and lipodystrophy. Other adverse effects observed included new 
and recurrent cancer although the relationship to raltegravir is unclear and in these 
cases other risk factors such as neutropenia, thrombocytopenia, and elevated liver 
enzymes were involved. Raltegravir may also cause an increase in creatine kinase, 
resulting in unexplained muscle pain, tenderness or weakness. Hypersensitivity 
reactions, increases in ALT, AST and total bilirubin, anaemia, neutropenia and gastritis 
may also occur. (Merck & Co., 2007) 
Post-approval of raltegravir, psychiatric disorders like anxiety and depression- including 
suicidal ideation and behavior, paranoia (particularly in patients with a pre-existing 
history of psychiatric illness), rash and stevens-johnson syndrome have been reported 
(Graziano and Djuricich, 2009).  
Elvitegravir is another integrase inhibitor under development, currently in phase III 
clinical trials (Stanic and Grana, 2009).    
2.4 ARV Combinations 
As stated in Chapter 1, ARVs are administered in combination in order to achieve 
maximal viral suppression, reduce individual ARV doses (and hence reduce toxicity) 
and prevent or delay development of resistance. The selection of drugs should be 
based on existing data on effectiveness, resistance profile and on the individual patient 
situation, taking into account the adverse effect profile, potential interactions, and 
additive toxicities in each patient. A HAART regimen usually consists of three ARV 
drugs from different classes.  
Factors to be considered when selecting initial regimens for treatment naïve patients 
include: 
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 Comorbidity such as hepatitis B, C, TB, psychiatric disease, cardiovascular disease, 
renal disease, chemical dependency, liver disease, pregnancy and other significant 
conditions 
 Patient adherence potential 
 Convenience - considering pill burden, dosing frequency, dosage forms, refrigeration 
requirements, food and fluid considerations 
 Potential adverse effects – for example, women, particularly those with body mass 
index > 28 are at a higher risk of developing lactic acidosis and therefore d4T is 
contraindicated in these patients 
 Potential drug-drug interactions with concurrently administered drugs, self medicated 
or prescribed 
 Pregnancy potential - for example, women of a child bearing age or who do not have 
effective and consistent contraception should not receive efavirenz due to its 
teratogenicity 
 Genotypic resistance testing results - showing resistance patterns of the particular 
patient’s HIV strain 
 Gender – In certain cases women are more likely to develop adverse effects than 
men, for instance with regards to lactic acidosis, the female gender is a risk factor 
 Pre-treatment cd4 cell count- low cd4 counts predispose patients to more adverse 
effects discussed further below. On the other hand, NVP induced acute hepatitis is 
usually seen in patients with higher cd4 counts 
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 If ABC is considered, HLA B* 5701 is tested; patients who test positive are likely to 
develop a hypersensitivity reaction with ABC and hence an alternative NRTI should 
be considered. (Department of Health and Human Services, 2008) 
The following NRTIs combinations should be avoided; 
 AZT and d4T – due to antagonistic effect  
 d4T and ddC – due to similar toxicity profiles 
 3TC and FTC – as they are used interchangeably 
 TDF and ddI combined with an NNRTI – associated with high rates of early 
virological failure. (WHO, 2010) 
Hence selection of a HAART regimen should be individualized for each patient taking 
into consideration their circumstances. The ARV regimens available in South Africa are 
tabulated below: 
Table 2.5 Currently available ARV regimens in the South African public sector 
(Adapted from: Department of Health, 2010) 
Regimen Drugs Comments 
First Line 
 
TDF+3TC/FTC+EFV/NVP  EFV for TB co-infected patients 
 NVP for women of child bearing 
age not on reliable contraception 
d4T+3TC+EFV/NVP  If well tolerated with no adverse 
effects patients to remain on 
treatment. Substitute with TDF in 
high risk patients (high BMI, older, 
female, receiving TB treatment) 
AZT+3TC+EFV/NVP  In cases where TDF is 
contraindicated (renal insufficiency) 
Second Line 
 
TDF+3TC/FTC+  LPV/r  For patients failing on d4T or AZT 
based regimens 
AZT+3TC+LPV/r  For patients failing on TDF based 
first line regimens 
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In the USA, the ARV regimens differ from those used in South Africa, most notably d4T 
is not commonly used as it is considered a toxic drug. Currently preferred regimens are 
made of two NRTIs and an NNRTI or a ritonavir boosted PI. For the NNRTI based 
regimens, EFV is the preferred NNRTI, except in the first trimester of pregnancy or in 
sexually active women of childbearing age with ineffective or inconsistent contraception. 
NVP may be used as the alternative NNRTI in females with a pre-treatment CD4 cell 
count < 250 cells/mm3 and males <400 cells/mm3, due to higher risk of these patients to 
develop acute hepatitis (Department of Health and Human Services, 2008).  
The USA has a wider variety of ARVs when compared with South Africa, due to, 
amongst other reasons, availability of resources. The table below shows the regimens 
used in the USA as preferred (first line) and alternative (second line) treatment (the 
appropriate regimens are obtained by selecting one component from column A and one 
from column B). 
 
Table 2.6 ARV regimens used in the U.S.A as first and second line treatment 
(Adapted from: Department of Health and Human Services, 2008) 
                           Column A Column B 
 NNRTI PI NRTI 
Preferred  EFV -ATZ+RTV (od) 
-FPV+RTV(bd) 
-DRV+RTV(od) 
-LPV/RTV(od or bd) 
TDF+FTC 
Alternative NVP -ATZ (unboosted, od) 
-FPV(unboosted, bd) 
-FPV+RTV(od) 
-SQV+RTV(bd) 
-ABC+3TC 
-ddI+3TC 
-AZT+3TC 
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Recent studies have indicated the need for a salvage therapy for patients responding 
poorly to second line therapy. This salvage therapy, a third line regimen, should include 
drugs such as integrase inhibitors, newer generation NNRTIs and newer PIs. 
Randomized controlled studies have been conducted in developed countries for this 
suggested third line regimen and the results have been favourable. Raltegravir, 
etravirine and ritonavir-boosted darunavir is one such combination under review as a 
third line regimen. (WHO, 2010) 
2.5 Adverse Effects Associated with ARVs 
A drug reaction includes all adverse events linked to drug administration, despite the 
cause (Riedl and Casillas, 2003). It has been defined as “a noxious or undesired effect 
to an organism that occurs at doses of a drug used for prophylaxis, diagnosis or 
treatment” (Couper and Mehta, 2002). It may be indicated by change such as death, 
altered food or water consumption, changes in body and organ weights, enzyme levels, 
or visible illness. A drug effect is termed as adverse if it results in functional or 
anatomical damage, or if it causes change that is irreversible in the homeostasis of the 
organism, or increases the vulnerability of the organism to other chemical or biological 
stresses. When these effects are considered to be secondary to a main or therapeutic 
effect, they are termed side-effects (Couper and Mehta, 2002).  
Drug adverse effects are classified as either Type A or Type B. Type A reactions 
account for about 70-80% of drug adverse reactions and are due to drug factors, 
including the pharmacological action of the drug or its active metabolites. Unlike Type A 
reactions, Type B drug reactions are due to patient factors and not drug characteristics. 
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Type B reactions include idiosyncratic reactions, allergic or immunologic reactions and 
carcinogenic or teratogenic effects. (Eisenhauer, 2002) 
Adverse effects have been reported with all ARVs and are among the most common 
reasons for switching or discontinuation of therapy and for medication non-adherence 
(Department of Health and Human Services, 2008). The adverse effects experienced by 
HIV and AIDS patients after the initiation of HAART are often non-specific as they may 
be due to patient factors, disease or treatment characteristics.  
HIV infection is characterized by a wide range of symptoms including pain, fatigue, 
dyspnoea, cough and sleep disorders, which often present significant challenges in the 
lives of the infected patients. Adverse effects of ARVs may at times resemble the 
symptoms of HIV disease and lead to impaired quality of life and level of functioning. 
Consequently, it is essential to establish that the symptoms experienced by the patients 
are in fact related to the ARV therapy, before deciding on the appropriate management 
of the symptoms. This requires HCPs to have optimal understanding of HAART 
regimens and their associated complications. (Schiller, 2005)  
Ideally ARVs should be selective towards HIV, aiming to hinder different targets in its 
lifecycle and having minimal effect on the normal human cells. This however, is not the 
case and the result is that these drugs are associated with numerous adverse effects 
that have both short-term and long-term consequences (Johnson et al., 2005).  
Since ARV drugs are taken in combination, deciding what contribution individual drugs 
have to symptoms that are manifest, as well as deciding what symptoms are due to HIV 
disease, or are completely unrelated either to the drugs or to the illness, is a challenge 
(Department of Health, 2005). Adverse effects associated with ARVs are classified as 
short term (such as diarrhea, nausea, vomiting) and long term (such as fat 
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redistribution) (Stanic and Grana, 2009). The risk of developing specific adverse effects 
varies with different drugs, drug classes and patients (Montessori et al., 2004).  
Some adverse effects of ARVs are summarized in the figure below. In some cases, only 
a certain drug causes a particular adverse effect and these are shown in parentheses 
below.  
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Figure 2.3 Adverse effects of ARVS 
(Source: Montessori et al., 2004, p.232) 
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2.5.1 ARV class adverse effects 
Each ARV drug is associated with its own specific adverse effects that may be unique to 
that particular ARV or common in the ARV class in which the drug falls (Montessori et 
al., 2004).  Several adverse effects are common to many of the antiretroviral drugs, but 
these effects vary in severity for each individual drug. The class specific adverse effects 
of the different ARV classes are tabulated below. 
 
Table 2.7 ARV class adverse effects 
(Adapted from: Stanic and Grana, 2009, p.53) 
ARV drug class Associated adverse effects 
NRTIs  GI Intolerance 
 Peripheral neuropathy 
 Lactic acidosis 
 Pancreatitis 
 Bone marrow suppression 
 Lipoatrophy (especially d4T and AZT) 
 Renal toxicity (especially with TDF) 
NNRTIs  Rash 
 Liver toxicity 
 Dyslipidemias  
PIs  GI intolerance 
 Metabolic disorders (including fat maldistribution, insulin 
resistance, dyslipidemia) 
FIs  Injection site reactions 
 GI intolerance 
 Respiratory infections 
 Myalgias 
CCR5 inhibitors  Liver toxicity 
 GI intolerance 
Integrase 
inhibitors 
 Nausea 
 Diarrhea 
 Headache 
 Pyrexia  
 
 37 
 
2.5.2 Specific ARV adverse effects  
The following table indicates the adverse effects commonly associated with specific 
NRTIs, NNRTIs and PIs.  
 
Table 2.8 Adverse effects associated with specific ARVs 
(Department of Health and Human Services, 2008) 
ARV 
Class 
ARV drug Common adverse effects Comments 
 
 
 
NRTIs 
 
Zidovudine  Anemia, neutropenia 
 Fatigue, insomnia, 
malaise, headache 
 Nausea, vomiting 
 Myalgia, myopathy 
 Hyperpigmentation of 
skin and nail beds 
 Fatigue, nausea, 
headache, and myalgia 
usually resolve 2-4 weeks 
after initiation 
 Granulocytopenia has 
also been reported 
Didanosine  Pancreatitis 
 Lactic acidosis 
 Peripheral neuropathy 
 Nausea, diarrhea 
 Combination with d4T 
should be avoided 
 
Lamivudine  Headache 
 Dry mouth 
 GIT effects (including 
mild abdominal 
discomfort and nausea) 
 Generally well tolerated 
 
Emtricitabine  Headache, nausea, 
insomnia 
 Hyperpigmentation of 
palms and soles (most 
frequently seen in dark-
skinned people) 
 In hepatitis B co-infection, 
hepatitis may flare upon 
discontinuation of FTC 
Stavudine  Peripheral neuropathy 
 Pancreatitis 
 Dyslipidemia 
 Diarrhea 
 Lactic acidosis 
 Increased risk of 
peripheral neuropathy 
and lactic acidosis when 
combined with ddI 
 
Abacavir  Hypersensitivity 
syndrome; rash occurs 
in about half of cases 
 Rash 
 Headache, nausea, 
vomiting, diarrhea 
 Counsel patients on signs 
of hypersensitivity 
syndrome 
 In case of hypersensitivity 
syndrome, ABC must be 
discontinued permanently 
Tenofovir  Flatulence, nausea,  In patients with HIV and 
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ARV 
Class 
ARV drug Common adverse effects Comments 
diarrhea, abdominal 
discomfort 
 Asthenia 
 Acute renal 
insufficiency, Fanconi 
syndrome 
 Chronic renal 
insufficiency  
hepatitis B co-infection, 
hepatitis may flare upon 
discontinuation of 
tenofovir. 
 Adjust dosage for renal 
insufficiency or failure.  
 
 
 
NNRTIs 
 
Nevirapine  Rash 
 Elevations in liver 
function tests, hepatitis, 
liver failure  
 Initial dose of 200 mg per 
day for first 14 days, then 
200 mg twice daily, 
decreases frequency of 
rash 
 Should not be initiated in 
women with CD4 counts 
of >250 cells/ml or men 
with CD4 counts of >400 
cells/ml 
 Monitor liver tests closely 
for the first 16 weeks of 
treatment  
Efavirenz  Elevations in liver 
function tests 
 Abnormal/vivid dreams, 
somnolence, 
drowsiness, dizziness, 
confusion 
 Hyperlipidemia 
 
 CNS symptoms are 
common; severity usually 
decreases within 2-4 
weeks 
 Contraindicated during 
pregnancy and for use by 
women who may become 
pregnant (teratogenic) 
Delavirdine  Fatigue 
 Elevations in liver 
function tests, hepatitis 
 Nausea, diarrhea 
 Seldom used as it is less 
potent than other NNRTIs 
 
 
 
 
PIs 
 
Amprenavir  Diarrhea, nausea, 
vomiting 
 Elevations in liver 
function tests 
 Rash  
 May cause rash in 
patients sensitive to or 
intolerant of sulfonamides 
Atazanavir  Unconjugated 
hyperbilirubinaemia 
 Dyslipidaemia (low 
potential) 
 
Darunavir  Diarrhea 
 Nausea 
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ARV 
Class 
ARV drug Common adverse effects Comments 
 Rash 
 Dyslipidemias 
 Insulin resistance 
(moderate potential) 
Fosamprenavir  Diarrhoea 
 Nausea 
 Vomiting 
 Abdominal cramps 
 Headache 
 Fatigue 
 Increased thirst or 
urination, mood changes 
and peripheral 
neuropathy are rare but 
possible adverse effects 
Indinavir  Nephrolithiasis, flank 
pain 
 Hyperbilirubinemia 
 Elevations in liver 
function tests 
 Alopecia, dry skin, 
ingrown nails 
 Insomnia 
 Taste perversion  
 Patients should drink at 
least 1.5 liters of fluid 
daily to reduce risk of 
nephrolithias 
 
Lopinavir/ritonavir  Diarrhoea, nausea, 
vomiting 
 Dyslipidemia 
 Elevations in liver 
function tests 
 Taste perversion  
 Oral solution contains 
42% alcohol; avoid 
combining with 
metronidazole or 
disulfiram  
Nelfinavir  Diarrhoea 
 Nausea, vomiting 
 Elevations in liver 
function tests 
 Fatigue  
 Diarrhoea is very 
common; usually can be 
managed with 
antidiarrheals such as 
loperamide and 
diphenoxylate/atropine.  
Ritonavir  Nausea, vomiting, 
diarrhoea, abdominal 
pain 
 Elevations in liver 
function tests 
 Fatigue 
 Circumoral or 
peripheral numbness 
 Taste perversion 
 Hyperuricemia  
 RTV significant 
interactions with many 
other medications.  
Saquinavir  Nausea, vomiting, 
diarrhoea 
 Elevations in liver 
 Must be used in 
combination with low-
dose ritonavir.  
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ARV 
Class 
ARV drug Common adverse effects Comments 
function tests 
 Headache 
 Oral ulcerations  
 
2.5.2.1 ARV metabolic disorders 
Metabolic disorders refer to a group of adverse effects that have been linked to long 
term use of ARVs. They include dyslipidaemias, lipodystrophy, diabetes mellitus, insulin 
resistance and decreased bone mineral density. Individual metabolic disorders are 
further discussed below. (Montessori et al., 2004) 
 
Table 2.9 Features of ARV-mediated metabolic syndrome 
(Adapted from: Montessori et al., 2004, p.234) 
Condition Observation/ test 
Clinical 
Central fat accumulation Intra-abdominal, dorsocervical spine, breast 
hypertrophy, lipomas 
Peripheral lipoatrophy Face, legs, arms, buttocks 
Laboratory 
Dyslipidaemia Hypertriglyceridaemia, low HDL cholesterol, 
high LDL cholesterol  
Diabetes High fasting blood glucose and HbA1c levels 
Insulin resistance Increased insulin and c-peptide levels 
Osteoporosis Bone densitometry 
Note: HDL = high density lipoprotein, LDL = low density lipoprotein, HbA1c = 
haemoglobin A1c (glycosylated haemoglobin) 
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2.5.2.1.1 Lipodystrophy 
Lipodystrophy, first described in 1998, is also known as fat redistribution and it refers to 
a disorder that the body uses and stores fat (Montessori et al., 2004). The main clinical 
features of lipodystrophy are fat wasting/ peripheral fat loss, also known as lipoatrophy 
and central fat accumulation, also known as hyperadiposity or lipohypertrophy.  
Lipodystrophy is primarily caused by PIs although d4T and AZT may also cause 
lipodystrophy (Department of Health and Human Services, 2008). Montessori and 
colleagues (2004) report that the overall prevalence of at least one physical abnormality 
associated with lipodystrophy is estimated to be about 50% after more than a year of 
ARV therapy, while Shibuyama and co-workers (2006) suggest that lipodystrophy is 
reported in 20% to 80% of patients receiving HAART. 
Lipoatrophy usually occurs in the face (resulting in sunken cheeks, temples and eyes), 
arms and legs (where it may result in veins becoming more visible) and the buttocks. 
Lipohypertrophy is usually observed in the dorso-cervical region (buffalo hump), the 
abdominal region (crixivan potbelly) and in the breasts of both men and women 
(gynaecomastia). Lipodystrophy generally develops steadily, months after initiation of 
therapy. Some clinical features of lipodystrophy are illustrated in the figure below. 
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Figure 2.4 Clinical features of lipodystrophy 
(Source: Carr and Cooper, 2000, p.1426) 
 
The pathogenesis of lipodystrophy is poorly understood, but the cause is most likely to 
be due to several factors, with combined endocrine and metabolic abnormalities having 
effects on fat distribution (Montessori et al., 2004). Risk factors for developing 
lipodystrophy include; 
 increasing age 
 white ethnicity 
 obesity  
 advanced HIV and AIDS disease 
 low baseline body mass index. (Department of Health and Human Services, 2008) 
Lipodystrophy diagnosis is based on physical examination of fat changes to the body, 
including measurements of changes in circumference of the arms, thighs, waist, hips 
and neck. Lipodystrophy causes significant cosmetic concerns to patients and ultimately 
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threatens the privacy of their HIV positive status. Inability to effectively manage 
lipodystrophy threatens the effectiveness of ART as patients may discontinue treatment. 
Patients ought to be counselled extensively regarding these disfiguring effects so that 
they are aware of their possible development and to avoid poor adherence because of 
the associated abnormality.  
Non-pharmacological methods of managing lipodystrophy include exercise, low fat diets 
and smoking cessation (Regensberg and Makiwane, 2009). In severe cases patients 
may consider surgery or growth hormone therapy (Department of Health and Human 
Services, 2008). The disadvantage of using growth hormone therapy is that it decreases 
fat accumulation, but this effect is reversed on discontinuation and this method of 
treatment is expensive. The FDA approved the injectable drug Sculptra® (poly-L-lactic 
acid) to treat facial wasting in August 2004. Sculptra® is made from similar material to 
that used in dissolvable sutures and is used to fill sunken cheeks, eyes and other areas 
affected by lipoatrophy. The long term safety of Sculptra® needs to be monitored, as 
recommended by the FDA. (Gold, 2010)  
Lipoatrophy may be reversed to some extent, by switching to TDF or ABC, which are 
not associated with lipodystrophy. However, although switching to other agents may 
slow or stop progression, it may not fully reverse effects (Department of Health and 
Human Services, 2008). In patients with risk factors for lipodystrophy (stated above), 
avoidance of thymidine nucleosides such as AZT and d4T may help prevent 
lipoatrophy. 
Montessori and co-workers (2004) suggest that an increase in visceral and abdominal 
fat as seen with lipodystrophy has been linked to an increased risk for glucose 
intolerance. It is therefore recommended that patients with fat redistribution be screened 
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for glucose (diabetes mellitus and glucose intolerance) and lipid metabolism (high levels 
of triglycerides, total cholesterol, LDL cholesterol, low HDL cholesterol) disorders. 
Clinicians should monitor patients closely and recommend regular exercise, proper 
nutrition and provide psychological support where necessary (Department of Health, 
2008). 
2.5.2.1.2 Dyslipidaemia 
Serum lipid changes that occur with HAART may be of concern due to the potential for 
complications of premature atherosclerosis and coronary artery disease. Both NNRTIs 
and PIs have been shown to increase triglyceride and total cholesterol levels 
(Shibuyama et al., 2006). However, NNRTIs cause dyslipidaemias to a lesser extent 
than PIs (Capili and Anastasi, 2006). Dyslipidaemias, associated with increased risk of 
cardiovascular disease, occur in approximately 70% of HIV infected patients receiving 
ARV treatment (Montessori et al., 2004). Severe triglyceridemia, low high density 
lipoprotein (HDL) cholesterol and high low density lipoprotein (LDL) cholesterol are the 
clinical features of dyslipidaemia.  
According to Shibuyama and co-workers (2006), HAART regimens containing PIs often 
increase triglycerides, total cholesterol and LDL cholesterol but their effects on HDL 
cholesterol is unclear. The proposed mechanism by which PI-induced dyslipidaemias 
occurs is that they “bind to or interfere with LDL receptor-related protein and 
cytoplasmic retinoic acid binding protein type 1, both of which are lipid regulatory 
proteins involved in fat storage and lipid release” (Montessori et al., 2004).  
Regimens containing PIs have been found to increase total cholesterol and LDL 
cholesterol by about of 30mg/dL. Ritonavir has the highest rate of dyslipidaemias while 
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fosamprenavir and saquinavir have lower rates and atazanavir typically does not result 
into significant dyslipidaemias. (Shibuyama et al., 2006) 
Patients should be assessed for risk factors such as familial hyperlipidaemia, diabetes 
mellitus, Cushing’s disease, obesity, hypothyroidism, hypogonadism, and hepatic and 
renal disease which may contribute in dyslipidaemias. Drugs such as beta blockers, 
thiazide diuretics, corticosteroids, thyroid hormones, androgens and estrogens may also 
affect serum lipid levels and as such, use of these medications by patients, should be 
established. (Capili and Anastasi, 2006)  
Although currently proposed treatments for dyslipidaemias in HIV are not always 
effective in lowering serum lipids to acceptable levels and may cause a concern of drug 
interactions with ARVs, the following are suggested for management; 
 Diet and Exercise: Diet has been shown to be useful in lowering total cholesterol, 
LDL cholesterol and triglycerides and is the first line approach to managing 
dyslipidaemias. In a randomized study examining the effects of diet and exercise 
versus the use of atorvastatin in 44 HIV infected patients with hypertriglyceridaemia, 
it was revealed that diet and exercise lowered total cholesterol by 11% and 
triglycerides by 21% while atorvastatin lowered total cholesterol by 19% and 
triglycerides by 21% (Capili and Anastasi, 2006).    
 Medication: 3-hydroxy-methylglutaryl coenzyme A reductase inhibitors (statins) such 
as pravastatin, fluvastatin and lovastatin are recommended for the management of 
elevated LDL cholesterol while fibrates such as gemfibrozil and fenofibrate are 
recommended for management of hypertriglyceridaemia (Capili and Anastasi, 2006). 
Pravastatin is preferred due to its low potential for drug interactions with PIs as it is 
not extensively metabolized by the CYP450 system. Statins and fibrates may be 
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combined if the serum lipid level is not sufficiently lowered by either agent alone 
(Shibuyama et al., 2006). 
 Switching therapies: PIs may be substituted with either an NRTI or NNRTI or even 
with “less metabolically active” PIs in order to lower elevated lipids. This option 
however may expose the patients to the possibility of new adverse effects as well as 
limit their future treatment options (Capili and Anastasi, 2006).  
 Omega 3: Omega 3 fatty acids, for example in fish and fish oil, have been shown to 
lower triglycerides. These fatty acids act by inhibiting the synthesis of very low-
density lipoproteins (VLDL) and triglycerides (Capili and Anastasi, 2006). 
2.5.2.1.3 Hyperglycaemia 
According to Shibuyama and co-workers (2006), the development of insulin resistance 
is common with PI containing HAART regimens but, not all PIs are equally implicated. 
Insulin resistance has been reported in 30% to 90% of patients receiving PI-based 
HAART, with true diabetes occurring in only 1% to 11% patients. Insulin resistance may 
also be a symptom associated with HIV infection, due to the effects of the virus on the 
pancreatic beta cells and hence insulin secretion (Montessori et al., 2004). 
Blood glucose changes are usually measurable about two to three months after 
initiation of ART. Clinical monitoring of patients’ fasting blood glucose levels at baseline 
and at 3 to 6 months intervals, when receiving PI-based HAART is recommended. 
Random glucose, fasting blood glucose and haemoglobin A1c measurements may not 
be reliable methods to measure insulin resistance because of compensatory increases 
in insulin. Other methods of testing include measuring fasting insulin, C-peptide and oral 
glucose tolerance for patients with borderline fasting glucose. (Shibuyama et al., 2006) 
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Management of most cases of hyperglycaemia is through diet and exercise. Shibuyama 
and colleagues (2006) suggest that diet should contain 50-60% carbohydrates, 10-20% 
proteins, <30% fat, <100mg cholesterol daily and <10% total calories from saturated fat. 
For cases which fail to respond to diet and exercise and triglyceride levels remain 
greater than 10mmol/L or total cholesterol greater than 7,5 mmol/L, drug therapy is 
warranted (Regensberg and Makiwane, 2009). In these cases, agents used to improve 
insulin resistance include; 
 Sulfonylureas 
 Insulin sensitizing drugs such as metformin and thiazolidinediones 
The insulin sensitizing agents may also reduce visceral fat accumulation and possibly 
result in a reduction of cardiovascular risk.    
2.5.2.1.4 Osteonecrosis, osteopenia and osteoporosis 
Osteonecrosis has been reported in both adults and children receiving HAART and it 
results in apoptosis of several components of the bone such as fat marrow and 
mineralized tissue (Montessori et al., 2004). Osteonecrosis usually results from poor 
circulation and mostly affects the femoral and humeral heads (Regensberg and 
Makiwane, 2009). In children, avascular necrosis of the hips is referred to as “Legg-
Calvé-Perthes disease” (Dybul et al., 2002). Osteopenia refers to a moderate decrease 
in bone mineral density while osteoporosis is a severe decrease in bone mineral 
density.  
Before the introduction of HAART, osteoporosis was thought to be as result of either 
poor nutrition or increased cytokines due to infection. Although the exact 
pathophysiology is unclear, the following possibilities have been proposed; 
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 Osteoporosis occurring in conjunction with ARV-associated lactic acidosis, where 
the phosphate may act as a buffer 
 PIs  inhibition of osteoblast activity while stimulating osteoclast activity thereby 
inhibiting new bone formation 
 Inhibition of CYP450 enzymes that mediate vitamin D activation. (Montessori et al., 
2004) 
The risk factors for osteoporosis include HIV infection, alcohol abuse, 
haemoglobinopathies, corticosteroid therapy, hyperlipidemia and certain 
hypercoagulability states (Dybul et al., 2002). Patients on HAART, with additional risk 
factors for osteoporosis, need to be considered for evaluation. The diagnosis of 
osteoporosis is achieved by measuring bone mineral density usually using dual-energy 
x-ray absorptiometry (DEXA) (Montessori et al., 2004).  
Osteonecrosis is a rare condition but it can lead to joint replacement, therefore patients 
who present with constant knee, hip or shoulder pain, particularly when there is no 
trauma should be evaluated for osteonecrosis (Dybul et al., 2002). 
Patients suspected to have osteoporosis need to be referred to a specialist for further 
investigation. Treatment of osteoporosis includes the following; 
 Vitamin D and calcium supplementation 
 Weight bearing exercise 
 Hormone replacement therapy including estrogen, particularly for postmenopausal 
women on HAART 
 Biphosphonates, raloxifene and calcitonin therapy in severe cases such as fractures. 
(Montessori et al., 2004) 
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2.5.2.2 ARV mitochondrial toxicity 
The main role of mitochondria is the production of energy as adenosine triphosphate 
(ATP) via oxidative phosphorylation. Mitochondria also play a regulatory function in 
cellular survival (White, 2001) and glucose and fat metabolism (Montaner et al., 2004). 
NRTIs and NtRTIs are phosphorylated intracellularly before they are incorporated into 
the viral DNA chain by viral reverse transciptase enzyme, preventing DNA elongation 
and viral replication. DNA polymerase γ (an enzyme involved in the replication of 
mitochondrial DNA) resembles HIV reverse transcriptase and therefore NRTIs may also 
inhibit it, leading to interference with mitochondrial DNA formation. (Montaner et al., 
2004) 
Mitochondrial toxicity is initially characterized by a reduction in energy production with 
an accompanying increase in lactate production (Montaner et al., 2004). The NRTIs are 
associated with mitochondrial toxicities ranging from myopathy, neuropathy, heptic 
steatosis, pancreatitis and lactic acidosis. Lactic acidosis and pancreatitis are the most 
serious (Carr and Cooper, 2000). Individual mitochondrial toxicities are discussed 
below. 
2.5.2.2.1 Lactic acidosis 
Hyperlactataemia and lactic acidosis are conditions characterised by an increase in 
venous lactate levels. Due to the life threatening nature of lactic acidosis it is important 
for patients and HCPs to be aware of the symptoms and the management thereof 
(Montessori et al., 2004).  Lactic acidosis may present alone or with hepatic steatosis 
(accumulation of triglycerides resulting from the inhibition of fatty acid oxidation) (White, 
2001).  
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Lactic acidosis onset may be abrupt or gradual with initial non-specific symptoms such 
as;  
 Gastrointestinal disorders such as nausea, vomiting and abdominal pain 
 Muscular abnormality  
 Weight loss 
 Unexplained fatigue 
 Enlarged and tender liver 
 Cold or blue hands 
 Cardiac dysrhythmias. (Department of Health and Human Services, 2008) 
Other severe symptoms may include; 
 Hypotension 
 Kussmaul’s breathing 
 Loss of consciousness. (Regensberg and Makiwane, 2009) 
Lactic acidosis has been reported with AZT, ddI and d4T especially in patients on 
therapy for more than 6 months. These NRTIs interfere with the functionality of 
mitochondria. The mechanism of lactic acidosis is shown in Figure 2.9 below. The 
dashed lines in the figure represent the processes occurring in the mitochondria that 
require normal mitochondrial function. These steps are impaired by NRTIs resulting in 
accumulation of pyruvate and NADH (the reduced form of nicotinamide adenine 
dinucleotide- NAD) which further enhances the conversion of pyruvate into lactate, 
leading to lactic acidosis.  
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AcetylCoA= acetylcoenzyme A 
ATP= adenosine triphosphate, 
LDH= lactate dehydrogenase 
Figure 2.5 The mechanism of NRTI-associated lactic acidosis 
(Source: Montessori et al., 2004, p.233) 
 
Confirmatory lactic acidosis laboratory tests indicate elevated random serum lactate 
levels (> 5mmol/L), elevated lactate-pyruvate levels, increased creatine phosphokinase, 
decreased serum pH and/or low bicarbonate concentration (<20mmol/L) (Shibuyama et 
al., 2006). The anion gap (which represents the concentration of all unmeasured anions 
in the plasma) may also be elevated in the case of lactic acidosis, that is, [Na] – ([Cl] + 
[HCO3]) >10 mmol/l (Montessori et al., 2004). Measuring peripheral venous lactate 
levels may not be useful in distinguishing patients at risk for severe lactic acidosis and 
those suffering from chronic hyperlactatemia (elevated venous lactate). Therefore, 
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measuring the ratio of mitochondrial DNA to nuclear DNA may be a more sensitive and 
reliable method of evaluating patients at risk of severe lactic acidosis (Montessori et al., 
2004).  
The risk factors for lactic acidosis are not fully understood but may include the following; 
 HIV infection, as it usually results in mitochondrial necrosis even in the absence 
of ARV therapy 
 Combination of ddI and hydroxyurea or ribavirin  
 d4T, AZT, ddI use (especially d4T and combination of d4T and ddI )  
 Long duration of NRTI use (> 6 months)  
 Excellent adherence to therapy 
 Gender (females more susceptible)  
 Obesity and nutritional deficiency of cofactors and vitamins essential for 
mitochondrial function, such as thiamine and riboflavin (Montessori et al., 2004) 
 Pregnancy (especially with use of d4T and ddI)  
 Chronic renal failure 
 High body mass index (Department of Health and Human Service, 2008). 
Management of lactic acidosis is largely supportive. According to the Department of 
Health and Human Service (2008), lactic acidosis should be managed as follows; 
 Lactate 2-5 mmol/L: monitor patients monthly and look out for clinical symptoms 
 Lactate 5-10 mmol/L (symptomatic): Stop all ART and refer the patient immediately. 
Exclude other causes of raised lactate such as;  
o sepsis 
o renal failure 
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o diabetic ketoacidosis 
 Lactate >10 mmol/L: Stop all antiretroviral drugs immediately and seek urgent expert 
help (30% mortality reported) 
 Metabolic acidosis with raised lactate: Stop all ART and seek urgent expert help 
 Supportive care including,  
o respiratory support 
o monitoring cardiac function 
o intravenous fluid therapy  
o administering agents such as riboflavin (vitamin B2), thiamine (vitamin B1), co-
enzyme Q, -10 carnitine, or vitamins C, E and K  
 Other measures attempted include plasmapheresis, high-dose corticosteroid and 
intravenous immunoglobulin.   
Patient recovery usually takes months and may range from complete recovery to 
substantial residual deficits. The symptoms may be irreversible in various patients while 
lactic acidosis may be fatal in others. The patient should generally not be re-challenged 
with the offending agent even after recovery. If the patients bicarbonate level is less 
than 15 mmol/L, NRTIs may not be restarted, instead PIs should be introduced. Instead, 
NRTIs with fewer propensities of mitochondrial toxicities such as ABC, TDF, 3TC, FTC, 
should be used. However, these may not be introduced until the patient’s lactate level 
returns to normal. Close monitoring of the patient’s serum bicarbonate or lactate after 
restarting NRTIs is recommended (Department of Health and Human Services, 2008). 
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2.5.2.2.2 Hepatotoxicity 
Hepatotoxicity generally refers to liver damage which encompasses several conditions 
namely;  
 Hepatitis (inflammation of the liver) 
 Hepatic necrosis (death of the liver cells) 
 Hepatic steatosis (accumulation of fat in the liver). (Department of Health and 
Human Services, 2008) 
Hepatotoxicity may also lead to “hepatic tissue eosinophilia, hepatoparenchymal and 
periportal infiltration with lymphocytes and plasma cells” (Shibuyama et al., 2006). 
Most ARV agents are associated with hepatotoxicity and transaminitis. NRTIs, 
particularly d4T and ddI may cause hepatic steatosis, generally after 6 months of 
therapy. NNRTIs, particularly NVP and EFV may cause hepatitis after 2-3 months of 
therapy which is sometimes related to hypersensitivity reactions, for example NVP 
associated rash and fever. The mechanism by which PIs cause hepatitis is unknown 
although the rate of hepatotoxicity is about twice as high in patients with hepatitis B or C 
co-infection (Montessori et al., 2004). Conversely, it has been suggested that long term 
use of PIs may have a beneficial effect on the progression of liver fibrosis in patients co-
infected with hepatitis C.  Certain case of hepatitis are idiosyncratic while others arise 
from immune reconstitution where by the restored immune system recognizes previous 
infection in chronic carriers of hepatitis B or C (Carr and Cooper, 2000).  
Symptoms of hepatotoxicity include; 
 abrupt onset of flu-like symptoms including nausea, vomiting, myalgia, fatigue 
 abdominal pain 
 jaundice 
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 fever with or without skin rash 
 sometimes progresses to hepatic failure with encephalopathy (Department of Health 
and Human Services, 2008). 
According to the Department of Health and Human Services (2008) the risk factors for 
the development of hepatotoxicity include; 
 underlying liver disease prior to starting ARVs 
 treatment-naive patients with higher CD4 count at initiation (>250 cells/mm
3 
in 
women and >400 cells/mm
3 
in men) 
 female gender (including pregnant women) 
 HIV negative individuals when NVP is used for post-exposure prophylaxis 
 high NVP concentration (which may be as a result of drug interactions with drugs 
that may inhibit CYP450 enzyme metabolism of NVP) 
 co-infection with hepatitis B or C virus 
 elevated liver enzymes at baseline 
 alcoholism  
 concomitant use of other hepatotoxic drugs.  
Early identification of hepatotoxicity is critical. For NVP associated hepatotoxicity, some 
guidelines may be followed in order to prevent and/or monitor patients. Firstly, initiation 
of NVP in women with CD4 >250 cells/mm
3 
or men with CD4 >400 cells/mm
3 unless the 
benefit clearly outweighs the risk should be avoided. Patients should be counselled 
regarding signs and symptoms of hepatitis and advised to stop NVP and seek medical 
attention immediately if signs and symptoms of hepatitis, severe skin rash, or 
hypersensitivity reactions develop (Department of Health and Human Services, 2008). 
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Baseline ALT and AST should be performed and liver function tests (LFTs) monitored 
regularly. In patients with normal transaminase levels, LFTs should be performed every 
month for the first 3 months of NNRTI therapy and then every 3 months if levels remain 
normal. Patients with raised transaminases need to be monitored every two weeks and 
then monthly after they stabilize (Shibuyama et al., 2006). It is recommended that 
hepatitis B surface antigen tests be performed for all patients at baseline (Regensberg 
and Makiwane, 2009). 
The management of hepatotoxicity involves the following; 
 The offending ARVs should be immediately discontinued when ALT and/or AST is 
greater than 5-10 ULN. Caution should be taken in discontinuation of 3TC, FTC, or 
TDF in hepatitis B co-infected patients as they may experience a flare up 
 All other hepatotoxic agents should also be discontinued if possible  
 Other causes of hepatitis such as alcoholism, viral hepatitis, chronic hepatitis B with 
3TC, FTC, or TDF withdrawal, or hepatitis B resistance should be ruled out 
 Aggressive supportive care should be given (Department of Health and Human 
Services, 2008) 
 If GGT, alkaline phosphatase or conjugate bilirubin are elevated, a liver ultra sound 
should be performed to rule out biliary obstruction which may be due to hepatic 
steatosis or TB permeation of the liver (Regensberg and Makiwane, 2009). 
Hepatic injury may still progress even with treatment discontinuation. Therefore, careful 
monitoring of hepatic function should continue until symptom resolution occurs. The 
patient may not be re-challenged with NVP if it was the offending ARV. The safety of 
other NNRTIs (such as EFV and DLV) in patients who experienced significant hepatic 
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event from NVP is unknown, therefore they should be used with caution. (Department of 
Health and Human Services, 2008) 
2.5.2.2.3 Pancreatitis 
Pancreatitis refers to inflammation of the pancreas and is marked by increased serum 
amylase and lipase concentrations. HIV infected people are at risk of developing 
pancreatitis due to immunodeficiency as well as exposure to pancreatotoxic drugs, such 
as pentamidine, for treatment of opportunistic infections (White, 2001). The most 
common causative ARV agent is ddI used alone or with d4T, HU or TDF. Didanosine 
alone has been reported to cause pancreatitis in about 1-7% of patients. When ddI is 
given in combination with HU, pancreatitis incidence increases by 4-5 fold (Department 
of Health and Human Services, 2008). 
The onset of pancreatitis is usually within weeks to months after initiation of therapy. 
The main symptoms are; 
 post-prandial abdominal pain 
 nausea and vomiting 
 shock 
 respiratory distress 
 decreased bowel sounds 
 fever, and 
 tachycardia. (Department of Health and Human Services, 2008) 
The risk factors for developing pancreatitis include; 
 high intracellular and/or serum ddI concentrations  
 previous history of pancreatitis  
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 alcoholism  
 hypertriglyceridemia 
 concomitant use of ddI with d4T, HU, or ribavirin 
 use of ddI in combination with TDF without ddI dose reduction. (Department of 
Health and Human Services, 2008) 
Shibuyama and colleagues (2006) suggest that females and patients with CD4 cell 
counts of less than 200 cells/mm3 are at risk of developing pancreatitis. Prevention of 
the occurrence of pancreatitis involves caution when using ddI in patients with a history 
of pancreatitis and avoiding the concomitant use of ddI with d4T, TDF, HU, ddC or 
ribavirin. Cotrimoxazole and pentamidine may also cause pancreatitis, increasing the 
risk of pancreatitis. When used in combination with TDF, the dose of ddI should be 
reduced as TDF increases plasma concentrations of ddI (Department of Health and 
Human Services, 2008). In patients who consume moderate to high amounts of alcohol 
regularly, ddI should be avoided as the risk of pancreatitis increases (Shibuyama et al., 
2006). 
The management of pancreatitis involves; 
 discontinuation of the offending  ARV agent(s) if there are laboratory results that 
indicate raised lipase and amylase (Shibuyama et al., 2006) 
 symptomatic management involving; 
o intravenous hydration 
o pain management 
o gradual resumption of oral intake of foods 
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o parenteral nutrition may be necessary in patients with persistent symptoms 
upon recommencement of oral intake. (Department of Health and Human 
Services, 2008) 
2.5.2.2.4 Neuropathy 
Peripheral neuropathy is an abnormality commonly caused by d4T, ddI and ddC. The 
onset of symptoms may occur within several weeks to months after initiation of therapy 
but it may manifest earlier in patients with pre-existing neuropathy. Peripheral 
neuropathy begins with numbness and paresthesia of toes and feet, which may 
progress to painful neuropathy of feet and calf. The upper extremities are seldom 
involved. Other symptoms include a burning sensation, aching sensation, cramps and 
altered temperature sensation in the affected areas (Shibuyama et al., 2006). It can be 
debilitating for some patients to the point of difficulty in walking or even intolerance for 
clothing on their feet, depending on the severity and the individual response of the 
patient.  Peripheral neuropathy is normally reversible with the termination of therapy, 
and treatment may be cautiously resumed if the associated problems resolve 
adequately.  However, it may be irreversible despite discontinuation of the offending 
agent (Department of Health and Human Services, 2008). 
Increased immunosuppression increases the incidence of peripheral neuropathy. It is 
difficult however to distinguish between HIV related and ARV related peripheral 
neuropathy although ARV related neuropathy is thought to be more painful and 
progress more rapidly. NRTIs are thought to cause peripheral neuropathy by interfering 
with oxidative metabolism leading to lower acetyl-carnitine production, low serum 
hydroxycobalamine and inhibition of nervous growth factor. (White, 2001) 
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Risk factors for developing peripheral neuropathy include; 
 pre-existing peripheral neuropathy either related to HIV infection or due to distal 
sensory painful axonal neuropathy (Shibuyama et al., 2006) 
 combination therapy; ddC is more neurotoxic that ddI, d4T and 3TC but ddI 
combined with d4T is more toxic than either drug administered alone (Shibuyama et 
al., 2006) 
 concomitant use of neurotoxic drugs such as isoniazid 
 nutritional deficiency 
 advanced HIV disease indicated by low CD4 cell counts (<200 cells/mm3) 
 high dose or concomitant use of drugs that may interact with and increase the 
plasma concentration of these drugs. (Department of Health and Human Services, 
2008) 
In order to prevent the development of peripheral neuropathy HCPs should avoid using 
implicated agents in patients at risk and if possible, avoid the use of these agents in 
combination. This however may not always be possible due to the increased incidence 
of opportunistic infections, associated with HIV, which need to be treated. For instance 
a patient with a CD4 count of 50 cells/mm3 or less, with other HIV-related illnesses, 
diagnosed with TB would need to be initiated on both HAART and TB medication. 
However, in order to try and minimize the additive adverse effects of these drugs, the 
patient should be initiated on TB medication at least two weeks before starting HAART. 
It is essential that the patient is able to tolerate TB medication before initiation of 
HAART (Department of Health, 2004). It is also necessary to monitor patients at each 
encounter to assess whether they are experiencing symptoms indicative of peripheral 
neuropathy such as a tingling or numb sensation in their hands and feet.  
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The management of peripheral neuropathy may involve discontinuing the offending 
agent before the pain becomes disabling. This may stop further progression, but in 
some cases the symptoms may be irreversible (Department of Health and Human 
Services, 2008). Pharmacological management may include treatment of the neuralgic 
pain associated with peripheral neuropathy with agents such as pyridoxine, opiates (e.g. 
tramadol), non-steroidal anti-inflammatory drugs, amitriptyline, neurontin, topical 
capsaicin and topical lidocaine. Gabapentin, lamotrigine, oxycarbamazepine and 
topiramate may also be used. These agents have variable successes in managing 
peripheral neuropathy (Department of Health and Human Services, 2008). Valproic acid 
and carbamazepine are beneficial for lancinating pain. Anecdotal reports have shown 
that vitamin B complex may also be useful although these effects are yet to be well 
established (Shibuyama et al., 2006).  
2.5.2.3 Haematological toxicity 
HIV infection has been associated with haematological toxicities such as anaemia, 
neutropenia and thrombocytopenia. About 15% to 61% of adults with HIV infection 
experience haematological toxicity. HIV related thrombocytopenia has been shown to 
improve with AZT therapy. AZT therapy causes anaemia or neutropenia in about 1.1% 
and 9.7%. White (2001) suggests that AZT associated haematological toxicity is as a 
result of its effect on haem metabolism or gene expression while Shibuyama and 
colleagues (2006) further elaborate that AZT inhibits erythroid burst-forming units and 
human granulocyte-macrophage colony-forming units by competitively inhibiting 
thymidine triphosphate.  
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Patients with pre-existing anaemia, lower CD4 cell counts, increased age and of black 
ethnicity are reported to be at a higher risk of developing anaemia. Decreased 
erythropoietin, alterations in cytokine production and certain opportunistic infections 
may also increase the risk of anaemia. A high dose of AZT as well as concomitant use 
of bone marrow suppressants such as cotrimoxazole, ribavirin, hydroxyurea, 
pyrimethamine, interferon-alfa and ganciclovir may also increase the risk of bone 
marrow suppression (Department of Health and Human Services, 2008). The 
concomitant use of AZT with other bone marrow suppressants should be avoided 
although it may not always be possible since these agents are commonly used in 
treating opportunistic infections associated with HIV progression. 
Patients treated with AZT-containing regimens require close monitoring of full and 
differential blood counts on initiation of therapy, followed by monthly monitoring for three 
months, and then once every six months (Safrin, 2004).  The quality of life of anaemic 
patients is affected due to nausea, fatigue and weakness that result from low 
haemoglobin levels.  
AZT should be avoided in patients with haemoglobin <10 mmol/L and neutrophils less 
than 1.5 mmol/L. The management of bone marrow suppression with haemoglobin less 
than 8 mmol/L and neutrophils less than 1 mmol/L may involve switching AZT to 
another NRTI and discontinuing concomitant bone marrow suppressant if there is an 
alternative option (Regensberg and Makiwane, 2009). In the case of neutropenia, the 
exact cause should be identified and treatment with filgrastim, which regulates the 
production and release of functional neutrophils from the bone marrow initiated (Gibbon, 
2005). Similarly, for anemia, other possible causes should be identified and managed 
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appropriately. Erythropoietin therapy and blood transfusion may be indicated in some 
cases. 
2.5.2.4 Renal toxicity 
There have been reported cases of renal toxicity, including, renal tubular dysfunction, 
acute renal failure and Fanconi syndrome reported among patients taking TDF. TDF 
renal toxicity initially presents as “hypophosphatemia resulting from both reduced 
phosphate reabsorbtion and excessive loss of phosphates into urine”. (Buchacz et al., 
2006, p. 451-452) 
Other markers of renal toxicity associated with TDF are serum cystatin C (a protein 
produced by nucleated cells) and β2-microglobulin (more sensitive marker of TDF 
associated renal toxicity) (Ndegwa and Nkansah, 2008).  
Studies have however documented a positive renal safety profile of TDF in patients with 
normal baseline renal function, with no reported cases of renal failure. Risk factors for 
electrolyte disorders include; 
 previous hypophosphatemia 
 HIV infection 
 use of acyclic nucleotide analogues such as cidofovir and tenefovir 
 some ARVs such as lopinavir/ritonavir 
 renal disease 
 Comorbidities such as diabetes and hypertension. (Ndegwa and Nkansah, 2008) 
It is recommended that patients be assessed for any existing renal disease before TDF 
is initiated. This may include glucosuria, proteinuria and estimated glomerular filtration 
rate (GFR). If there is no proteinuria at this stage then patients,particularly those at risk 
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of developing proteinuria (such as black race, advanced HIV disease, hepatitis C and 
the above mentioned risk factors) should be monitored annually. (Ndegwa and 
Nkansah, 2008) 
The table below shows the recommended dosing for TDF for different GFR values. 
 
Table 2.10 Dosing recommendations for TDF 
(Adapted from: Ndegwa and Nkansah, 2008, p.6) 
Creatine clearance (ml/min) TDF dose 
≥ 50 300mg od 
30-49 300mg every 48 hours 
10-29 300mg twice weekly 
< 10 (patients with end stage renal disease 
requiring hemodialysis) 
300mg every 7 days or after a total of 12 
hours of dialysis (estimated at 4hours per 
dialysis). TDF is administered after dialysis 
 
TDF is generally well tolerated but further studies are required to assist in properly 
understanding and managing TDF-associated nephrotoxicity. 
2.5.2.5 Central nervous system (CNS) effects 
EFV is the ARV drug most commonly associated with CNS effects. EFV related CNS 
effects range from 1-116 days and last for a median of 13 days (Shibuyama et al., 
2006). More than 50% of patients taking EFV may experience CNS symptoms 
(Department of Health and Human Services, 2008). These CNS effects include 
drowsiness, nervousness, irritability, somnolence, insomnia, abnormal/vivid dreams or 
nighmares, dizziness, impaired concentration and attention span, depression, 
hallucination, exacerbation of psychiatric disorders, psychosis, paranoia, aggression, 
 65 
 
manic reactions and suicidal ideation. Symptoms usually subside within 2-4 weeks of 
therapy.  
Risk factors for the development of CNS effects include the following; 
 pre-existing psychiatric illnesses  
 injectable drug use 
 concomitant use of psychoactive drugs or alcohol   
 genetic predisposition to slower clearance related to black ethnicity. (Department of 
Health and Human Services, 2008) 
In order to minimize or prevent the occurrence of CNS effects, patients should be 
advised to take EFV at bedtime or 2–3 hours before bedtime because adverse effects 
may be more tolerable. Patients should be warned that EFV may impair their ability to 
perform activities requiring alertness or physical co-ordination during the first
 
2–4 weeks 
of therapy (Gibbon, 2005). 
If the symptoms persist and cause significant impairment in the patient’s normal 
functioning or worsens psychiatric illness, then EFV should be discontinued 
(Department of Health and Human Services, 2008). Insomnia may be managed with 
zolpidem, a benzodiazepine-related drug, which has minimal interaction with EFV 
(Gibbon, 2005). 
Due to the possible CNS effects of efavirenz, the recommended protocol for initiating 
treatment with efavirenz is; 
 Screen patients for and stabilize pre-existing neuropsychiatric  symptoms. 
 Reassure the patients that EFV is effective in managing HIV, CNS adverse effects 
are usually mild to moderate and time limited (2-4 weeks) and they rarely result in 
discontinuations of therapy. 
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 New and persistent CNS symptoms should be addressed. Early and effective 
management of CNS side effects in the patient taking EFV is imperative to improve 
patient outcomes (Department of Health, 2008). 
2.5.2.6 Gastrointestinal (GIT) effects 
Gastrointestinal problems are the most common side effects of almost all ARV drugs 
including NRTIs, NNRTIs and particularly PIs and occur especially during the early 
stages of therapy (Schieferstein and Buhk, 2006). GIT effects reported include 
abdominal discomfort, nausea and vomiting, loss of appetite, diarrhoea, abdominal pain, 
pancreatitis, constipation, meteorism and heartburn. Nausea is a common symptom 
with AZT-containing regimens, diarrhea occurs frequently with AZT, ddI and all PIs, 
particularly with ritonavir and nelfinavir. Treatment with AZT, may in rare cases, lead to 
a severe form of gastritic pain, nausea and vomiting in the early phase of therapy, in 
which case it should be discontinued (Schieferstein and Buhk, 2006). 
Patients should be informed that most GIT symptoms are self-limiting but some can 
persist for some time or reappear and could be a sign of a serious condition. GIT effects 
can be troublesome and greatly impact drug therapy outcome and the patient’s quality 
of life. GI side effects can cause dehydration, electrolyte imbalance, weight loss and 
malabsorption leading to low plasma drug levels with the risk of emergence of resistant 
viral strains (Schieferstein and Buhk, 2006). 
If the administration of drugs on an empty stomach leads to nausea and vomiting, most 
drugs can also be taken together with meals. However, when drugs such as ddI, 
indinavir, rifampin have to be administered on an empty stomach, small quantities of 
low-fat salty crackers may reduce the nausea. Ginger, peppermint or chamomile teas or 
 67 
 
sweets may also be helpful. Care should be taken with fatty foods and dairy products. 
Coffee, smoking, alcohol, aspirin and very spicy foods should be avoided if possible 
(Schieferstein and Buhk, 2006). 
For symptomatic treatment of nausea, metoclopramide has been demonstrated to be 
useful. Dimenhydrinate, cimetidine, ranitidine or ondansetron may also be administered. 
Anti-emetic drugs should not only be administered if the patient is already nauseated, 
but should rather be taken regularly for prophylaxis, ideally 30 to 45 minutes before 
HAART. If taken on a regular basis, attention should be paid to side effects such as 
dyskinesia. After a few weeks, anti-emetic doses can be slowly tapered down. If nausea 
persists for more than two months, a change of treatment should be considered, or else 
adherence problems may occur (Schieferstein and Buhk, 2006). 
It is important that the underlying cause or complication of GI problems be identified in 
order to take proper corrective measures. For instance if diarrhoea occurs, infection and 
lactose intolerance should first be excluded (Department of Health and Human 
Services, 2008). In patients with severe diarrhoea, the priority is to treat dehydration 
and loss of electrolytes. Difficult to digest foodstuffs (particularly those rich in fats or 
glucose) should be avoided and those that are easy to digest such as potatoes, rice, 
noodles, eaten instead  (Schieferstein and Buhk, 2006). 
The cornerstone of symptomatic treatment of diarrhoea is loperamide which inhibits 
bowel movement. If loperamide is ineffective, opiates may be used as an alternative, 
with caution due to the risk of intestinal obstruction, especially if overdosed. PI-
associated diarrhoea may be alleviated by calcium, taken as calcium carbonate 500 mg 
twice a day. However, as calcium binds to many other substances, it should be taken 
two hours before or after taking ARVs. The probiotics, Saccharomyces boulardii and 
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Lactobacillus acidophilus are used in infectious diarrhea and for the prevention of 
antibiotic-associated diarrhoea. They can sometimes ameliorate medication-associated 
diarrhoea. Psyllium which may also be effective should not be taken together with 
loperamide or opium tincture, or at the same time as HIV medication. (Schieferstein and 
Buhk, 2006) 
2.5.2.7 Hypersensitivity reactions 
Hypersensitivity reactions are a common occurrence with drug therapy although their 
exact pathogenesis is unknown. They occur about 100 times more frequently in the HIV 
positive population than in HIV negative patients (Carr and Cooper, 2000). All NNRTIs, 
the NRTI ABC, and the PI amprenavir usually cause hypersensitivity. Amprenavir is a 
sulfonamide and should therefore be administered with great caution in patients with 
sulfonamide allergies. Hypersensitivity reactions with NVP and EFV usually occur within 
the second or third week of treatment (Schieferstein and Buhk, 2006). The risk factors 
for hypersensitivity reactions are; 
 advanced disease 
 immune reconstitution 
 long exposure and high doses of treatment  
 glutathione deficiency which may alter drug metabolism 
 slow acetylators 
 co-existing infections for instance with cytomegalovirus or Epstein Barr virus. (Carr 
and Cooper, 2000) 
The hypersensitivity reaction is usually an erythematous, maculopapular, pruritic, and 
confluent rash distributed over the trunk and arm as shown in Figure 2.6 below. Fever, 
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myalgias, rigors and arthralgias may precede the rash (Carr and Cooper, 2000). Further 
symptoms include fatigue and mucosal ulceration. Severe but rare reactions such as 
Stevens Johnson Syndrome (SJS), toxic epidermal necrolysis and hepatitis have been 
reported and require immediate intervention by an expert should they occur 
(Schieferstein and Buhk, 2006). 
 
Figure 2.6 Stevens Johnson Syndrome 
(Source: Fagot et al., 2001) 
 
ABC causes a hypersensitivity reaction in 5-10% of patients which can be fatal. The 
hypersensitivity reaction is not dose dependent and usually involves multi-organ 
systems. ABC hypersensitivity reaction is characterized by fever and usually 
accompanied by general malaise, nausea, vomiting, diarrhoea and abdominal. Rash 
may occur but is often mild. ABC must be discontinued and never rechallenged as 
several deaths and life threatening hypotension have been reported with rechallenge 
(Department of Health and Human Services, 2008). The symptoms usually occur within 
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6 weeks after initiation of therapy, but can occur anytime during treatment with ABC 
(Schieferstein and Buhk, 2006). 
Approximately half the cases of ARV hypersensitivity resolve spontaneously during 
therapy. However, in the cases of mucosal involvement, exfoliation, blistering, severe 
hepatic dysfunction with transaminases more than 5 times the ULN, fever (>39°C) and 
severe pruritus, offending drugs should be discontinued (Carr and Cooper, 2000). 
Antipyretics and antipruritics are commonly used. In the case of mild to moderate 
NNRTI hypersensitivity, re-challenge is not contraindicated but should be preferably 
done under observation, in a hospital setting.  
 
Figure 2.7 A drug hypersensitivity reaction 
(Source: Carr and Cooper, 2000, p.1424) 
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2.6 Future Developments 
In the past few years the release of novel ARVs has provided new treatment options 
particularly for treatment experienced patients. Several drugs that provide an expansion 
of already existing ARV classes and additional new classes are under development. 
These drugs will take several years before they are available. 
Below is a summary of the drugs further along in the developmental process (those in 
pre-clinical and early development are excluded). 
 
Table 2.11 HIV drugs in development 
(Adapted from Graziano and Djuricich, 2009) 
 
2.7 Monitoring Patients Receiving HAART 
Montessori and colleagues (2004) suggest that patients receiving HAART should have 
routine monitoring every three months in order to determine whether the treatment is 
Agent ARV Class Status 
AMD11070 CXCR4 antagonist Suspended/Phase 2 
Amdoxovir NRTI Phase 2 
Apricitabine NRTI Phase 2/3 
Bevirimat  
(PA-457) 
Maturation inhibitor Phase 2 
Eltegravir Integrase inhibitor Phase 3 
IDX899 NNRTI Phase 2 
KP-1461 Viral decay accelerator Suspended/Phase 2 
PRO 140 Entry inhibitor/ monoclonal 
antibody 
Phase 2 
RDEA806 NNRTI Phase 2 
Rilpivirine NNRTI Phase 3 
TNX-355 CD4 blocker/ monoclonal 
antibody 
Phase 2 
Vicriviroc CCR5 antagonist Phase 3 
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working or not and what the effects of the treatment are on the normal bodily function. 
The tests to be performed include; 
 CD4 cell count and viral load in order to determine patients’ adherence to 
treatment or detect treatment failure early. CD4 monitoring is recommended to be 
performed every 4-6 months while viral load is initially to be done 6-8 weeks after 
initiating therapy and then routinely, every 4-6 months. A log reduction of 1, in viral 
load, is expected within about 8 weeks of commencing ARV therapy and after 16-24 
weeks it is expected to be undetectable, that is, <50 copies/ml. Treatment failure is 
defined as a “sustained increase to >1000 copies/ml” (Regensberg and Makiwane, 
2009). CD4 cell count rises rapidly within the first few weeks and then steadily 
thereafter with an average rise of 150 cells/mm3 in the first year and approximately 
80 cells/mm3 yearly thereafter.  
 Other tests include complete and differential blood counts, electrolytes, creatinine, 
liver function tests, bilirubin, amylase, total cholesterol, LDL cholesterol, HDL 
cholesterol, triglycerides,blood glucose. Patients also need to be monitored for 
dyslipidemias, diabetes, lipodystrophy. 
According to the National Department of Health (2008), the following routine monitoring 
of ART regimens should be performed. 
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Table 2.12 Routine monitoring for first line regimens (at the time of the study) 
(Adapted from: Department of Health, 2008) 
Regimen Drugs Monitoring 
Tests 
Frequency 
1a d4T / 3TC / EFV 
 
 CD4 
 VL 
 
 ALT 
 
 FBC 
 Hep BsAg 
 Staging, 6 monthly 
 At 3 months, then   6 
monthly 
 Baseline 
 
 Baseline 
 Baseline 
1b d4T / 3TC / NVP 
 
 CD4 
 VL 
 
 ALT 
 
 FBC 
 Hep BsAg 
 
 Staging, 6 monthly 
 At 3 months then 6 
monthly 
 Baseline, week 2, 4, 8, 
12 thereafter 6 monthly 
 Baseline 
 Baseline  
 
1c AZT / 3TC / EFV 
or NVP 
 
 CD4 
 VL 
 
 ALT (if NVP 
use) 
 FBC 
 
 Hep BsAg 
 
 Staging, 6 monthly 
 At 3 months then 6 
monthly 
 Baseline, week 2, 4, 8, 
12 thereafter 6 monthly 
 Baseline then monthly 
for 3 months then at 6 
months then 6-monthly 
 Baseline  
 
1d TDF / 3TC / EFV 
or NVP 
 
 CD4 
 VL 
 
 ALT (if NVP 
use) 
 
 Creatinine 
clearance  
 
 FBC 
 Hep BsAg 
 Staging, 6 monthly 
 At 3 months then 6 
monthly 
 Baseline, week 2, 4, 8, 
12 thereafter 6 monthly 
 
 Baseline, monthly x3, 6 
months, then 6 
monthly 
 Baseline  
 Baseline 
 VL- Viral load 
 ALT- Alanine aminotransferase 
 FBC- Full blood count 
 Hep BsAg- Hepatitis B surface antigen 
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Therapeutic drug monitoring (TDM) has also been suggested as a method of monitoring 
ARV treatment although studies are still being conducted to determine the usefulness of 
TDM. TDM has been defined as “the adjustment of drug doses based on plasma 
concentrations in order to attain values within a therapeutic range associated with 
maximal virological suppression and /or minimal adverse effects”. (Paul, 2010)  
TDM may be useful for NNRTIs and PIs which have high inter-patient variability in 
serum concentrations but not NRTIs because there has been no evidence of a 
correlation between plasma concentration and intracellular triphosphate active drugs. 
Concerns with the accuracy of drug assays and lack of agreed parameters to predict 
drug therapeutic response have presented challenges with TDM as a method of 
monitoring ART. (Paul, 2010) 
Patient self-monitoring diaries are yet another way of monitoring patients on ARVs. A 
patient self-monitoring system ensures that patients are actively involved in their 
monitoring. It mainly aims to identify subjective data such as the patient experience of 
pain, fatigue and other symptoms. Self-monitoring, for HIV positive patients, provides a 
way for the patients to follow up their own progress. (Gómez et al., 2002) 
A type of self-monitoring diary, commonly referred to as a pill diary, has been used in 
HIV positive patients to monitor adherence to ARVs. Web-based patient self-monitoring 
has also been used, although it may not be feasible for majority of patients in resource 
limited countries. The information contained in patient self-monitoring diaries includes; 
 Personal data - such as their date of birth, gender, date they were diagnosed 
with HIV. 
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 Clinical data – including their baseline CD4 cell count and subsequent CD4 
counts and baseline viral loads as well as subsequent viral loads. Opportunistic 
infections and other co-morbidities are also included here. 
 Life style data – including substance use, such as smoking, alcohol consumption 
and recreational drugs. It also includes patient’s subjective symptoms and moods 
such as sadness, pain, fatigue, appetite and others. The patients use visual 
analogue scales to visualize and enter subjective data.   
 Treatment data – this includes, ARVs and other drugs taken for any reason, 
including complementary and alternative treatments. Adherence to treatment 
may also be assessed by the patients. (Gómez, Cáceres, López and Del Pozo, 
2002) 
The goal of these diaries is get patients to record therapy, including doses and any 
changes to treatment, adherence, perceived adverse effects and perceived benefits 
of treatment. (Gómez, Cáceres, López and Del Pozo, 2002) 
The patient diary developed for this study was mainly aimed at identifying adverse 
effects or symptoms of adverse effects experienced and reported by patients. The 
other information regarding patients’ treatment (including current ARV regimen, 
treatment change and concomitant medications) and clinical progress (including 
comments on general well-being, virological suppression and co-morbid disease 
states) was obtained from patient records. 
2.7.1 Treatment change 
Numerous treatment naïve patients receiving their first ART usually achieve 
undetectable viral loads after 24 weeks. The most commonly cited reason for treatment 
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change within the first 3 months of ART is drug toxicity, with lipodystrophy and 
metabolic disorders being the major concern. (Hart, Curtis, Wilkins and Johnson, 2007)  
Treatment failure, including clinical failure, immunological failure and virological failure, 
has also been cited as an important reason for treatment change. Clinical failure is 
characterized by new or recurrent opportunistic infections or the onset of or recurrent 
WHO clinical stage 3. Immunological failure is characterized by a drop in CD4 cell count 
by more than 50% or a drop in CD4 count to baseline or less. Virological failure has 
been defined as failure to suppress viral load to undetectable levels, detecting the virus 
after a long period of un-detectability, that is, loss of virological control and less than 
ten-fold decrease in viral load from baseline after 8-12 weeks of ART. (Smith, 2010)  
Treatment failure may occur as a result of; 
 Inadequate drug delivery – due to malabsorption, poor adherence or vomiting 
 Sub-optimal plasma concentration of HAART – resulting from drug interactions, 
incorrect dosing 
 Patient genetic variations – such as rapid drug clearance, excessive drug 
metabolism, poor drug activation, pre-existing resistance 
 Interruption of therapy. (Smith, 2010) 
 Other reasons for treatment change include adherence difficulties, patient choice due 
to compromised quality of life, patients planning pregnancy or pregnant, comorbidity 
and potential for drug interactions and poor CD4 response. (Hart, Curtis, Wilkins and 
Johnson, 2007) 
Clinicians need to carefully weigh the risks with the benefits of changing patients’ 
treatment. The risk of increased drug resistance with a resultant loss of future treatment 
options needs to be considered. Therapeutic failure is often associated with poor 
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adherence and therefore in such cases changing treatment may not change the non-
adherence issue. Intensive counseling is recommended in such instances before 
proceeding to change therapy. When therapy is changed for non-adherence patients, 
they should receive easier to adhere to treatments with lower pill burden and less 
dosing frequency.  
Advantages of an early switch are that the immune system may be preserved and 
viremia controlled, hence preventing clinical progression of the infection and avoiding 
further development of resistance.  (Smith, 2010) 
ARV toxicities such as severe GIT effects, physical changes or life threatening effects 
such as organ damage may necessitate treatment change. Smith (2010) states that it is 
estimated that about 50% of patients receiving HAART for 3 years will require a 
treatment change due to ARV adverse effects. Due to the high incidence of treatment 
change due to ARV drug toxicity, a section on recommended drug substitutions was 
included in the adverse effect monitoring tool to act as a quick reference for the HCPs 
when considering treatment change of ARVs due to specific adverse effects. 
2.8 Adherence to ARV Treatment 
Much research has been conducted in the area of adherence to ARV treatment. 
According to the National Department of Health (2008), ideal adherence means that 
patients must take more than 95% of their doses that is, missing less than 3 doses per 
month. Patients taking less than 95% of their doses are at risk of developing resistance 
and eventually may have limited future treatment options.  
Certain behaviors such as missing clinic sessions, taking incorrect doses, taking 
medication at the wrong times, lack of understanding of instructions, adjusting doses 
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due to adverse effects or stopping medication have been attributed to non-adherence 
patterns (Chesney, 2003).  
Some of the barriers to adherence are listed below; 
 Drug factors 
o Regimen complexity 
o Adverse effects 
 Patient factors 
o Belief system 
o Patient-HCP relationship 
o Psychosocial issues      
2.8.1 Drug factors 
These are the factors that involve the actual drugs as discussed below. 
2.8.1.1 Regimen complexity 
HAART is complicated by multiple daily doses to be taken at specific times of the day, 
everyday for life. It is further complicated by food restrictions, and the possible adverse 
effects. In addition to these factors, HIV positive patients usually take multiple drugs for 
prophylaxis or treatment of different conditions such as opportunistic infections; 
therefore there is a propensity for drug interactions. Regimens that fit into the patient’s 
lifestyle or schedule as well as the patient’s attitude to their treatment rather than the 
dosing schedule of the drugs have been reported to be better predictors of adherence 
(Chesney, 2003).  
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2.8.1.2 Adverse effects 
The adverse effects discussed above, pose a great threat to adherence. The limitations 
to adherence that arise from adverse effects are sometimes dependent on patient 
factors, discussed below. Approximately 50% of patients receiving HAART experience 
adverse effects and up to 25% of these patients stop their treatment within the first year 
of treatment leaving them defenseless against the virus and possibly resulting in drug 
resistance, a loss of drug efficacy and the loss of future treatment options (Schiller, 
2005). Approximately 25% of patients do not take the recommended dosages of their 
medication due to concerns regarding the side effects. Patients, who report significant 
side effects, are often non-adherent (Schieferstein and Buhk, 2006). 
2.8.2 Patient factors 
According to Chesney (2003), patients who are less adherent have reported more 
significant confusion over their dosing schedule.  
2.8.2.1 Belief system 
Some patients do not understand their disease progression or how HAART works and 
therefore the utmost importance of adherence. These patients are therefore at higher 
risk of non-adherence. Patients with positive belief systems, such as believing that 
HAART works have been reported to be more adherent to their treatment regimen. 
Recreational drug users have a belief that ARVs reduce the “high” they get from their 
drugs and thus are likely to not be adherent. (Chesney, 2003)  
2.8.2.2 Patient-HCP relationship 
Patient-HCP relationships, where the HCPs routinely offer counseling to the patients, 
may aid in improving patient adherence to their treatment. Concordance rather than 
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compliance would help patients as it would mean individualizing treatment to suit 
patients’own lifestyles. The patient-HCP relationship would also address patient 
perceptions of HCP competence, clarity of communication, patient involvement in their 
treatment as well as any regimen inconvenience. HCPs need to address any adverse 
effects or any treatment problems with patients at each clinic visit in order to ensure the 
relationship is maintained and patients adhere correctly to their treatment (Chesney, 
2003).  
2.8.2.3 Psychosocial issues 
Intravenous drug use may affect the ability of patients to adhere to their treatment. 
Depression, stress, negative feelings and hopelessness are also significant predictors 
of non-adherence. Patients need support from both their health care providers and 
family in order to cope with life’s stresses and continue adhering to their medication. 
(Chesney, 2003) 
2.8.3 Methods for improving adherence 
The following have been suggested as ways of improving patient adherence; 
 Involving patients in decisions affecting their treatment 
 Instructing and educating patients in behavioral skills that augment adherence 
 Patients need to understand the consequences of non-adherence such as treatment 
failure, disease progression and even death 
 Patients and HCPs need to have a relationship that involves routine monitoring and 
counseling 
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 Making treatment practical, for example morning doses may be associated with 
brushing teeth and evening doses with programs like the evening news. Cell phone 
reminders may also be of assistance 
 HCPs should discuss the possible adverse effects of ARVs and some practical ways 
to manage them may be a pro-active way of improving adherence 
 A “treatment-buddy” system may ensure patients remain accountable and consistent 
in taking their treatment. (Chesney, 2003) 
2.9  Drug Interactions Involving ARVs 
2.9.1 Drug-drug interactions 
Drug interactions have become an increasingly complex challenge for HCPs treating 
HIV-infected patients. Generally, drug interactions can be classified into two broad 
categories: 
• interactions altering pharmacokinetics 
• interactions affecting pharmacodynamics (Meemken and Dickinson, 2006). 
Although both are likely to be problematic in patients receiving HAART, pharmacokinetic 
interactions are more frequent and more difficult to predict due to the complex nature of 
drug metabolism. Most interactions are minor and may not be obvious or of any clinical 
significance; however there are a number of interactions that may cause a decrease in 
patient or clinical outcomes, therapeutic failures, mild to moderate toxicity and severe to 
life threatening toxicities. Clinically significant drug interactions are those that produce at 
least a 30% change in pharmacokinetic parameters.  
Drug interactions arise in almost all HIV positive patients who receiving treatment due to 
the average number of drugs (for HIV and opportunistic infections), food interactions, 
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vitamins, complementary and herbal or traditional medicines that the patient may be 
taking (Meemken and Dickinson, 2006). 
2.9.1.1 Pharmacokinetic interactions 
Pharmacokinetic drug interactions are classified according to the pharmacokinetic 
parameters they affect; absorption, distribution, metabolism, or elimination of other 
drugs. Most common drug interactions encountered in HIV infection involve those that 
affect metabolism or absorption. Drug interactions involving metabolism are the most 
common and difficult to predict. Drugs used in HAART, especially NNRTIs and PIs, are 
metabolized via the CYP450 enzyme system. CYP3A4 is the enzyme responsible for 
the majority of drug metabolism, although CYP2C19 and CYP2D6 are also common 
and, to a lesser extent, CYP1A2 (Department of Health, 2005). The abundance of 
CYP450 enzymes are illustrated below. 
 
Figure 2.8 Abundance of CYP450 enzymes in the human liver 
(Adapted from: Banoo, 2008) 
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Drugs may interact with the CYP450 enzymes in one of three ways: 
 through inhibition (resulting in potentially toxic levels due to decreased drug 
metabolism), 
 through induction (resulting in sub-therapeutic levels due to increased drug 
metabolism) 
 by acting as a substrate. (Department of Health, 2005) 
2.9.1.2 Pharmacodynamic interactions 
Pharmacodynamic interactions occur when one drug causes an alteration in the 
pharmacologic response (including efficacy and toxicity) of a second without a 
consequent change in drug concentrations or pharmacokinetic parameters. In this type 
of interaction, the pharmacologic response from the drug may be antagonistic, additive, 
or synergistic as discussed below; 
 Antagonistic effects result in the drug’s pharmacologic effect being reduced due to 
concurrent therapy, for instance co-administration of AZT and d4T, where by AZT 
may interfere with the phosphorylation of d4T thus antagonizing its effects 
 Additive effects occur when the use of two drugs leads to enhanced pharmacologic 
activity, such as   
 Synergy occurs when the use of two or more drugs concurrently results in an effect 
that is greater than the addition of all of the drugs together, that is, the effect is 
exponential, not additive (Department of Health, 2005). 
Drug interactions may take place when ARVs are co-administered with other drugs 
which are substrates of, or induce or inhibit certain CYP enzymes. Therefore, 
practitioners need to possess an in depth knowledge of potential drug-drug interactions 
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and always check before co-administering other drugs with ARVs. This will prevent the 
potential problem of toxicity which may be fatal or sub-therapeutic ARV levels, which 
predisposes patients to resistance. 
In order to prevent potential drug interactions, the following should be considered; 
 Patients should be counselled with regarding self medication with over the counter 
products or herbal products and urged to consult with their HCP before taking any 
other medicines 
 HCPs need to enquire at each visit whether the patients are receiving any other 
medications 
 Drugs with potential interactions should be avoided unless benefits outweigh risks 
(Mohammed et al., 2005). 
2.9.2 Drug-food Interactions 
Food may enhance or inhibit the absorption, metabolism, distribution and excretion of 
drugs. Dietary management to improve the efficacy of a drug includes taking it with 
food, on an empty stomach, taking it with particular foods or avoiding particular foods as 
shown in the following table. 
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Table 2.13 ARV drugs and food restrictions 
(Adapted from: Department of Health, 2005) 
Drug Food restriction Other restrictions 
Efavirenz Take on an empty stomach, food seems to 
increase absorption 
Avoid alcohol 
Nevirapine Not affected by food None 
Stavudine Give without regard to meals None 
Lamivudine Take without regard to meals (though may 
delay absorption) 
None 
Didanosine Take on an empty stomach, 1hr before a 
meal or 2hrs after 
Buffered tablets can 
be dispersed in clear 
apple juice 
Zidovudine Take with low fat meal None 
Lopinavir/ritonavir Food significantly increases plasma 
concentration; Take with meals 
None 
 
2.9.3 Herb/traditional/complementary-drug Interactions 
It is estimated that about 90% of HIV positive patients take some complementary or 
herbal medicine (Deparment of Health, 2005). This implies that a majority of patients on 
ARTs will also be taking some form of herbal, traditional or complementary medicine. 
Research on herbal or traditional medicines is still very limited. There is inadequate 
HCP experience combining herbal, traditional or complementary medicines with ARVs. 
HCPs should document as much as possible the name, source and quantity of any 
other medicines that their patients take. They should counsel patients on the possibility 
of drug interactions that may result in therapeutic failure or toxicities (Department of 
Health, 2005). The following complementary medicines have however been 
documented to have an effect on the CYP450 enzyme system: 
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 St. John’s wort (Induction of CYP3A4) 
 Garlic (Induction of intestinal CYP450) 
 Sutherlandia and “African potato” (Inhibits cytochrome P450). (Banoo, 2008) 
Ginseng, melatonin, milk thistle, geniposide and skullcap have also been reported to 
have an effect on the CYP450 system (Department of Health, 2005). Because of 
possible drug interactions with ARVs patients should be advised to refrain from 
concurrently using the herbal remedies with ARVs. They should be encouraged to 
report any and all symptoms they may experience which may cause them to seek 
alternative remedies. Phytovigilance which involves the safety of complementary and 
traditional medicines is also necessary in the South African context because of the large 
population that takes traditional medicines (Department of Health, 2005).  
2.10 Pharmacovigilance Relating to ARV Therapy 
When the HIV epidemic begun, there was an urgent need to develop drugs to arrest the 
disease progression but the need and importance of safety monitoring of the drugs 
appears to have been neglected. More recently, it is evident that regardless of the 
success of HAART, drug toxicity remains a weighty issue. (Bisson, 2003)  
Pharmacovigilance has been defined in the WHO handbook of pharmacovigilance of 
ARVs (2009, p.1) as “the science and activities relating to the detection, assessment, 
understanding and prevention of adverse effects or any other drug-related problem”. 
Pharmacovigilance involves the following: 
 monitoring medicines used in everyday practice to identify current and/or previous 
unidentified adverse effects 
 assessing the risks and benefits of medicines  
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 providing information to users to optimize safe and effective use of medicines 
 monitoring the impact of any action taken. (WHO, 2009) 
Pharmacovigilance is aimed at detecting previously unknown adverse effects of drugs 
(Bisson, 2003). The primary goal of pharmacovigilance is to ensure the safe and 
effective use of medicines in order to improve patient well-being and public health 
(Department of Health, 2005).  
Drug safety is monitored pre- and post approval, with pre-approval monitoring providing 
information on efficacy, adverse events and immediate drug safety and post approval 
monitoring establishing sustained safety of the drugs (Bisson, 2003).  
The WHO (2009) has described two types of pharmacovigilance that can be used to 
monitor for drug safety, namely; 
 Passive pharmacovigilance - Also referred to as spontaneous or voluntary 
pharmacovigilance. It implies that there are no active measures taken to detect 
adverse effects and that reporting is entirely dependent on the initiative and 
motivation of the reporter. Passive pharmacovigilance is the most commonly used all 
over the world as it is easy to establish and inexpensive to run. 
 Active pharmacovigilance - Also referred to as proactive reporting. Here, active 
measures are taken in order to detect adverse effects for instance by directly asking 
patients or screening their medical records. This method is more elaborate, but 
delivers more accurate and reliable results compared to passive pharmacovigilance.  
Different countries have different methods set up for pharmacovigilance but the WHO 
describes the requirement for reporting and recording adverse events. An ARV adverse 
effect reporting form (Appendix 7) is a sample of an ARV adverse effect recording tool 
in use. This recording tool provides for identification of adverse effects patients 
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experience and interventions taken. The monitoring tool developed for this study is 
aimed at identifying symptoms indicative of adverse effects as well as actual adverse 
effects whilst also rating the severity of these effects. This is because of the need to 
identify adverse effects early in order to prevent fatalities and avoid patients stopping 
their treatment. Any necessary tests and interventions can therefore be made and 
recorded in attempts to identify and prevent adverse effects, particularly the life 
threatening effects.  The tool was not only an adverse effect monitoring tool but also 
provided the HCP with a reference for managing specific adverse effects (including the 
possible causative ARV agents) as well as recommended ARV drug substitutions for 
specific adverse effects (see Appendix 1b).  
In 1987 a regulatory infrastructure to monitor pharmacovigilance activities was 
established in South Africa. This program is conducted by the pharmacovigilance center 
based at the University of Cape Town - called the National Adverse Drug Event 
Monitoring Center. This institution functions as a WHO collaborating center and 
provides support to the Medicine Control Council's (MCC) safety monitoring program. 
The pharmacovigilance program involves a national adverse drug reaction-reporting 
database, which is compatible with the WHO pharmacovigilance database (Department 
of Health, 2005). All ARV centres should have the adverse event reporting forms which 
may then be sent to the pharmacovigilance centre for record keeping.  
In her speech during the opening of the pharmacogivilance centre, Dr Tshabalala-
Msimang (2004) stated that the risk and toxicity profile of ARVs needs to be understood 
in South African settings and the complexities associated with various regimens 
continually assessed and suitably and responsibly managed.  
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CHAPTER 3 
METHODOLOGY AND DATA COLLECTION 
Introduction 
This chapter describes the strategy and methodology used to meet the primary aim of 
this study which was to evaluate the extent to which monitoring strategies, including an 
adverse effect monitoring tool to be used by HCPs to monitor patients, and a self-
monitoring patient diary can contribute to the early identification and management of 
adverse effects associated with ARVs. 
3.1 Study Aim and Objectives 
The primary aim of the study is to evaluate the extent to which monitoring strategies, 
including a tool to be used by HCPs, and a self-monitoring patient diary can contribute 
to the early identification and management of adverse effects associated with ARVs. 
The objectives of this study are to: 
i. Implement the tool previously developed and piloted by Diergaardt (2005) and 
modified by Mulinge (2008)  
ii. Develop and implement a patient diary for the patients to monitor their adverse 
effects  
iii. Determine the extent to which the above strategies facilitate the identification of 
adverse events associated with ARV treatment 
iv. Determine the perceived ease of use of the monitoring tool by HCPs and the 
diaries by the patients.  
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3.2 Literature Review 
An in depth literature review was conducted on ARVs including their mechanism of 
action, adverse effects, the pharmacological and non-pharmacological management of 
these adverse effects, contraindications, drug interactions as well as pharmacovigilance 
practices relating to ARVs. New ARVs available in the United States and those under 
development were included in the review. The currently available methods of monitoring 
patients for adverse effects were also included in the discussion.  
3.3 Study Setting 
The study was conducted at a private HIV and AIDS clinic, hereafter referred to as the 
Centre, in Uitenhage, in the Eastern Cape Province of South Africa. The Centre was 
chosen following a pilot study, conducted there by Mulinge (2008), which led to the 
realization that it would be appropriate to expand the study, including changes to the 
pilot study and a new strategy of monitoring (self-diary). There are over two hundred 
patients receiving HAART at the Centre. 
3.4 Study Population and Sample 
The target study population was all the patients at the Centre who were receiving 
HAART. The study sample was made up of one hundred and sixty patients from the 
study population who were chosen using convenience sampling. The sample population 
was grouped into four categories each consisting of 40 patients: 
 Control Group (neither the monitoring tool nor the diary  were used) 
 Tool Group (only the monitoring tool was used) 
 Diary Group (only the patient diary was used)  
 Tool-Diary Group (both the tool and patient diary were used).  
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Patients were allocated to each group by HCPs at the clinic, by means of convenience 
sampling. The inclusion criteria to participate in the study included that the patients be 
HIV positive and receiving HAART, and after the nature and purpose of the study was 
fully explained to them, that they be willing to participate and be able to sign informed 
consent. 
The patients were allocated study numbers and the four groups were represented by 
four different coloured stickers (placed on the patients’ files) as shown in Figure 3.1 
below. This was done by the researcher in order to minimize the work the HCPs were to 
do and to ensure uniformity and accuracy.  
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Figure 3.1: The study sample 
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monitored for adverse 
effects using only the 
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effects. They continued with 
their clinic program as usual 
The diary group was 
monitored for adverse 
effects using only the 
patient self-monitoring 
diary 
SAMPLE 
POPULATION 
This group was monitored for 
adverse effects using both the 
adverse effect monitoring tool 
and the patient self-monitoring 
diary 
 93 
 
Clearly labelled research packages were prepared for each study group containing the 
following; 
 Control group 
o Informed consent forms 
o Green stickers with study numbers 
 Tool group 
o Informed consent forms 
o Pink stickers with study numbers 
o Pink ring-bound monitoring tools each with a pink sticker containing the 
patient study number. 
 Diary group 
o Informed consent forms 
o Blue stickers with study numbers 
o Patient self-monitoring diaries each with a blue sticker containing the patient 
study number. 
 Tool-Diary group 
o Informed consent forms 
o Yellow stickers with study numbers 
o Yellow ring-bound monitoring tools, each with a yellow sticker containing the 
patient study number 
o Patient self-monitoring diaries each with a yellow sticker containing the 
patient study number. 
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3.5 Research Design 
This study was experimental in nature, seeking to describe the extent to which the use 
of an adverse effect monitoring tool and/or the use of a patient self-monitoring diary 
impacted on the early identification and management of adverse effects associated with 
ARV use (Peter, 2007). It was a randomized controlled study with participants being 
assigned to one of four groups, as described in Section 3.3 above. 
3.6 Data Collection Tools 
3.6.1 Antiretroviral recording and monitoring chart (adverse effect monitoring 
tool) 
In the pilot study (Mulinge, 2008), unstructured and informal meetings were held with 
the HCPs at the Centre, in order to determine the manner in which they monitor ARV 
adverse effects and to determine their requirements for a specific tool to monitor these 
adverse effects. After taking into consideration the recommendations of Diergaardt’s 
study (2005), Mulinge’s study (2008) and the requirements of the HCPs at the study 
site, the adverse effects monitoring tool was modified and adapted for the study site 
(Appendix 1a and Appendix 1b). Feedback from the HCPs involved in the previous 
study (Mulinge 2008) indicated that the previous tool (Appendix 1c) was too extensive 
and time consuming. Therefore, one of the modifications included splitting the previous 
tool into two separate forms: a Researcher’s Data collection Form (Appendix 2) and the 
Antiretroviral Recording and Monitoring chart (the Tool - Appendix 1b).  
The researcher’s data collection form, a history taking tool, was used by the researcher 
towards the end of the study to collect relevant data (for the three months study period) 
from patient files while the tool was used by the HCPs to record aspects involving 
adverse effects of ARVs. The tool also included the South African Department of Health 
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(2008) recommendations for further management of specific adverse effects and ARV 
substitutions in cases of specific toxicities. 
A chart with the human body indicating the different ARV adverse effects included in the 
monitoring tool was colour printed and laminated and a copy was provided to each HCP 
participating in the study (Appendix 1a). The HCPs used this chart as a reference point 
to direct them to the relevant place in the tool where they were to record adverse effects 
experienced by the patients (Appendix 1b). The chart was therefore a prompt, assisting 
with ease of identification of the symptoms of the different adverse effects and the tool 
was used to record these in details; including severity, any interventions made and the 
outcomes of these interventions. The chart was included to make it easier to record the 
symptoms the patients were experiencing hence it reduced the time it would have taken 
to locate those symptoms on the tool.  
3.6.2 Self-monitoring patient diary 
A patient diary provides for the patient to assess their own health status without clinician 
bias and to evaluate the impact of their treatment (Zanni, 2007). HIV infection is often 
accompanied by other co-morbid disease states. Patients taking ARVs may experience 
adverse effects which may be similar to disease states or conditions that they have 
previously experienced.  The patients may therefore overlook these adverse effects and 
fail to mention them to the HCP during their regular follow up sessions. Patients may 
also feel rushed while in consultation with the HCPs due to the allocated consultation 
time, judged or uncomfortable talking about their symptoms or may even forget to 
mention certain symptoms they have experienced or are currently experiencing. It is 
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because of this possibility that a patient diary was developed. The diary aimed to 
identify such symptoms or adverse effects if they existed.  
The patients used the diary to self-monitor for any symptoms they experienced during 
the study period. An initial pilot study of the diary (Appendix 3a) was conducted on four 
patients (not included in the final study), for a period of two weeks to assess the 
usability, validity and reliability of the diary. The researcher then collected the four 
diaries and made necessary modifications suggested by the patients and the HCPs 
before compiling the final diary to be implemented (Appendix 3b).  
Instructions on how to use the diaries were communicated to the HCPs by the 
researcher; both verbally in an informal meeting and in writing, in the form of colour 
printed and laminated copies. 
Patients in the two categories involving the diary (Diary Group and Tool-Diary Group) 
were given their diaries by the HCPs to take home. The diaries included a figure of the 
human body which patients used to identify symptoms they are experiencing. The 
intention was for patients to indicate against the symptoms indicated on the figure they 
experienced, or add any symptoms that were not included on the figure, and include the 
date they experienced those symptoms. They would then complete weekly journals 
indicating the severity of their symptoms, any interventions made and the result of the 
intervention(s). Illiterate patients or patients who cannot communicate in English were 
asked to merely draw a line/arrow pointing to the affected body part and the HCP would 
then follow up and intervene as required. 
The HCPs explained the use of the diary to the patients and instructed them to return 
their diaries at their next scheduled clinic visit. The diaries were to be presented at each 
clinic visit. The HCPs were required to sign the diaries on receiving them and any 
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necessary investigations and interventions could then be made based on the patients 
recorded symptoms.  
At the end of the study period, the HCPs conducted an evaluation of the diaries, 
including the patients’ perspectives and the HCPs perspectives of the different aspects 
of the diary, using the diary evaluation form provided (Appendix 4). This feedback was 
obtained from the patients when they handed in their diaries at the end of the study 
period and stored with the diaries.  
3.7 Data Collection 
Before commencing, the researcher explained the nature and purpose of the study to 
the HCPs and the team that would be involved in the data collection. The HCPs and 
data collection team were asked to sign informed consent forms (Appendix 5) stating 
willingness to participate in the study. In turn, the HCPs explained the study to the 
patients and obtained signed informed consent forms (Appendix 5) provided by the 
researcher, from them.  
At the beginning of the study the researcher met with the HCPs at the Centre and 
explained the study to them. The researcher also demonstrated how the project was to 
be conducted, including randomly assigning patients to groups, and collecting the data. 
Due to set backs in the printing of the tools and diaries, the control group began the 
study earlier than the other groups. The other groups then began three weeks later, 
when the control group already had the required number of patients (forty).  
The modified monitoring tool was used by the HCPs at the Centre in the course of their 
work for a period of three months, August to October, 2009. The researcher, after 
requesting for (Appendix 6a) and obtaining written permission (Appendix 6b) from the 
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Director of the Centre and informed consent from the participating HCPs and patients, 
documented relevant patient details, from the patient files, using the data collection 
form, at the end of the study period. This data was safely stored in a separate box and 
locked away to maintain patient confidentiality. 
The researcher assigned each participating patient a unique study  number on the 
relevant colour sticker, which were placed on each document in an envelope, such that 
all the HCPs had to do was randomly select a research package and proceed 
appropriately for the patient in that particular group. These research packages, in the 
form of envelopes, containing all relevant documentation for each patient in each group, 
were stored in separate clearly labeled boxes. The boxes had a checklist, prepared by 
the researcher, that was ticked off by the receptionist each time a patient was assigned 
to a particular group, to ensure uniformity in the number of patients per group. The 
checklist was for use by the HCPs and other clinical staff participating in the study, for 
easy retrieval of information.  
During the three month study period, the researcher met regularly with the HCPs to 
provide ongoing support and follow up. At the end of the study period, the researcher 
collected the completed diaries and monitoring tools from the HCPs for analysis.  
Data relating to the adverse effect monitoring and management of the Control Group 
was obtained from patient files, by the researcher, using the researcher’s data collection 
form, since there was no monitoring tool provided to the HCPs for use in this group.   
In a post-intervention briefing, the researcher met with the HCPs responsible for the 
collection of the data at the Centre and in an unstructured interview, obtained their 
views regarding the usefulness of the tool and diary. The debriefing was also used to 
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assess any short comings in the tool and hence make recommendations for future 
modifications or adjustments. 
A summary of the processes involved in the collection of data are described in Figure 
3.2 below: 
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Figure 3.2: An overview of the research methodology 
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3.8 Data Analysis 
Data from all the research tools were captured using Microsoft Excel® software. All the 
data was entered by the researcher in order to maintain accuracy and consistency. A 
statistician was consulted for assistance with the analysis and SPSS® was used for the 
purposes of statistical analysis. In order to evaluate the effectiveness of the monitoring 
strategies, the identified adverse effects were analyzed using descriptive statistics.   
3.9 Ethical Considerations 
HIV and AIDS is a highly stigmatized condition and infected individuals are considered 
to be a vulnerable group. Because of its sensitive nature and the vulnerability of this 
group of people, patient confidentiality and ethical consideration were of utmost 
importance.  
In order to give careful attention to the ethical considerations involved in the study, the 
following steps were undertaken: 
 The researcher requested permission to conduct the study at the Centre  
 A letter of approval for the study was obtained from the Chairman of the Centre 
(Appendix 6b).  
 The HCPs participating in the study were provided with a detailed explanation of the 
proposed study after which they signed informed consent forms. 
 The HCPs participating in the study explained the study to the patients where after 
they obtained written informed consent from patients willing to participate. The 
researcher did not have any direct contact with the patients.  
 102 
 
 Patient confidentiality was maintained by making use of unique patient study 
numbers and no patient names and/or personal details were linked to the data. All 
individual patient information was treated with utmost confidentiality. 
 The statistician who was consulted for guidance with the data analysis had access to 
the Microsoft Excel® spreadsheet, which only had patient study numbers. Therefore, 
patient confidentiality was not breached at any point in time.  
 Any interventions made to the treatment of patients experiencing adverse effects 
were done by the HCPs, according to their professional judgment and in the normal 
course of their work and were not at any time individually suggested or carried out 
by the researcher. 
 Ethical approval was sought and obtained from the NMMU Research Ethics 
Committee (Human).  
The tool under investigation was used by HCPs at the Centre in the normal course of 
their work. It was also the HCPs who gave the diaries to the patients ensuring that the 
researcher did not have direct contact with the patients at the Centre. The study was 
conducted in accordance with the ethical principles of the Declaration of Helsinki (World 
Medical Association, 2002). 
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CHAPTER 4 
RESULTS AND DISCUSSION 
In order to establish the effectiveness of the methods used for identification and 
monitoring of adverse effects, the findings of this study and the statistical analysis 
thereof will be presented and discussed in this chapter.  
4.1 Study sample 
4.1.1 Number of participants 
The total number of patients recruited for participation in the research was 160, 40 
patients per study group. However due to human error, 10 patients were assigned to 2 
different groups. Another patient’s file was missing at the clinic and therefore a total of 
11 participants have been omitted from the analysis of the results. With these factors 
taken into account, the total number of participants was 149.  
4.1.2 Participants gender and age 
The study sample consisted of 43 males (28.9%) and 106 females (71.1%). This gender 
distribution might have been expected since a UNAIDS report (2008) indicates that in 
sub-Saharan Africa women account for about 60% new HIV infections and that 14 
women are infected for every 10 males.    
Table 4.1 below shows the random gender and age distribution among the participants 
in the four different study groups. 
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 Table 4.1 Gender and age distribution of the respondents 
Characteristic Control(n=35) 
Tool 
(n=38) 
Diary 
(n=38) 
Tool-Diary 
(n=38) 
Gender 
 
Male 
Female 
 
28.6% (10) 
71.4% (25) 
 
60.5% (23) 
39.5% (15) 
 
21.1% (8) 
78.9% (30) 
 
5.3% (2) 
94.7% (36) 
Age Group 
05 -  17 
18 - 25 
26 - 35 
36 - 45 
46 - 55 
56 - 65 
 
0 
8.6% (3) 
37.1% (13) 
31.4% (11) 
22.9% (8) 
0 
 
2.6% (1) 
0 
39.5% (15) 
31.6% (12) 
23.7% (9) 
2.6% (1) 
 
0 
0 
36.8% (14) 
47.4% (18) 
13.2% (5) 
2.6% (1) 
 
0 
7.9% (3) 
44.7% (17) 
42.1% (16) 
5.3% (2) 
0 
 
From the table it is evident that that there is a difference in the number of males and 
females that participated in the study. The number of females that participated was 106 
and the number of males was 43, a difference of 63 persons.  
The highest numbers of the respondents in the study were in the age group of 26 – 35 
(39.6% of participants) and 36 – 45 (38.3% of participants). This observation was 
expected as the majority of HIV infections are in persons between 15 and 44 years of 
age (UNAIDS global report, 2010). Figure 4.1 below, shows the distribution of the 
participants’ ages. 
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Figure 4.1 Participants mean age curve (n=149) 
As shown in the graph above, there was a normal distribution of the ages of the study 
participants although the graph was skewed to the left (0.188) with a standard error of 
0.199 which implies that there was bias towards the younger ages throughout the study 
groups.  
4.1.3 Substance use 
Of the 149 participants, one admitted to smoking whilst 15 admitted to alcohol 
consumption. Although there is no further evidence from this study, substance abuse, 
including smoking, alcohol consumption and other recreational drugs may lead abusers 
to risky behaviours such as feeling uninhibited, impulsive and seeking stimulus (Bryant, 
2006). This may lead to sex without condoms hence risking infecting others, or missing 
treatment doses due to altered consciousness or possible interactions with ARVs. 
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According to Dybul and co-workers (2002), alcohol consumption in HIV patients has 
also been associated with the following: 
 non-adherence to treatment 
 increased risk of hepatotoxicity in patients receiving HAART 
 osteonecrosis in patients receiving HAART 
 increased potential for drug interactions, for example increasing plasma 
concentrations of  ABC to toxic levels.  
Considering the data collected for the research participants who admitted to alcohol 
consumption (n=15), the following was noted; 
 Two patients were not taking their medication regularly 
 Two admitted to missing treatment on weekends whilst drinking.  
 Two were found to have raised gamma-glutamyl transpeptidase (GGT) 
 One patient was late in collecting their medication,  
 Another patient defaulted for a 2 week period. 
 
 
Figure 4.2 Effects of alcohol consumption on the study participants (n=15) 
25.0%
25.0%
25.0%
12.5%
12.5%
Did not take medicines 
regularly
Missed treatments on 
weekend
Raised GGT
Late to collect medicine
Defaulted treatment 
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In 46.7% (n=15) of the patients who admitted to alcohol consumption, there was no 
recorded effect of the alcohol on their health or treatment. In more than half of the 
patients who admitted to taking alcohol (53.3%), there was a negative effect either to 
their health (such as raised GGT) or an effect on their treatment (such as poor 
adherence, defaulting), recorded. These effects were to be expected as alcohol may 
alter the consciousness of an individual and cause behavioral changes as suggested by 
Bryant (2006). Bryant (2006) further suggests that no safe level of alcohol consumption 
has been identified, particularly for patients receiving HAART. The records of three of 
these patients reflected that they had been counselled regarding their alcohol 
consumption. A total of 15 patients (n=149) were reported to be defaulters, or not taking 
their medication regularly. 33.3% of these were alcohol consumers while 66.7% were 
not reported to be alcohol consumers.  
4.2 Co-morbidities 
Many patients who develop severe opportunistic infections are usually unaware of their 
HIV positive status (Hoffmann, 2006). CD4 cell count is directly related to development 
of infections, with low CD4 counts being associated with higher risk of developing 
opportunistic infections. Immune reconstitution inflammatory syndrome (IRIS) may also 
present as an opportunistic infection. All opportunistic infections in HIV positive patients 
need to be treated quickly and adequately in order to prevent further damage to the 
immune system. 
The co-morbidities observed in this study will be discussed with respect to their WHO 
staging and whether they are related to HIV and AIDS or not. According to the WHO 
(2005), clinical staging of HIV and AIDS is as follows. 
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Table 4.2 WHO clinical staging of HIV and AIDS 
(Adapted from WHO, 2005, pp.5-6) 
WHO Staging Characteristics/Comorbidities 
Stage 1  Asymptomatic 
 Persistent general lymphadenopathy 
Stage 2  Moderate unexplained weight loss (<10% of presumed or 
measured body weight) 
 Recurrent respiratory tract infections (RTIs, sinusitis, 
bronchitis, otitis media, pharyngitis) 
 Herpes zoster 
 Angular cheilitis 
 Recurrent oral ulcerations 
 Papular pruritic eruptions 
 Seborrhoeic dermatitis 
 Fungal nail infections 
Stage 3  Severe weight loss (>10% of presumed or measured body 
weight) 
 Unexplained chronic diarrhoea for longer than one month 
 Unexplained persistent fever (intermittent or constant for 
longer than one month) 
 Oral candidiasis 
 Oral hairy leukoplakia 
 Pulmonary tuberculosis (TB) diagnosed in last two years 
 Severe presumed bacterial infections (e.g. pneumonia, 
empyema, pyomyositis, bone or joint infection, meningitis, 
bacteraemia 
 Acute necrotizing ulcerative stomatitis, gingivitis or 
periodontitis 
Stage 4  HIV wasting syndrome 
 Pneumocystis pneumonia 
 Recurrent severe or radiological bacterial pneumonia 
 Chronic herpes simplex infection (orolabial, genital or 
anorectal of more than one month’s duration) 
 Oesophageal candidiasis 
 Extrapulmonary TB 
 Kaposi’s sarcoma 
 CNS toxoplasmosis 
 HIV encephalopathy 
 
The above WHO clinical staging was used to classify the participants in the study as 
shown in Table 4.3 below. 
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Table 4.3 WHO clinical staging of the study respondents 
WHO Staging 
Control 
(n= 35) 
Tool 
(n= 38) 
Diary 
(n= 38) 
Tool-Diary 
(n= 38) 
Stage 1 
 
Stage 2 
Stage 3 
Stage 4 
74.3% (26) 
2.9% (1) 
22.9% (8) 
0 
 
47.4% (18) 
2.6% (1) 
28.9% (11) 
21.1% (8) 
 
42.1% (16) 
5.3% (2) 
42.1% (16) 
10.5% (4) 
 
42.1% (16) 
5.3% (2) 
47.4% (18) 
5.3% (2) 
 
The above WHO clinical staging is illustrated in Figure 4.3 below. 
 
Figure 4.3 Respondents WHO clinical staging (n=149) 
The above suggests that about half of the patients (51.0%) could be classified as stage 
1 of HIV and AIDS, whilst only 4.0% were classified stage 2. AIDS-related co-
Stage 1, 51.01%
Stage 2, 4.03%
Stage 3, 35.56%
Stage 4, 9.4%
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morbidities were identified in 74 of the 149 patients in the study. Several patients often 
presented with more than one of the following co-morbidities.  
 TB 
 Oral candidiasis 
 Lymphadenopathy 
 PCP 
 Vaginal candidiasis 
 Oral hairy leukoplakia 
 Shingles 
 Cryptococcal meningitis 
 Genital warts (HPV infection) 
 CMV eye infection 
 Herpes zoster infection 
 Kaposi’s Sarcoma 
AIDS defining illnesses may be categorized as opportunistic infections, wasting 
syndrome, malignancies and diseases affecting the CNS and peripheral nervous 
systems. Patients with advanced HIV infection may respond poorly to HAART with 
resulting IRIS or treatment failure due to the extent of damage to their immune system. 
They are also more susceptible to adverse effects than patients whose infection is not 
advanced. (WHO, 2010) Special attention ought to be given to the monitoring of 
patients with advanced HIV disease and these conditions treated aggressively.  
The most common co-morbidity identified in the study was TB, with 30.2% (n=149) of 
the patients having TB during the study period. Oral candidiasis was also commonly 
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reported among the patients with 14.1% (n=149) of participants presenting with it, whilst 
lymphadenopathy followed with 8.05% of the patients presenting with swollen lymph 
nodes. The least reported conditions were CMV eye infection (0.7%; n=149) and 
Kaposi’s Sarcoma (0.7%; n=149). 
The non-AIDS related illnesses identified in the study (n=149) are shown below. The 
majority of patients often presented with more than one co-morbidity. The identified co-
morbidities were grouped as follows as there were numerous individual conditions; 
 Infection (84 patients) - Upper respiratory tract infections (URTIs) were the most 
common with 49 patients presenting with URTIs. 
 GIT disorders (66 patients) - Majority of patients in this group (28 patients) presented 
with abdominal cramps. 
 Skin disorders (19 patients) - Hyperpigmentation was the most reported skin 
disorder with 4 patients presenting with skin hyperpigmentation. 
 Blood and urine abnormalities (12 patients) - Anaemia and proteinuria, each with 4 
patients presenting, were the most common abnormalities recorded for this 
category. 
 Chronic conditions (17 patients) - 11 of the 17 patients were known hypertensives. 
 Respiratory (41 patients) - 35 patients presented with cough within the 3 months 
study period. 
 Psychosocial (24 patients) - 19 patients reported some kind of stress in their lives for 
various reasons, including loss in the family and work related stress among others. 
 Pain (53 patients) - In this category the most reported form of pain was headache, 
reported by 39 patients.  
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 Miscellaneous (44 patients) - This category was made up of different conditions the 
most common of which was fatigue, reported by 12 patients.  
Although the above conditions are non-AIDS related, they may be more frequent and 
serious in immuno-compromised patients. Immediate treatment needs to be 
administered in order to prevent advancement of these conditions which may further 
compromise the immunity of the patients. With respect to chronic conditions requiring 
long term treatment, special considerations in order to ensure that drug-drug 
interactions are avoided in order to avoid sub-therapeutic plasma concentrations of ARV 
or accumulation to toxic levels.  
4.3 Concomitant Medication 
It is important to note any and all medication the patients take concurrently with their 
ARVs particularly because of the potential for drug interactions that may result in sub-
therapeutic or toxic levels of ARVs (see Section 2.9.1 above). Some patients in the 
study received more than one other medication, besides their ARVs, in the 3 months of 
the study. The following medications were used with ARVs in the study sample. 
 Anti-infective agents - this group included co-trimoxazole, dapsone, amoxicillin, 
fluconazole and TB medication. 
 Supplements- including iron, folic acid, brewer’s yeast, vitamin C and vitamin B 
complex. 
 Chronic disease medication- including antihypertensives, simvastatin, gliclazide, 
metformin, colchicine and barbiturates. 
 Contraceptives- included Nur-isterate® (norethisterone enantate), Depo-Provera® 
(medroxyprogesterone acetate) and Triphasil® (ethinyl oestradiol and 
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levonorgesterol). It was recorded that patients were counselled to use condoms 
although some reported that their partners did not want to use them whilst others 
were trying to conceive.  
 Pain medication- Including paracetamol and codeine or paracetamol alone. 
 Topical preparations- such as aqueous cream, zinc ointment and betamethasone 
cream were prescribed to patients with different skin problems. 
 Other medications- These included anti-tussives, flu medication, amitriptyline, 
prednisone and sutherlandia. 
The above reported medicines do not seem to match the number and nature of the 
reported co-morbidities in Section 4.2. This may be due to several possible reasons 
including; 
 patients self medicating and not reporting to the HCPs 
 patients visiting their general practitioners in other clinics or hospitals and receiving 
medication for their co-morbidities 
 patients admitted to hospital and hence the medication they received is not recorded 
at the Centre 
 inadequate recording of concomitantly used medications by HCPs at the Centre. 
In order to avoid the potential problem of drug interactions, it is essential for the HCPs 
to ensure that they ask patients whether they are receiving any other treatment besides 
ARVs. This needs to be done in a manner that does not intimidate the patients but 
rather makes them feel comfortable enough to report any self medication. The result 
would be that there would be better documentation of all medications used by the 
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patients and hence patients can be advised appropriately about any potential 
interactions. 
4.4 ARV Regimens 
At the time of the study the recommended ARV regimens according to the South African 
Department of Health guidelines (2008) were as follows; 
 First Line 
o 1a- d4T/3TC/EFV 
o 1b- d4T/3TC/NVP 
o 1c- AZT/3T/EFV or NVP 
 Second Line 
o 2a- AZT/ddI/Lopinavir-ritonavir 
o 2b- TDF/3TC/Lopinavir-ritonavir 
o 2c- AZT/ddI/Double dose Lopinavir-ritonavir 
Due to the variations in patients’ response to treatment, these standard regimens are 
not always adhered to. The following are some of the possible reasons for regimens 
other than the standard recommended ones; 
 In certain cases clinicians change treatment for  various reasons such as replacing 
agents which have caused intolerable adverse effects with agents from the same 
group or a different group with a better profile.  
 In other cases, regimens are changed due to treatment failure, discussed in Section 
2.7.1 above, resulting in individualized regimens that may be different from the 
standard recommended regimens. 
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 For some patients, their economic status may determine the treatment that they may 
be able to receive. People who can afford to buy ARVs may be started on newer 
regimens not available to everyone in the country.  
The ARV regimens identified in this study are shown in the table below.  
 
Table 4.4 ARV regimens in the study 
First Line Second Line 
d4T/ddI/EFV ddI/AZT/Lopinavir 
d4T/3TC/EFV ddI/3TC/ Lopinavir 
d4T/3TC/NVP TDF/3TC/ Lopinavir 
AZT/3TC/NVP AZT/3TC/ Lopinavir 
TDF/FTC/EFV TDF/FTC/ Lopinavir 
TDF/FTC/NVP d4T/ddI/ Lopinavir 
TDF/3TC/EFV d4T/3TC/ Lopinavir 
ddI/3TC/EFV SQV/ Lopinavir 
TDF/FTC/3TC/EFV  
 
 
Figure 4.4 below illustrates the ARV regimens observed across the four study groups. 
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Figure 4.4 ARV regimens in the different study groups 
 
Of the 149 patients in the study, 81.2% were receiving first line regimens whilst 18.8% 
were receiving second line regimens. Second line regimens are usually reserved and 
used as salvage therapy in patients not responding to first line regimens due to 
treatment failure (see Section 4.6), resistance or adverse effects to first line regimens.  
4.5 Adverse Effects Identified 
The reporting of adverse effects by participants in the different study groups is 
summarised in Table 4.5 below.  
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Table 4.5 Adverse effects recorded for the different study groups 
Study Groups 
Reported Adverse Effects 
Yes No 
Control (n=35) 51.4% (18) 48.6% (17) 
Tool (n=38) 50.0% (19) 50.0% (19) 
Diary (n=38) 60.5% (23) 39.5% (15) 
Tool-Diary (n=38) 50.0% (19) 50.0% (19) 
 
The above data was collected from the Centre’s patient records by the researcher and 
recorded in the data collection form and not the individual adverse effects monitoring 
tools, that is, the tool and the diary. From the table above, it is observed that 53.0% of 
the patients in the study (n=149) reported adverse effects or symptoms of adverse 
effects that were identified and recorded using the Centre’s monitoring method. This 
was expected as it is estimated that about 50% of patients receiving HAART experience 
adverse effects (Schiller, 2005). 
The specific adverse effects identified in this study have been grouped for reasons of 
statistical analysis and are listed below.  
 Biological - including raised liver enzymes, anaemia, hyperlactatemia, lactic 
acidosis, anaemia, pancreatitis, pancytopenia, tachypnoea, tachycardia,  
 CNS - including dizziness, drowsiness, moody, nightmares, insomnia, hallucinations, 
memory problems 
 GIT - including abdominal cramps, nausea, vomiting, diarrhoea, loss of appetite, 
post prandial abdominal pain, heart burn,   
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 Physical - including weight gain, weight loss, gynaecomastia, lipodystrophy 
(Crixivan potbelly and buffalo hump), fat wasting, rash, muscle pain, loss of hair, 
hyperpigmentation, increased hunger and thirst, fatigue, headaches, peripheral 
neuropathy 
Some patients presented with more than one category of adverse effects. The following 
table breaks down the adverse effects identified in the Centre for the four study groups 
according to the above stated categories.  
 
Table 4.6 Adverse effects identified using the Centre’s method of monitoring 
 
Study Groups 
Adverse Effects 
Biological CNS GIT Physical 
Control (n=35) 5 6 3 8 
Tool (n=38) 6 9 1 10 
Diary (n=38) 7 6 2 19 
Tool-Diary (n=38) 4 1 1 17 
 
The above table indicates adverse effects recorded for the four study groups in the 
patients’ files, that is, the Centre’s monitoring method. This excludes information 
obtained from the monitoring strategies.  
The monitoring strategies used in this study were useful in identifying some adverse 
effects or symptoms that were not identified using the Centre’s normal method of 
monitoring. These “extra” effects were included in the analysis of the effectiveness of 
the monitoring strategies and included muscle pains, memory problems, night sweats, 
difficulty walking, hallucinations, dizziness, headaches and constipation. The following 
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table illustrates the frequency of identification of these “extra” adverse effects categories 
for the Tool, Diary and Tool-Diary group.  
 
Table 4.7 Adverse effects identified using the research monitoring strategies only 
(“Extra adverse effects”) 
Adverse effects Tool Diary Tool-Diary 
Biological 3 0 3 
CNS 3 10 13 
GIT 5 6 6 
Physical 3 6 7 
 
In order to determine the  effectiveness of the interventions, a comparison can be  made 
between the adverse effects identified using the Centre’s usual method of monitoring 
patients and the tool, diary and tool-diary methods used in the study. This will be done 
per study group in order to establish the effectiveness of each monitoring strategy. 
Since the monitoring strategies were not incorporated into patients’ clinical records, but 
were treated as a separate means of monitoring, the comparisons made will be 
between the adverse effects identified by the Centre versus the monitoring strategies, 
for each study group as shown below.   
4.5.1 Adverse effects identified using the adverse effects monitoring tool alone 
A comparison will be made for the tool group between the adverse effects identified for 
the patients in this group using the Centre’s monitoring method and those identified 
using the adverse effect monitoring tool for the 38 patients in the Tool group.  
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Table 4.8 Comparison of the Tool and Centre’s adverse effects monitoring 
methods for the Tool Group 
 Centre Biological 
Total 
Significance 
Tool Biological No Yes  
 
- 
No 16 0 16 
Yes 3 0 3 
   19 
 Centre CNS 
Total 
Significance 
Tool CNS  No Yes 
0.516 
No 9 5 14 
Yes 4 1 5 
   19 
 Centre GIT 
Total 
Significance 
Tool GIT  No Yes  
 
- 
No 10 0 10 
Yes 9 0 9 
   19 
 Centre  Physical 
Total 
Significance 
Tool Physical No Yes  
 
0.141* 
No 9 2 11 
Yes 4 4 8 
   19 
Note:  
 *** significant at 99 percent confidence level ** significant at 95 percent confidence level * significant at 90 
percent confidence level using two tailed t-test. 
 Yes represents the frequency at which the adverse effect was detected while No indicates that the adverse effect 
was not detected. 
 
The above data applies to only 19 (50.0%; n=38) of the filled monitoring tools. 
Therefore, the other 19 tools have been excluded from the above comparison with the 
Centre’s method of monitoring for adverse effects in order to yield a more accurate 
result of how the two methods compare with regards to identification and recording of 
adverse effects.  
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The above table shows that the tool had a statistically significant effect on the reporting 
of physical adverse effects only at 90% confidence level. This means that the tool as 
compared to the Centre’s monitoring method was better in reporting of the physical 
adverse effects at the 90% confidence level. There was no significance change in 
reporting biological and GIT adverse effects as there were no reported cases of these 
effects.  
4.5.2 Adverse effects identified using the patient self-monitoring diary alone 
From the diary group 15 diaries were returned although one was not included in the 
analysis as it was written in Afrikaans which the researcher does not understand. 
Therefore, only 14 (36.8%; n=32) diaries were analysed and used to establish the 
effectiveness of the diary as compared to the Centre’s method of adverse effect 
monitoring in the identification and recording of adverse effects for the patients in the 
diary group. The comparison below is therefore of the adverse effects identified using 
the Centre’s method of monitoring for adverse effects versus those identified using the 
diary, for the 14 Diary group patients.  
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Table 4.9 Comparison of the Diary and Centre’s adverse effects monitoring 
methods for the Diary Group  
 Centre Biological 
Total 
Significance 
Diary Biological No Yes  
 
- 
No 11 3 14 
Yes 0 0 0 
   14 
 Centre CNS 
Total 
Significance 
Diary CNS  No Yes 
0.649 
No 4 1 5 
Yes 8 1 9 
   14 
 Centre GIT 
Total 
Significance 
Diary GIT  No Yes  
 
- 
No 7 7 14 
Yes 0 0 0 
   14 
 Centre  Physical 
Total 
Significance 
Diary Physical No Yes  
 
0.640 
No 5 3 8 
Yes 3 3 6 
   14 
Note:  
 *** significant at 99 percent confidence level ** significant at 95 percent confidence level * significant at 90 
percent confidence level using two tailed t-test. 
 Yes represents the frequency at which the adverse effect was detected while No indicates that the adverse effect 
was not detected. 
 
The table above indicates that the diary alone did not have any significant impact on 
adverse effect monitoring, that is, there was no substantial change when compared with 
the Center’s method of monitoring in all the categories of adverse effects.  The 
significance of the diary in monitoring for the biological and GIT adverse effects could 
not be established since there were no reported effects.  
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With regards to the biological adverse effects, the diary group was insufficient in 
reporting as these are mainly derived from blood tests and other tests. The diary would 
therefore only be useful in identifying symptoms of the biological adverse effects and 
not the actual biological adverse effects because it identified subjective symptoms.  
4.5.3 Adverse effects identified using the patient self-monitoring diary and the 
monitoring tool in combination 
Of the 38 patients in the Tool-Diary group only 17 (44.7%; n=38) will be analysed in 
terms of comparison with the clinic’s normal monitoring method as the rest of the diaries 
and tools were not returned or completed respectively.  A comparison will be made 
between the adverse effects identified by the Centre’s adverse effect monitoring method 
and those identified using the Tool-Diary method for the 17 patients in the Tool-Diary 
group. 
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Table 4.10 Comparison of the Tool-Diary and the Centre’s adverse effects 
monitoring methods for the Tool-Diary Group 
 Centre Biological 
Total 
Significance 
Tool-Diary 
Biological 
No Yes 
 
 
0.633 No 13 3 16 
Yes 1 0 1 
   17 
 Centre CNS 
Total 
Significance 
Tool-Diary CNS  No Yes 
0.388* 
No 7 0 7 
Yes 9 1 10 
   17 
 Centre GIT 
Total 
Significance 
Tool-Diary GIT  No Yes  
 
0.506 
No 11 1 12 
Yes 5 0 5 
   17 
 Centre  Physical 
Total 
Significance 
Tool-Diary 
Physical 
No Yes 
 
 
0.201* No 5 2 7 
Yes 4 6 10 
   17 
Note:  
 *** significant at 99 percent confidence level ** significant at 95 percent confidence level * significant at 90 
percent confidence level using two tailed t-test. 
 Yes represents the frequency at which the adverse effect was detected while No indicates that the adverse effect 
was not detected. 
 
It is evident from the above table that the tool and diary had a statistical significant effect 
on the reporting of CNS and physical adverse effect at 90% confidence level. This 
implies that using the tool and diary together was more effective in identification and 
reporting of these adverse effects as compared to the Centre’s method of monitoring. 
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The Tool-Diary method of monitoring did not have a notable significant effect on the 
identification of biological and GIT categories of adverse effects.  
4.6 Evaluation of the Monitoring Tools 
4.6.1 The adverse effect monitoring tool 
The evaluation for the perceived effectiveness of the tool was done through an informal 
feedback session with the HCPs involved in the study. The HCPs indicated that they 
were sometimes very busy and hence they did not fully utilize the monitoring tool. This 
was reflected by the number of monitoring tools that were utilized for the study (47.4%; 
n=76, that is, 38 Tool group and 38 Tool-Diary group). They also indicated that the 
whole study was very time consuming considering the already existing work load. This 
may be the reason that 52.6% (n=76) of the monitoring tools were not completed at all. 
Therefore, the results obtained from the comparison of the tool and the Centre’s 
monitoring method may not be a true representation of the adverse effects encountered 
by patients in this study or the usefulness of the tools.  
4.6.2 The patient self-monitoring diary 
The diary was made up of different sections which were to be completed by the 
patients. The analysis of these different sections of the diaries is combined for the 
diaries used in the Diary and Tool-Diary group as shown in the table below.  
Table 4.11 Analysis of the completion of the different sections of the patient self-
monitoring diary 
 
(n=32) 
Human Figure 
Weekly 
Journals 
Adherence 
Self - Rating 
Physical 
Changes 
Filled 5 28 29 5 
Not Filled 27 4 3 27 
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From the table above it is observed that only 15.6% (n=32) of the patients made use of 
the human figure provided in the diaries to pin-point adverse effects or symptoms that 
they were experiencing. 87.5% (n=32) of the weekly journals were filled and 90.6% 
(n=32) adherence self-ratings completed. The final section of the diary required the 
patients to state whether they have had any physical changes in their bodies since 
initiation of HAART and this was only completed by 15.6% (n=32) of the patients. It can 
therefore be concluded that the diary instructions were followed by majority of patients 
for two sections only (weekly journals and adherence rating) and not followed for the 
human figure and the physical changes part of the diary. 
A diary evaluation form was provided to the HCPs by the researcher in order to further 
evaluate the perceived usability and usefulness of the diary. This form was to be used 
at the end of the study, when the patients returned their diaries. The HCPs were to 
familiarize themselves with the evaluation forms and then ask the patients the questions 
in the different sections. The diary evaluation form had the following patient sections:  
 User-friendliness of the different sections of the diary 
 Clarity of instructions 
 Overall perception of the diary 
 Effect on their lives 
A final evaluation question directed to the HCP was included to establish the HCP’s 
perception of whether the diaries were useful in identification of adverse effects in their 
patients. For the Tool-Diary group, the HCPs were also asked to state whether they 
perceived the diary to be useful in identifying adverse effects not identified or recorded 
in the tool or the patient file.  
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The evaluation forms were not fully completed. The following figures illustrate the 
evaluation of the diary (n=33). 
  User-friendliness of the different sections of the diary - 30 responses  
The patients were asked to rate the diary as very user-friendly, fairly user-friendly or not 
user-friendly. 9.1 % (n=33) of the patients did not respond to this question. The figure 
below illustrates how user-friendly the patients found the diary (n=30). 
 
 
Figure 4.5 Perceived user-friendliness of the diary (n=30) 
 
 Clarity of instructions - 31 responses  
The patients were to rate the diary instructions as very clear, clear or not clear. The 
figure below shows how the patients rated the clarity of the instructions. 6.1% (n=31) of 
the evaluation forms did not have a response to this question. 
46.7%
46.7%
6.7%
Very user-friendly
Fairly user-friendly
Not user-friendly
 128 
 
 
Figure 4.6 Perceived clarity of instructions (n=31) 
 
Although more than half the patients (n=33) indicated that the diary instructions were 
clear, they did not always follow them. For instance, several patients did not fill in their 
weekly diaries, rate their adherence or tick any symptoms on the human diagram on the 
first page of the diary. Others still did not use the provided scale of one to ten to rate 
their adherence but rather used words such as “very well” or “very good” or just “good”, 
among others. When they missed any of their doses, some patients wrote the reasons 
as to why they missed.  
 Overall perception of the diary - 27 responses  
The perceived usability and usefulness of the diary was rated as shown in the figure 
below. In 18.2% of the evaluation forms, this question had no response. 
 
32.3%
61.3%
6.5%
Very clear
Clear
Not clear
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Figure 4.7 Perceived usability and usefulness of the diary (n=27) 
 
70.4% (n=27) of the patients thought the diary was fairly usable and helpful while 29.6% 
(n=27) rated the diary as very usable and helpful. The term “helpful” was used to refer to 
perceived usefulness or effectiveness. 
 Effect on their lives 
o Adherence - 28 responses (n=33) 
o Daily activities -27 responses (n=33) 
The patients who used the diary were asked to indicate whether the diaries had an 
effect on their adherence and their daily activities as illustrated in the figures below. 
 
29.6%
70.4%
0%
0%.
0%
Very usable and helpful
Fairly usable and helpful
Not usable and helpful
Usable but not helpful
Helpful but not useful
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Figure 4.8 Perceived effect on adherence (n=33) 
 
15.2% (n=28) of the evaluation forms did not have a response to this question. 
However, it is observed that the majority of the patients indicated that the diary aided 
in improving their adherence.  
 
93.9%
6.1%
Improved
Not improved
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Figure 4.9 Perceived effect of the diaries on the patients daily lives (n=33) 
 
No response was given to the question of effect on daily activities by 18.2% (n=27) of 
the patients. About 30% of patients felt that the diaries disrupted their daily lives either 
always or sometimes. They felt that the diary required a lot of work and was 
cumbersome and time consuming. Others felt it disrupted their daily lives because they 
did not understand the instructions properly, as reflected by the manner in which they 
completed or did not complete their diaries. However, 70.4% (n=27) of the patients 
reported that the diaries did not disrupt their lives.  
 Adverse effect identification - 23 responses  
This section was for the HCPs to indicate whether the diaries were useful in identifying 
adverse effects. They were further asked to indicate, in the case of the Tool-Diary 
group, whether the diaries were useful in identifying adverse effects not identified using 
the tool. The results of this evaluation are shown in the Figure 4.10 below. 
11.1%
18.5%
70.4%
Disrupted
Sometimes disrupted
Did not disrupt
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Figure 4.10 HCP perceived effectiveness of diaries in adverse effect identification 
(n=23) 
 
There was no response to this question for 30.3% (n=23) of the patients who returned 
their diaries. From the remaining patients, the HCPs indicated that the diaries were 
useful in adverse effect identification in 78.3% (n=23) of the patients. In the evaluation 
of the Tool-Diary group, the HCPs indicated that the diaries were useful in identifying 
adverse effects not indicated in the tool in 21.7% of the patients.  
In conclusion, the diary was reported to have been user-friendly, usable and helpful, the 
instructions pertaining to it were clear, and generally it improved adherence without 
disrupting patients’ daily activities. The diaries were also reported by the HCPs to be 
effective in aiding adverse effect identification. There were however a small number of 
patients who reported that the diary was cumbersome to use and time consuming. 
78.3%
0%
21.7%
Identified adverse effects
Did not identify adverse 
effects
Identified adverse effects 
not in tool (Tool-Diary)
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Only 31 of the 76 diaries distributed for the study were returned. Some reasons cited for 
this low return rate included patients forgetting to bring their diaries to the clinic and 
patients being transferred to different healthcare facilities.   
4.7 Treatment Change 
Of the 149 patients, 56.0% had their treatment changed for various reasons, indicated 
in Table 4.12below. 
 
Table 4.12 Reasons for treatment change 
Reason for change 
Control 
Group 
(n=35) 
Tool 
Group 
(n=38) 
Diary 
Group 
(n=38) 
Tool-Diary 
Group 
(n=38) 
Adverse effects 15 11 15 13 
Prevention of mother to 
child transmission 
(PMTCT) 
2 2 4 5 
Resistance (treatment 
failure) 
3 4 5 10 
Treatment changed but 
reason not stated in file 
7 7 4 6 
 
From the above table, it is evident that adverse effects were the main reason for 
treatment change, with 36.2% (n=149) of patients presenting with adverse effects 
necessitating treatment change. 14.8% (n=149) of patients had their treatment changed 
due to resistance, either as a result of treatment failure or defaulting. This observation 
was expected as adverse effects and treatment failure account for majority of treatment 
change as discussed in Section 2.7.1. The figure below illustrates the above findings.  
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Figure 4.11 Reasons for treatment change across study groups 
 
ARV toxicities that resulted in treatment change were severe peripheral neuropathy, 
lipodystrophy including Crixivan potbelly, gynaecomastia, lipoatrophy of arms and legs, 
severe CNS adverse effects including drowsiness, dizziness and hallucinations and 
severe GIT effects including diarrhoea, nausea and vomiting. 12.3% of the female 
patients (n=106) had their treatment changed as a result of PMTCT. A number of 
female patients whose CD4 cell count was above that required for HAART initiation 
discontinued ART after delivery out of choice, but were sometimes resistant to the same 
treatment when they commenced HAART, necessitated by low CD4 cell counts. 14.8% 
of the patients (n=149) were noted to have developed resistance to treatment 
characterized by treatment failure for reasons such as defaulting, for various reasons.  
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 CHAPTER 5  
CONCLUSION, LIMITATIONS AND RECOMMENDATIONS 
5.1 Conclusion 
Monitoring patients receiving HAART for adverse effects, with the aim of identifying 
potentially life threatening adverse effects, such as lactic acidosis, is of high importance. 
Once an adverse effect is suspected further tests may be conducted to verify any 
abnormalities in the normal body function. Physical adverse effects may also be 
problematic, particularly those that have the potential to be of cosmetic concern to 
patients and those that reduce patient’s quality of life by causing pain or disruption.   
Early identification of such adverse effects means that timely interventions are able to 
be made which may avoid loss of quality of life for patients and in some cases even 
prevent fatal outcomes. This also may mean that patients are less likely to default or 
discontinue treatment, for fear of adverse effects.  
The study was conducted with 149 participants, all receiving HAART and was aimed at 
evaluating three strategies employed for early adverse effect identification. The 
effectiveness of the three strategies, a patient self-recording diary, a HCP initiated 
adverse effect monitoring tool or a combination of both, were compared with the method 
usually used by HCPs at the study site.  
The table below shows the category of adverse effects each method was most effective 
in identifying when compared to the Centre’s method of monitoring for adverse effects 
at 90% confidence level. 
 
 136 
 
Table 5.1 Overall effectiveness of the monitoring strategies 
Adverse Effects Tool Diary Tool-Diary 
Biological - - - 
CNS - - 0.388 
GIT - - - 
Physical 0.141 - 0.201 
 
The above table indicates that the tool was statistically significant when used alone in 
the identification and recording of physical adverse effects, while the diary was not 
statistically significant at identification and recording of adverse effects at a 90% 
confidence level. Overall, combining the tool and diary methods of adverse effect 
monitoring appears to have been the most effective method of identifying and recording 
of CNS and physical adverse effects at 90% confidence level. This is to be expected 
because the HCPs use the tool at each clinic visit to record any symptoms or adverse 
effects experienced by the patients, whilst the patients take the diaries home and record 
any symptoms or adverse effects they experience in their daily lives. The Tool-Diary 
method of monitoring may also be more effective than simply recording experienced 
symptoms because the tool groups together symptoms of a particular adverse effect, 
thereby making it easier to speculate which adverse effect may be occurring before and 
makes deciding which tests to conduct easier. The diary is mainly useful in identifying 
subjective signs and symptoms experienced by the patients. Combining the two 
appears to yield the most favourable results. The tool when used alone may not be 
useful in detecting subjective symptoms while the diary on its own may not be useful in 
identifying any chemical blood or urine abnormalities. Another unintended but significant 
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effect of the diaries was the perceived improvement of adherence in 93.9% (n=33) of 
the patients. This may in turn aid in reducing adverse effects which tend to be common 
in non-adherent patients.   
Patients in the study who presented with adverse effects or symptoms of adverse 
effects that were then confirmed using the appropriate tests either had pharmacological 
or non-pharmacological interventions implemented or their treatment changed to more 
appropriate ARV regimens with a lower propensity for these effects. This was noted in 
all four study groups.   
Since the monitoring tool method was compared to the Centre’s method of monitoring 
for adverse effects for only 19 patients (50%; n=38) in the Tool group, the results 
obtained may not be generalisable. The same applies for the diary group, where only 14 
patients (36.8%, n=38) were analyzed and the Tool-Diary group where only 17 patients 
(44.7%; n=38) were included. In total, this only amounted to 50 patients (43.9%, n=114- 
Tool, Diary and Tool-Diary groups). The results of this study therefore need to be further 
investigated in larger sample groups in order to verify the true effectiveness of the 
monitoring strategies used.   
The results analyzed indicate that none of the comparisons between the monitoring 
strategies and the Centre’s monitoring method met the 95% confidence interval which is 
the most commonly used and accurate estimate in statistics. This inadequacy may be 
attributed to the poor return rate and or completion of the monitoring diaries and tools 
respectively. Out of 80 monitoring tools handed out, only 32 (15 Tool Group and 17 
Tool-Diary Group) were completed. The reason given for this by the HCPs was that they 
were often very busy and therefore just wrote in the patient files which are the Centre’s 
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records whilst forgetting to complete the monitoring tool. Of the 80 dairies handed out, 
only 33 were returned for analysis. The majority of the patients forgot to return their 
diaries to the clinic at each clinic visit whilst some of the patients were transferred to 
other wellness centres, during the study period.  
Therefore, the above results may not be a true representation of the overall 
effectiveness of the monitoring strategies in identification and recording of ARV adverse 
effects. However, despite these challenges, the monitoring strategies appear to have 
been helpful in adverse effect identification and recording. 
5.2 Limitations 
The limitations of this study are discussed below: 
 Firstly, the study period may have been too short to collect substantial data. The 
study period was further shortened by the time taken to assign patients to the 
different study groups.  
 Some patients, who had been on ARVs for a longer period, were given 2 or 3 
months supply of ARVs at a time. This was a problem as the study period was only 3 
months and therefore a proper follow up was not always possible for these patients.  
 It may have been difficult and rather cumbersome for the health care team 
participating in the study to record adverse effects in both the patient files and the 
monitoring tools. This therefore resulted in inconsistencies between the adverse 
effects recorded in the files and the tools. It is envisaged that in practice the 
monitoring tool would be incorporated into the patient file, removing the need for 
duplication. 
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 Because the adverse effects of ARVs are sometimes non-specific, for example 
headaches and GIT symptoms such as nausea, it is difficult to distinguish between 
co-morbidities and symptoms indicating adverse effects.  
 Another limitation of this study involves handing out diaries for patients to take 
home. This may cause problems when they do not return them for various reasons, 
accounting for the poor number of returned diaries. 
 The study was reported to be time consuming and hence may have been negatively 
perceived by the HCPs and seemed to have required too much effort, which was a 
hindrance due to their already busy schedules. This may be the reason why the 
tools were not fully utilized in the study. Again the incorporation of the tool into a 
patient record would assist in overcoming this problem. 
 The diaries were designed to be completed daily but only a minority of patients did 
that. This may be because they forgot, they were too tired to attend to it or it 
disrupted their daily activities.  
5.3 Recommendations for future research 
Early identification of ARV adverse effects may mean that potentially fatal adverse 
effects are managed on time and that bothersome adverse effects such as nausea, 
vomiting and diarrhoea are dealt with appropriately in order to ensure patients remain 
adherent to their treatment. Due to the non-specific nature of certain adverse effects, it 
may be necessary to incorporate a separate monitoring strategy, as was done in this 
study, in order to record adverse effects and distinguish them from co-morbidities. 
The results obtained in this study are indicate that these strategies have potential in 
symptom and adverse effect identification and recording. However, additional research 
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is required in order to verify the generalisability of the results and clarify the usability 
and effectiveness of these methods in pharmacovigilance of ARVs.  
The following are some recommendations for further studies;  
 Increasing the study period 
 In order to distinguish between early, mid-term versus late adverse effects, it is 
recommended that the duration of HAART treatment of the patients be incorporated 
into the data collection form, used by the researcher 
 Providing reminders to patients due for a clinic visit to bring back their diaries to the 
clinic via sms 
 Incorporating the monitoring tool into the patient record, in order to reduce the 
amount of writing for busy HCPs 
 Special attention ought to be given to those symptoms which are non-specific such 
as headaches in order to ensure they are not neglected without establishing their 
exact seriousness and implications for the patients.  
 The reasons for the poor return rate of the diaries and the poor filling of the 
monitoring tools may need to be further investigated in order to establish the exact 
cause of this poor response. This may be done through interviews with the HCPs 
involved as well as the available patients who did not return their diaries. 
Much research still needs to be conducted in order to establish the most effective 
method of monitoring patients for ARV adverse effects, including subjective and 
objective symptoms of adverse effects experienced. Other convenient means of 
adverse effect reporting by the patients need to be explored in order to ensure early 
identification of adverse effects which would in turn ensure that necessary interventions 
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are undertaken made in order to ensure that patients remain adherent to their 
treatment, improve their quality of life, prevent fatal adverse events and preserve their 
confidentiality.  
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 APPENDICES 
Appendix 1a 
 
 
 
 
-Headaches (6e) 
-Sleep disorders (10c) 
-Hallucinations (10d) 
-Abnormal heart beat (2h) 
-Tachycardia (5e, 10e) 
 
-Enlarged/tender (2g) 
-Hepatomegaly (3b) 
-↑ serum ALT concentration (3d) 
 
 
-Yellow (3a) 
-Blisters (6b) 
-Sunken eyes (9.1a) 
-Muscle spasms (10a) 
-Dyspnoea (2a, 7c) 
-Tachypnoea (2b) 
-Respiratory distress (5b) 
-Abdominal pain (2c, 5a) 
-Nausea (3c, 4a, 5c) 
-Vomiting (3c, 4b, 5d) 
-Diarrhoea (3c, 4c) 
-Constipation (4e) 
-↑ serum amylase and lipase (5f) 
-↑ insulin levels (8d) 
Lipodystrophy 
-Sunken face and cheeks (9.1a) 
-Veins on arms and legs more visible (9.1b) 
-Fat wasting in buttocks (9.1c) 
-Buffalo hump (9.2a) 
-Crixivan potbelly (9.2b) 
-Breast enlargement (9.2c) 
Others 
-Weight loss (2d, 8c) 
-Fatigue (2e, 7a) 
-Loss of appetite (4d) 
-Heart burn (4f) 
-Skin rash (6a) 
-Blisters in the mouth or genitals (6b) 
-Peeling skin (6c) 
-Fever (6d) 
-Chest pain (7b) 
-Anaemia (7d) 
-Neutropenia (7e) 
-↑ urination with glucose in the urine (8a) 
-↑ thirst and hunger (8b) 
-Change in calcium and phosphate levels (10f) 
-↓ haemoglobin (10g) 
-↓ MCV (mean corpuscular volume) (10h) 
 
-Tingling or numbness (1a) 
-Pain (1b) 
-Difficulty standing or walking (1c, 10b) 
-Cold blue hands (2f) 
 
ADVERSE EFFECT INDICATOR CHART 
 156 
 
Appendix 1b 
ANTIRETROVIRAL RECORDING AND MONITORING CHART 
 
Please note the following: 
1. If one of the following adverse effects is experienced (Refer to Figure 1 for code for adverse effect) , indicate the severity using 
the severity scale below: 
1=Mild; 2=Moderate; 3=Severe; 4=Excessive/Disabling 
2. Indicate in the intervention column any interventions made in relation to the adverse effect experienced and in the 
result/comment column the result of the intervention. The management of specific adverse effects is listed in Table 1; indicate 
the number of any intervention in the intervention column below (e.g. 9a – for discontinuing offending drugs in peripheral 
neuropathy). Indicate in full in the block provided any other intervention initiated (including any ARV substitutions made: Refer to 
Table 2). 
3. The three blocks provided for each symptom are for the three months study period. 
4. Table 2 indicates recommended ARV substitutions for specific adverse effects. 
 
Patient’s Current Regimen: ……………………………………………. 
Patient study no:  
Symptoms Date Severity Intervention Result/Comment 
HCP Initials 
and Signature 
1. Peripheral neuropathy:  (d4T, ddC, ddI) 
a. Tingling or numb sensation 
in hands and/or feet 
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b. Pain in hands and/or feet 
     
     
     
c. Difficulty walking or standing 
 
     
     
     
2. Lactic acidosis:  (NRTIs esp d4T, ddI, AZT) 
a. Dyspnoea (shortness of 
breath)  
     
     
     
b. Tachypnoea 
(hyperventilation) 
     
     
     
c. Abdominal pain 
     
     
     
d. Weigh loss 
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e. Fatigue (tired) 
     
     
     
f. Cold blue hands 
     
     
     
g. Enlarged/tender liver 
     
     
     
h. Abnormal heartbeat 
     
     
     
3. Hepatotoxicity: ( All NNRTIs, all PIs, most NRTIs) 
a. Jaundice (skin yellow tinge 
as well as white of eyes) 
     
     
     
b. Hepatomegaly 
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c. Nausea/vomiting/diarrhoea 
     
     
     
d. Increased serum ALT 
concentration 
     
     
     
4. GIT distress: ( All PIs, AZT, ddI) 
a. Nausea 
     
     
     
b. Vomiting 
     
     
     
c. Diarrhoea 
     
     
     
d. Loss of appetite 
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e. Constipation 
     
     
     
f. Heartburn 
     
     
     
5. Pancreatitis: ( ddI alone, ddI + d4T, hydroxyurea, TDF) 
a. Poststprandial abdominal 
pain 
     
     
     
b. Respiratory distress 
     
     
     
c. Nausea 
     
     
     
d. Vomiting 
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e. Tachycardia 
     
     
     
f. Increased serum amylase 
and lipase 
     
     
     
6. Hypersensitivity Reaction: (ABC, All NNRTIs and Amprenavir) 
a. Flat or raised spots with blisters 
in centre (skin rash) 
     
     
     
b. Blisters in the mouth, eyes and 
/or genitals 
     
     
     
c. Peeling of the skin resulting in 
sore 
     
     
     
d. Fever 
     
     
     
 162 
 
e. Headaches 
     
     
     
7. Bone marrow suppression: (AZT) 
a. Fatigue  
     
     
     
b. Chest pain 
     
     
     
c. Dyspnoea 
     
     
     
d. Decrease in RBCs/MCV 
(anaemia) 
     
     
     
e. Decrease in white blood cells 
(neutropenia) 
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8. Hyperglycaemia: (All PIs) 
a. Increased urination with glucose 
in urine 
     
     
     
b. Increased thirst and hunger 
     
     
     
c. Weight loss 
     
     
     
d. Increased insulin levels 
 
     
     
     
9.Lipodystrophy/Fat redistribution      
9.1 Fat wasting: ( NRTIs (d4T > AZT > TDF, ABC, 3TC, FTC), esp when combined with EFV) 
a. In face (sunken cheeks, temples 
and eyes) 
     
     
     
b. Arms and legs (veins are more      
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visible-condition called “roping”      
     
c. Buttocks 
     
     
     
9.2 Fat accumulation: ( PI- or NNRTI-based regimens & with thymidine analogs (e.g. d4T, AZT)) 
a. Dorsocervical region (forming 
buffalo hump) 
     
     
     
b. Abdomen (eg “Crixivan potbelly”) 
     
     
     
c. Breast development/ enlagement 
in both men and women 
     
     
     
10. Other 
a. Muscle spasms 
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b. Impaired mobility 
     
     
     
c. Sleep disorders 
     
     
     
d. Hallucinations 
     
     
     
e. Tachycardia  
     
     
     
f. Change in serum calcium and 
phosphate ion levels 
     
     
     
g. Decreased haemoglobin 
     
     
     
h. Decreased MCV 
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Table 1: MANAGEMENT OF SPECIFIC ARV ADVERSE EFFECTS 
ADVERSE 
EFFECT 
ASSOCIATED ARVs MANAGEMENT 
1. Anaemia and 
Neutropenia 
AZT a. AZT dose can be reduced to 200 mg 12 hourly 
b. If no improvement, AZT may be replaced with d4T (refer) 
2. Diarrhoea All PIs, AZT, ddI a. Bulk-forming agents, such as psyllium products  
b. Antimotility agents, such as loperamide or  diphenoxylate/ atropine  
c. Rehydration and electrolyte replacement 
 
 
3. Hepatotoxicity  All NNRTIs, all PIs, most 
NRTIs 
 
 
a. Rule out other causes of hepatotoxicity (e.g alcoholism, viral hepatitis, chronic 
HBV, 3TC, FTC, or TDF withdrawal, HBV resistance)  
b. For asymptomatic patients, if ALT>5-10xULN, consider discontinuing ARVS (or 
monitor closely unless bilirubin is also elevated) 
c. For symptomatic patients STOP all ARVs and other potential hepatotoxic agents 
d. After symptoms subside and serum transaminases normalize, start new ARV 
regimen without the offending agent 
 
 
4. Hyperlipidaemia All PIs, EFV, NVP a. Lifestyle modification: diet, exercise, reducing cholesterol and saturated fat 
intake, and/or smoking cessation  
b. If triglyceride >5.6 mmol/L after dietary changes or LDL >4.9 mmol/L or LDL >3.4 
mmol/L with 2 or more other ischaemic heart disease risk factors, commence 
fibrates (or atorvastatin 5-10mg or pravastatin). 
 
 
5. Lactic acidosis NRTIs esp d4T, ddI, 
AZT 
a. Lactate 2-5 mmol/L: monitor monthly 
b. Lactate 5-10 mmol/L with symptoms:STOP all ART and seek urgent expert help 
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(Adapted from Department of Health, 2004) 
 
 
 
6. Lipodystrophy Lipoatrophy  
NRTIs (d4T > AZT > 
TDF, ABC, 3TC, FTC), 
esp when combined 
with EFV 
  
Lipohypertrophy  
PI- or NNRTI-based 
regimens & with 
thymidine analogs 
(e.g. d4T, AZT)  
 
a. Encourage exercise to reduce fat accumulation 
b. Switch protease inhibitor to an NNRTI 
c. Fibrates for lowering cholesterol and triglyceride levels 
d. Insulin resistance can be improved with anti-diabetic agents 
7. Nausea & 
Vomiting 
All PIs, AZT, ddI a. Antiemetic half an hour before the ARV dose up to 3 times daily 
b. Switch to less emetogenic ARV if very problematic  
 
 
8. Pancreatitis ddI alone, ddI + d4T, 
hydroxyurea, TDF 
a. Reduce ddI dose when used with TDF 
b. Discontinue offending agent(s) 
c. Symptomatic management; pain control, bowel rest, IV hydration, then gradual 
resumption of oral intake 
 
 
9. Peripheral 
Neuropathy 
d4T, ddC, ddI a. Discontinue offending agent before the pain becomes disabling 
b. Pharmacological management; treatment of the neuralgic pain with pyridoxine, 
opiates (e.g. tramadol), NSAIDs, amitriptyline, neurontin, topical capsaicin and 
topical lidocaine.  
c. Gabapentin, lamotrigine, oxycarbamazepine and topiramate may also be used 
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Table 2: RECOMMENDED ARV SUBSTITUTIONS FOR SPECIFIC ADVERSE EFFECTS 
 
Regimen Toxicity Drug substitution 
d4T/3TC/EFZ 
(1a) 
 d4T-related neuropathy or pancreatitis 
 
 Switch d4T to AZT 
 
 EFV-related persistent CNS toxicity  Switch EFV to NVP 
d4T/3TC/NVP 
 (1b) 
 d4T-related neuropathy or pancreatitis 
 
 Switch d4T to AZT 
 NVP-related severe hepatotoxicity 
 
 Switch NVP to EFV (except early pregnancy) 
 NVP-related severe rash (but not life 
threatening) 
 
 Switch NVP to EFV 
 NVP-related life-threatening rash 
 
 Switch NVP to EFV or lopinavir/ ritonavir 
 Stevens-Johnson syndrome  Switch to lopinavir/ritonavir 
AZT/ ddI / 
lopinavir / ritonavir 
(2) 
 AZT related anaemia or neutropenia 
 
Switch AZT to d4T (monitor closely for peripheral 
neuropathy and lactic acidosis) 
 ddI related GIT side effects 
 
 Switch ddI for enteric coated ddI 
(Source: Department of Health, 2004) 
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Appendix 1c 
 
PREVIOUS ANTIRETROVIRAL ADVERSE EFFECTS MONITORING TOOL (2008) 
 
DATE: ………………                   Patient Study no: ……………… 
 
PATIENT DEMOGRAPHICS 
Gender:  
Weight:  
Height:  
BMI:  
Smoke Yes/No: 
How many per day? 
 
Alcohol Yes/No: 
How much in a day? 
 
Substance Use (eg 
marijuana; mandrax etc) 
Yes/No 
 
If so which substances:  
 
MEDICAL HISTORY: 
List all medication presently being taken: 
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List any previous medication taken (in the past month): 
 
 
 
 
 
 
 
 
 
 
 
 
 
List all medical conditions past and present: 
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ARV Medical History: 
Date diagnosed:  
Place at which diagnosed:  
 
 Doctor Nurse Other 
By whom 
diagnosed 
   
HCP who initiated 
initial regimen  
   
 
 
Current Antiretroviral Regimen: 
Medication name Dose Times to be taken 
   
   
   
   
   
 173 
 
 
Changes in Antiretroviral treatment: 
Previous 
drug 
Dose of 
previous 
drug 
New drug Dose of 
new drug 
Date 
changed 
Reason for change 
      
      
      
      
      
  
Comments by HCP: 
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Antiretroviral Monitoring Chart 
If one of the following adverse effects is experienced, indicate the severity using the guide below: 
1=mild; 2=moderate; 3=severe; 4=excessive/disabling 
Also indicate in the intervention column any interventions made in relation to the adverse effect experienced. 
 
Date observed: …………………. 
Current regimen: ………………………… 
Patient Study no: …………… 
Symptoms Severity Intervention Date 
1. Peripheral neuropathy    
 Tingling or numb sensation in 
hands and/or feet 
   
 Pain in hands and/or feet    
2. Lactic acidosis    
 Dyspnoea (shortness of breath)     
 Tachypnoea (rapid breathing)    
 Weigh loss    
 Fatigue (tired)    
 Cold blue hands    
 Enlarged/tender liver    
 Abnormal heartbeat    
3. Hepatotoxicity    
 Jaundice (skin yellow tinge as 
well as white of eyes) 
   
 Hepatomegaly    
 Nausea/vomiting/diarrhoea    
 Increased serum ALT 
concentration 
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4. GIT distress    
 Nausea    
 Vomiting    
 Diarrhoea    
 Loss of appetite    
 Constipation    
 Heartburn    
 
5. Pancreatitis 
   
 Moderate to severe abdominal 
pain 
   
 Shock    
 Respiratory distress    
 Nausea 
 Vomiting 
   
 Tachycardia    
 Increased serum amylase and 
lipase 
   
6. Skin rash    
 Flat or raised spots with blisters 
in centre 
   
 Blisters in the mouth, eyes and 
/or genitals 
   
 Peeling of the skin resulting in 
sore 
   
 Fever    
 Headaches    
7. Bone marrow suppression    
 Fatigue     
 Chest pain    
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 Dyspnoea    
 Decrease in RBCs/MCV 
(anaemia) 
   
 Decrease in white blood cells 
(neutropenia) 
   
8. Hyperglycaemia    
 Increased urination with 
glucose in urine 
   
 Increased thirst and hunger    
 Weight loss    
 Increased insulin levels    
9.Lipodystrophy/Fat redistribution    
9.1 Fat wasting     
 In face (sunken cheeks, 
temples and eyes) 
   
 Arms and legs (veins are more 
visible-condition called “roping” 
   
 Buttocks    
9.2 Fat accumulation    
 Dorsocervical region (forming 
buffalo hump) 
   
 Abdomen (eg “Crixivan 
potbelly”) 
   
 Breast 
development/enlagement in 
both men and women 
   
10. Other    
 Muscle spasms    
 Impaired mobility    
 Sleep disorders    
 Hallucinations    
 Tachycardia     
 Change in serum calcium and 
phosphate ion levels 
   
 Decreased haemoglobin    
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 Decreased MCV    
 
Name of HCP who made the intervention:……………………… 
Signature of HCP…………………………………………………………… 
Indicate whether or not the patient was counselled on the adverse effect prior to experiencing it (Y/N): 
………………… 
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Appendix 2 
RESEARCHER’S DATA COLLECTION FORM 
                     Patient Study no: ……………… 
 
PATIENT DEMOGRAPHICS 
Gender:  
Age  
Weight:  
Height:  
BMI:  
Smoke Yes/No: 
How many per day? 
 
Alcohol Yes/No: 
How much in a day? 
 
Substance Use (eg 
marijuana; mandrax etc) 
Yes/No 
 
If so which substances:  
 
MEDICAL HISTORY: 
List all medication presently being taken: 
AUGUST SEPTEMBER OCTOBER 
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Any previous medication taken (in the past month): 
 
 
All medical conditions past and present: 
Past Present 
 August  September October 
   
 
Current Antiretroviral Regimen: 
Medication name Dose Times to be taken 
   
   
   
   
   
 
Changes in Antiretroviral treatment: 
Previous 
drug 
Dose of 
previous 
drug 
New drug Dose of 
new drug 
Date 
changed 
Reason for change 
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HCPs General comments (including patient adherence): 
AUGUST  SEPTEMBER OCTOBER 
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Appendix 3a 
PATIENT SELF-MONITORING DIARY (Pilot Diary) 
Please note the following:                    
1. If you experience the symptoms indicated in the figure below, indicate with a tick (√) and write the date next 
as shown in the example.  
2. Indicate any other symptoms you feel that are not in the figure. 
3. Complete the weekly tables below following the example shown in week 1 table. 
4. Take your diary to the clinic at each visit. 
 
-Heart beating fast 
-Heart burn 
-Difficulty breathing 
-Headaches 
-Nightmares 
-Sleep disorders 
-Seeing things (hallucinating) 
-Difficulty walking 
-Muscle spasms 
-Pins and needles  √ (16/04/09) 
-Pain 
-Stomach ache 
-Diarrhoea 
-Constipation 
-Nausea 
-Vomiting 
 
-Pins and needles 
-Pain 
-Cold blue hands 
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Use the following severity scale to indicate how painful or uncomfortable the symptom you experience 
is. 
Severity scale (1 to 4): 
1 - Able to carry out daily activities normally 
2 – Symptoms mildly affect my day 
3 – Severe symptoms but gained relief after you did something about it 
4 – Severe symptoms and no relief after you did something about it 
 
 
Use the following adherence scale to rate how you took your ARVs each week. 
 
Adherence scale (0 to 10) 
0 – Did not take my tablets this week 
5 - I took half my doses this week 
10 – I took all my tablets this week 
 
 
 
 
 **Including whether you stopped or skipped your ARVs 
 
 
 
Week 1 
To be filled in by Nurse 
Date What did 
you feel? 
Severity What did you 
do about 
it?** 
Result/ 
Comment 
When 
reported 
Intervention Nurse’s 
Signature 
1/05/09 Headache 2 Took 2 
Panado 
tablets 
Headache 
reduced 
   
 
 
 
       
 
 
       
 
 
       
 
 
       
 
 
       
 
 
       
 
 
       
 
How good were you at taking your medication this week?  
 
 
 
 
 
  
 
 
 
List any changes that you have experienced physically since you started taking ARVs. 
  
  
  
  
  
  
  
  
  
  
  
  
  
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Appendix 3b 
PATIENT SELF-MONITORING DIARY (Modified Diary) 
Please note the following:                    
1. If you experience the symptoms indicated in the figure below, indicate with a tick (√) and write the 
date next as shown in the example.  
2. Indicate any other symptoms you feel that are not in the figure. 
3. Complete the weekly tables below following the example shown in week 1 table. 
4. Take your diary to the clinic at each visit. 
 
 
-Heart beating fast 
-Heart burn 
-Difficulty breathing 
-Headaches 
-Nightmares 
-Sleep disorders 
-Seeing things (hallucinating) 
-Difficulty walking 
-Muscle spasms 
-Pins and needles  √ (16/04/09) 
-Pain 
-Stomach ache 
-Diarrhoea 
-Constipation 
-Nausea 
-Vomiting 
 
-Pins and needles 
-Pain 
-Cold blue hands 
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Use the following severity scale to indicate how painful or uncomfortable the symptom you 
experience is. 
 
Severity scale (1 to 4): 
1 - Able to carry out daily activities normally 
2 – Symptoms mildly affect my day 
3 – Severe symptoms but gained relief after you did something about it 
4 – Severe symptoms and no relief after you did something about it 
 
 
Use the following adherence scale to rate how you took your ARVs each week. 
 
Adherence scale (0 to 10) 
0 – Did not take my tablets this week 
5 - I took half my doses this week 
10 – I took all my tablets this week 
 
 
 
 
 **Including whether you stopped or skipped your ARVs 
 187 
 
Week 1 
 
 
How good were you at taking your medication this week?  
To be filled in by Nurse 
Date What did you 
feel? 
Severity What did you do 
about it?** 
Result/ Comment When 
reported 
Intervention Nurse’s 
Signature 
1/05/09 Headache 2 Took 2 Panado 
tablets 
Headache reduced    
 
 
 
       
 
 
       
 
 
       
 
 
       
 
 
       
 
 
       
 
 
       
 **Including whether you stopped or skipped your ARVs 
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Week 2 
 
How good were you at taking your medication this week?  
 
To be filled in by Nurse 
Date What did you 
feel? 
Severity What did you do 
about it?** 
Result/ Comment When 
reported 
Intervention Nurse’s 
Signature 
 
 
       
 
 
       
 
 
       
 
 
       
 
 
       
 
 
       
 
 
       
 **Including whether you stopped or skipped your ARVs 
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Week 3 
 
 
How good were you at taking your medication this week?  
 
To be filled in by Nurse 
Date What did you 
feel? 
Severity What did you do 
about it?** 
Result/ Comment When 
reported 
Intervention Nurse’s 
Signature 
 
 
       
 
 
       
 
 
       
 
 
       
 
 
       
 
 
       
 
 
       
 **Including whether you stopped or skipped your ARVs 
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Week 4 
 
 
How good were you at taking your medication this week?  
 
To be filled in by Nurse 
Date What did you 
feel? 
Severity What did you do 
about it?** 
Result/ Comment When 
reported 
Intervention Nurse’s 
Signature 
 
 
       
 
 
       
 
 
       
 
 
       
 
 
       
 
 
       
 
 
       
 **Including whether you stopped or skipped your ARVs 
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Week 5 
 
 
How good were you at taking your medication this week?  
 
To be filled in by Nurse 
Date What did you 
feel? 
Severity What did you do 
about it?** 
Result/ Comment When 
reported 
Intervention Nurse’s 
Signature 
 
 
       
 
 
       
 
 
       
 
 
       
 
 
       
 
 
       
 
 
       
 **Including whether you stopped or skipped your ARVs 
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Week 6 
 
 
How good were you at taking your medication this week?  
 
To be filled in by Nurse 
Date What did you 
feel? 
Severity What did you do 
about it?** 
Result/ Comment When 
reported 
Intervention Nurse’s 
Signature 
 
 
       
 
 
       
 
 
       
 
 
       
 
 
       
 
 
       
 
 
       
 **Including whether you stopped or skipped your ARVs 
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Week 7 
 
 
How good were you at taking your medication this week?  
 
To be filled in by Nurse 
Date What did you 
feel? 
Severity What did you do 
about it?** 
Result/ Comment When 
reported 
Intervention Nurse’s 
Signature 
 
 
       
 
 
       
 
 
       
 
 
       
 
 
       
 
 
       
 
 
       
 **Including whether you stopped or skipped your ARVs 
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Week 8 
 
 
 
How good were you at taking your medication this week?  
To be filled in by Nurse 
Date What did you 
feel? 
Severity What did you do 
about it?** 
Result/ Comment When 
reported 
Intervention Nurse’s 
Signature 
 
 
       
 
 
       
 
 
       
 
 
       
 
 
       
 
 
       
 
 
       
 **Including whether you stopped or skipped your ARVs 
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Week 9 
 
 
How good were you at taking your medication this week?  
 
To be filled in by Nurse 
Date What did you 
feel? 
Severity What did you do 
about it?** 
Result/ Comment When 
reported 
Intervention Nurse’s 
Signature 
 
 
       
 
 
       
 
 
       
 
 
       
 
 
       
 
 
       
 
 
       
 **Including whether you stopped or skipped your ARVs 
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Week 10 
 
 
How good were you at taking your medication this week?  
 
To be filled in by Nurse 
Date What did you 
feel? 
Severity What did you do 
about it?** 
Result/ Comment When 
reported 
Intervention Nurse’s 
Signature 
 
 
       
 
 
       
 
 
       
 
 
       
 
 
       
 
 
       
 
 
       
 **Including whether you stopped or skipped your ARVs 
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Week 11 
 
 
How good were you at taking your medication this week?  
 
To be filled in by Nurse 
Date What did you 
feel? 
Severity What did you do 
about it?** 
Result/ Comment When 
reported 
Intervention Nurse’s 
Signature 
 
 
       
 
 
       
 
 
       
 
 
       
 
 
       
 
 
       
 
 
       
 **Including whether you stopped or skipped your ARVs 
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Week 12 
 
 
How good were you at taking your medication this week?  
To be filled in by Nurse 
Date What did you 
feel? 
Severity What did you do 
about it?** 
Result/ Comment When 
reported 
Intervention Nurse’s 
Signature 
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List any changes that you have experienced physically since you started taking ARVs. 
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
 
 
 
 
 200 
 
Appendix 4 
 
PATIENT SELF-MONITORING DIARY EVALUATION FORM  
PATIENT STUDY NUMBER 
Please note the following: 
This form is only to be used on patients who used the diary, i.e. patients in the Diary Group (Blue) and 
Tool-Diary Group (Yellow) 
 Circle the appropriate patient’s perception in the following aspects of the patient 
diary 
 User-friendliness of the different sections of the diary  
1= Very user-friendly (It was easy to use without too much effort) 
2= Fairly user-friendly (It was fairy easy to use with some effort) 
3= Not user-friendly (It was difficult/cumbersome to use) 
 Clarity of instructions  
V.C= Very clear (They easily understood the instructions and followed them correctly) 
C= Clear (They understood the instructions on careful reading and followed them correctly) 
N.C= Not clear (They struggled to understand the instructions and may not have followed them 
correctly) 
 Overall perception of the diary  
o Very usable and helpful 
o Fairly usable and helpful 
o Not usable and helpful 
o Usable but not helpful 
o Helpful but not usable 
 Effect on their lives 
a) Adherence 
Did the diary help improve their adherence  
Y= Yes 
N= No 
b) Daily activities 
Did the diary affect or disrupt their normal daily activities 
Y= Yes, it was too time consuming it disrupted their daily activities 
S= Sometimes 
N= No, it did not disrupt their lives 
 
 Circle  your appropriate personal perception of the patient diary (to be filled in by the 
HCP) 
 Adverse effect identification of the patient diary 
Y= It was useful in adverse effect identification 
N= It was not useful in adverse effect identification 
Z= It was useful in identification of adverse effects not identified by the tool (this section is for 
patients in the Tool-Diary Group-Yellow ONLY) 
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Appendix 5 
WRITTEN CONSENT FORM TEMPLATE (HCP and Patients) 
NELSON MANDELA METROPOLITAN UNIVERSITY 
INFORMATION AND INFORMED CONSENT FORM 
RESEARCHER’S DETAILS 
Title of the research project 
 
 
Reference number  
Principal investigator 
 
Address  
Postal Code  
Contact telephone number 
(private numbers not advisable) 
 
 
A. DECLARATION BY OR ON BEHALF OF PARTICIPANT  Initial 
I, the participant and the 
undersigned 
 
(full names) 
  
ID number  
 
A.1 HEREBY CONFIRM AS FOLLOWS:  Initial 
I, the participant, was invited to participate in the above-mentioned research project   
that is being undertaken by  
From  
of the Nelson Mandela Metropolitan University. 
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 THE FOLLOWING ASPECTS HAVE BEEN EXPLAINED TO ME, THE PARTICIPANT:  Initial 
2.1 Aim:      
   
2.2 Procedures:      
2.3 Risks:    
2.4 Possible benefits:      
2.5 Confidentiality:      
2.6 Access to findings:    
2.7 
Voluntary 
participation / refusal 
/ discontinuation: 
My participation is voluntary YES NO   
My decision whether or not to participate will 
in no way affect my present or future care / 
employment / lifestyle 
TRUE FALSE 
 
3. THE INFORMATION ABOVE WAS EXPLAINED TO ME/THE PARTICIPANT BY:  Initial 
(name of relevant person)   
In Afrikaans  English  Xhosa  Other  
and I am in command of this language, or it was satisfactorily translated to me by 
(name of translator) 
I was given the opportunity to ask questions and all these questions were answered satisfactorily. 
 
4. 
No pressure was exerted on me to consent to participation and I understand that I may withdraw 
at any stage without penalisation. 
  
 
5. Participation in this study will not result in any additional cost to myself.   
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A.2 I HEREBY VOLUNTARILY CONSENT TO PARTICIPATE IN THE ABOVE-MENTIONED PROJECT: 
Signed/confirmed at  on  20 
 
 
 
 
 
Signature or right thumb print of participant 
Signature of witness: 
Full name of witness: 
 
B. STATEMENT BY OR ON BEHALF OF INVESTIGATOR(S) 
I,  declare that: 
1.  
I have explained the information given in this document to (name of patient/participant) 
and / or his / her representative (name of representative) 
2. He / she was encouraged and given ample time to ask me any questions; 
3. 
This conversation was conducted in Afrikaans  English  Xhosa  Other  
And no translator was used OR this conversation was translated into 
(language)  by (name of translator) 
4. I have detached Section D and handed it to the participant YES NO 
Signed/confirmed at  on  20 
Signature of interviewer 
Signature of witness: 
Full name of witness: 
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C. IMPORTANT MESSAGE TO PATIENT/REPRESENTATIVE OF PARTICIPANT 
 
Dear participant/representative of the participant 
 
Thank you for your/the participant’s participation in this study.  Should, at any time during the study: 
 
- an emergency arise as a result of the research, or 
- you require any further information with regard to the study, or 
- the following occur 
 
 
 
 
 
 
 (indicate any circumstances which should be reported to the investigator) 
 
Kindly contact  
at telephone number  
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Appendix 6a 
REQUEST LETTER TO CONDUCT STUDY 
 
 
 
 
 
 
Summerstrand South Campus 
Faculty of Health Sciences 
Department of Pharmacy 
Tel . +27 (0)41 504-2128   Fax. +27 (0)41 504-2744  
          pharmacy@nmmu.ac.za 
 
        28th April 2009 
 
 
ATTENTION: The Chairman: Uitenhage and Despatch Independent Practitioners 
Association  
SUBJECT: Request for permission to conduct a study at UDIPA 
Dear Dr Naidoo, 
I am hereby requesting permission to conduct a research project at the UDIPA Life and 
Wellness Centre, in collaboration with my supervisors Ms S Burton and Mrs. B Gold. The aim of 
the research project is to evaluate the extent to which monitoring strategies, including a tool to 
be used by healthcare professionals (HCPs), and a self-monitoring patient diary can contribute 
to the early identification and management of adverse effects associated with ARVs. 
 
The health care professionals and the patients involved in the study will be provided with 
informed consent forms which they will be required to complete, should they choose to 
participate in the study. The researcher will meet with the HCPs, explain the project to them and 
obtain their written informed consent. Since I will at no time have direct contact with the patients, 
the HCPs will describe the project to the patients and obtain their written informed consent. I will 
then collect these. 
 
The target sample population will be grouped into four categories of a minimum of 40 patients 
each: a Control Group (no monitoring tool will be used- normal clinic procedures will continue), a 
Tool Group (only the monitoring tool will be used), a Diary Group (only the patient diary will be 
• PO Box 77000 •  Nelson Mandela Metropolitan University 
• Port Elizabeth • 6031 •  South Africa •  www.nmmu.ac.za 
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used) and a Tool-Diary Group (both the tool and diary will be used). The different groups will be 
identified by different coloured stickers. Patients will be selected by means of convenience 
sampling and the data will be collected by the HCPs and then given to the researcher. The 
patient diary is attached. 
 
A previous study to determine the usefulness and usability of a revised monitoring tool was 
conducted at UDIPA. One of the findings and the recommendations of the HCP involved in that 
study was that the previous tool was too long and hence time consuming and cumbersome. 
Modifications were thus made to the tool, including separating the history taking part and the 
adverse effect monitoring part into two separate sections. The history taking section is to be 
used by the researcher and the monitoring tool by the HCP. I would like to request permission to 
collect relevant data from patient files as a part of the history taking. The patients will be made 
aware of this by the HCPs and their written consent is required. The patients will be assigned 
study numbers and their personal details will be kept confidential at all times. The HCPs will use 
the monitoring tool and at the end of the study period, get feedback from the patients who will 
have used the diary regarding the usability of the diary. 
 
Data collection is estimated to run over a period of three months, starting in June 2009.  A 
research report summarizing the findings will be written and submitted to UDIPA and the 
Pharmacy Department in the Faculty of Health Sciences at the Nelson Mandela Metropolitan 
University (NMMU). A paper will be prepared for publication in an accredited journal and the 
results will be presented at a local, national or international conference.  This will form part of 
my fulfilment criteria for completion of my Masters degree in Pharmacy at this institution. More 
information on the study can be found on the attached research proposal as submitted to the 
Pharmacy Department, the Faculty of Health Sciences Research Innovation and Technology 
Committee, and the Research Ethics Committee (Human) at the NMMU. Please feel free to 
contact myself or my supervisors should you have any queries in this regard.  
 
Thank you for your consideration.  
 
Yours faithfully 
 
Florence Mulinge 
Mobile: 084 854 0118 
E-mail: flomulinge@gmail.com  
(Researcher) 
 
 
 
Beverley Gold (Mrs)    Sue Burton (Ms) 
Lecturer: Department of Pharmacy  Lecturer: Department of Pharmacy 
W: 041 504 4290; Cell 082 572 7332 W: 041 504 4212 
(Supervisor)     (Supervisor) 
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Appendix 6b 
STUDY APPROVAL LETTER 
 
                                                                                     UDIPA LIFE & WELLNESS CENTRE 
38 A Cuyler Street 
Cuyler Hospital Grounds 
P. O. Box 832 
Uitenhage 
Tel / Fax 041- 9911892 
“Defending your health” 
 
Date: 28th April 2009 
 
Re: NMMU Pharmacology Research Project 
 
We hereby grant permission for the research project at Udipa Life Centre for 2009. 
 
Thank you for your interest. 
 
Yours faithfully 
Dr L. M. Naidoo 
Udipa Chairperson 
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Appendix 7 
 
A SAMPLE OF AN ARV ADVERSE EFFECTS MONITORING TOOL 
 
